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Summary Statement  
The aim of this thesis is to evaluate and optimise current pharmacotherapeutic 
options in rhinosinusitis. There is often a marked variation in treatment response in 
those afflicted with chronic rhinosinusitis, both within and between patients, 
attributable in part to different disease phenotypes/endotypes, poor awareness of 
treatment optimization options, and trivialization of symptoms by patients and 
physicians. Characteristically, these factors contribute to a typical remitting and 
relapsing disease course. The objectives of this work are to improve the therapeutic 
index and reach of commonly used medications by boosting efficacy whilst reducing 
concomitant side effects.  
The third chapter explores the use of initial oral steroids in patients with chronic 
rhinosinusitis and nasal polyposis, focusing on the role of the ostiomeatal complex in 
the perpetuation of disease symptoms. Often a short course of oral steroids is used in 
patients with moderate to severe disease to achieve initial control before 
maintenance with intranasal steroids. This is termed as a ‘medical polypectomy’ and 
anecdotally is commonly used in patients with chronic rhinosinusitis with nasal 
polyposis (CRSwNP). However, the evidence for its efficacy is tenuous and there are 
no data to evaluate if it indeed re-establishes ostiomeatal sinus complex drainage 
which is a condicio sine qua non of ensuring long-term symptom resolution. Further, 
it is known that monotherapy with nasal steroids may result in loss of symptom 
control. We have therefore in a double-blind placebo controlled trial (Chapter 4) 
evaluated the effect of this initial induction with oral steroids on subsequent 
sequential intranasal therapy. Perhaps, however, more crucially we have for the first 
time comprehensively addressed the safety of both oral and topical steroids in 
patients with CRSwNP who have other concomitant steroid-dependent illnesses like 
 15!
asthma and COPD. A particularly refractory subset of those with CRSwNP also have 
aspirin intolerance and asthma. While recent guidelines have recommended more 
aspirin challenge testing in these patients, it is unclear what the significance of a 
positive test is in the absence of overt clinical symptoms or in patients with only 
moderate disease. This is addressed in Chapter 5, as this significant phenotype of 
aspirin intolerant rhinosinusitis need close monitoring, dose optimization, 
polytherapy, and in selected cases may be suitable for aspirin desensitization. 
Penultimately, we evaluate in a double-blind placebo controlled trial (Chapter 6) the 
tachyphylaxis and rebound congestion that blights the medium to long-term use of 
sympathomimetic nasal decongestant sprays like oxymetazoline and if this can be 
reversed by the concomitant use of nasal steroids. We also characterized nasal blood 
flow as an outcome to evaluate in these patients and its relation to other rhinological 
outcome measures (Chapter 7).  
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Chapter 1: Introduction and 
Literature Review 
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DEFINITIONS 
Rhinitis is an umbrella term for a heterogeneous group of disorders, with diverse 
phenotypes and disease courses, but commonly defined as having inflammation of 
the nasal mucosa. This inflammation may in turn be influenced by factors such as 
infections, allergies, chemicals, drugs and hormones. Rhinitis is frequently 
associated with a variety of debilitating symptoms including rhinorrhoea, postnasal 
discharge, blockage, sneezing, itching, and hyposmia. Since rhinitis and sinusitis 
usually contemporaneously manifest themselves in an afflicted individual, the term 
‘rhinitis’ has now evolved into the more encompassing ‘rhinosinusitis’. Indeed, most 
current guidelines now refer to this conglomerate of disorders as rhinosinusitis(1, 2). 
Among chronic rhinosinusitis (CRS), defined as having symptoms for more than 8-
12 weeks, allergic rhinitis (rhinosinusitis) represents the largest disease subtype 
amongst these disorders and is clearly the best studied. There seems to be an 
unintended dichotomy within the literature with allergic rhinosinusitis (AR) related 
research existing almost in parallel with studies on CRS. On one level, this perhaps 
reflects the fact that rhinosinusitis presents itself to a variety of practitioners such as 
otolaryngologists, allergologists, respiratory physicians, immunologists, and family 
physicians among others.  On the other hand, this underscores the lack of 
understanding on how AR, a predominantly IgE mediated process melds into CRS 
and the delineation of the journey from an initial insult to subsequent tissue change 
and finally disease perpetuation. The currently surmised role of allergy in CRS will 
be looked at a bit later. Briefly, there is sparse evidence to support the role of allergy 
in CRS, but it seems to be associated with more recalcitrant disease, often being 
discovered when initial surgical treatment fails to offer respite(3). Definitions of 
CRS vary depending on which international guideline is considered. The European 
 18!
Position Paper on Rhinosinusitis and Nasal Polyposis 2012 updated from 2007 
(EPOS)(4), the Canadian Clinical Practice Guidelines(5), the Rhinosinusitis 
Initiative (RI)(6), the Joint Task Force on Practice Parameters (JTFPP)(7), the 
Clinical Practice Guideline: Adult Sinusitis (CPG:AS)(8), and the British Society for 
Allergy and Clinical Immunology (BSACI)(9) are some of the current expert 
guidelines issued over available evidence and have issued varied definitions of CRS 
and its relationship to AR. Persistent AR could be included under the CRS 
definition: inflammation of the nasal and sinus mucosa of over 12 weeks duration. 
AR can be viewed as one pathway of sinonasal mucosal inflammation, that shares 
the same effector cells, cytokines and inflammatory mediators active in CRS(4). For 
the purposes of this thesis, AR is considered as a subset of CRS as in our experience 
over the last decade or so, we feel that the role of allergy in rhinosinusitis is 
underestimated. CRS can be further subdivided into with and without nasal 
polyposis. A subtype of CRS (usually with nasal polyposis) is fungal rhinosinusitis, 
which in its classical form has eosinophilic mucin with fungal hyphae and positive 
skin/blood tests for fungal antigens. The case for a fungal hypothesis in the 
aetiopathology of CRS, however, is tenuous at best. CRS with nasal polyposis 
(CRSwNP) is a distinct pathological subtype with a greater burden of symptoms and 
a higher relapse rate after treatment that those without polyposis(10). In spite of this 
observation, the actual distinction between the two disease phenotypes is less clear. 
The currently held view is that of distinct pathophysiological mechanisms leading to 
the predominance of one phenotype over the other with a more eosinophilic driven 
immunology underpinning those with nasal polyposis and possibly 
superantigens(11) and a greater role of neutrophils, bacterial infections and 
remodeling of the ostiomeatal complex in CRS without nasal polyposis(12).  
 19!
 
Figure 1: Multifactorial nature of chronic rhinosinusitis 
 
The above figure shows the multifactorial nature of CRS. The symbols illustrate the 
multiple factors implicated or investigated so far in CRS as opposed to direct 
causation and in certain cases such as atopy and allergic rhinitis, the relationship 
with chronic rhinosinusitis is far from clear. The detailed relationship between these 
factors and CRS and its phenotypes and endotypes is explored further in this chapter. 
Abbreviations – CRS, chronic rhinosinusitis; NP, nasal polyposis; OMC, ostiomeatal 
complcx; S aureus, staphylococcus aureus. 
We have for the purposes of this thesis chosen the definition of CRS as given in the 
EPOS guidance of 2007 and 2012(1, 13). CRS was defined as presence of two or 
more symptoms; one of which was nasal blockage/obstruction/congestion or nasal 
discharge (anterior/posterior nasal drip). In addition, the subject could have facial 
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pain/pressure, a reduction or loss of smell for at least 12 weeks and nasal endoscopy 
performed to evaluate the presence and severity of nasal polyposis as detailed in the 
methods section. A diagnosis of allergic rhinosinusitis was made according to the 
Allergic Rhinitis and its Impact on Asthma guidelines(2). We also evaluated those 
with aspirin intolerant rhinosinusitis (AIR) with and without asthma using both 
clinical assessment and nasal L-ASA (lysine aspirin) testing (see methods). Patients 
with AIR are known to represent the more severe and treatment resistant spectrum of 
CRSwNP, and with the limited avenues of therapy that are open to such patients, 
pharmacological optimization of current regimens is paramount to restoring quality 
of life. 
 
EPIDEMIOLOGY AND BURDEN 
CRS is one of the commonest chronic diseases affecting the developed world and is 
the commonest chronic respiratory disorder in the United States and Europe(14). In 
the 1997 National Health Interview Survey conducted by the U.S. Census Bureau for 
the National Centre for Health Statistics, Centres for Disease Control and 
Prevention, CRS ranked second among chronic health conditions(14). According to 
the National Institute of Allergy and Infectious Diseases Fact Sheet, CRS is the most 
commonly reported chronic disease, affecting nearly 32 million in the United States 
in 1997. In a study involving 73,364 subjects in Canada, the prevalence of CRS, 
defined by the question “Has the patient had sinusitis diagnosed by a health 
professional lasting for more than 6 months?” ranged from 3.4% in male to 5.7% in 
female subjects(15). On screening a non-ENT population, which may be considered 
representative of the general population in Belgium, 6% of subjects suffered from 
chronic nasal discharge(16). In the Skovde population-based study in Sweden , a 
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prevalence of 2.7% of nasal polyposis was estimated(17). A postal questionnaire 
survey sent to 4300 respondents in Southern Finland, estimated the prevalence of 
nasal polyps at 4%(18). Using a disease-specific questionnaire, the prevalence of 
nasal polyposis was reported as 2.1% in a sample of more than 10000 French 
people(19). A comparative study looking at secondary care patients in the 
otolaryngology outpatients in Aberdeen and Trinidad found a similar prevalence of 
CRS of approximately 9%(20). Almost a third of general practice referrals in adults 
and up to 50% of referrals in children are related to otolaryngological 
pathologies(21). More recently, in a postal questionnaire administered to 57,128 
responders living in 12 European countries based on the EPOS 2012 criteria, the 
estimated disease prevalence was 10.9% (range 6.9-27.1)(22).  The crux of all these 
data seems to be that a history driven approach seems to over-estimate prevalence 
and an endoscopy/physician driven approach underestimate it.  
CRS is a disease affecting all age groups but, perhaps with an onset in young 
adulthood(23). While some studies suggested a slight female preponderance, a large 
community-based study by Klossek and coworkers demonstrated no sex 
predilection(19). Pilan and coworkers showed a mean age of onset in their cluster-
sampling population study of 2000 adults in Sao Paulo of 40 (SD 21) years; 45.33% 
of whom were male(24). 
As a disease, CRS with and without nasal polyposis is prone to trivialisation by 
patients themselves and under-diagnosis by first contact practitioners like primary 
care physicians. CRS is diagnosed and managed by a wide variety of practitioners, 
including primary care physicians, otolaryngologists, pulmonologists and 
allergologists. It is one of the most common reasons for presenting to primary care 
and accounts for 21% of all adult antibiotic prescriptions in the US(25, 26). Adult 
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CRS triggers approximately 18 to 22 million annual physician visits and 545000 
annual emergency department attendances in the United States(27). In a survey using 
the Medical Outcomes Short Form 36-Item Questionnaire, patients with CRS had 
worse quality of life and more impaired social functioning than chronic conditions 
such as chronic obstructive pulmonary disease, angina, congestive heart failure, and 
back pain(28). More recently, in the first and one of the largest multicentre 
epidemiological studies in Europe of its kind, the population prevalence of CRS was 
estimated at 10.9% (range 6.9-27.1%)(22). In another recent study by Global Allergy 
and Asthma European Network there was a strong demonstrable association between 
CRS and asthma (adjusted OR: 3.47; 95% CI: 3.20-3.76) across all age-groups. The 
association with asthma was stronger in those reporting both CRS and allergic 
rhinitis (adjusted OR: 11.85; 95% CI: 10.57-13.17)(29). While the strong link 
between CRS and asthma has been established, its putative associations with chronic 
cough syndrome, depression and even lung malignancy are less well appreciated(30-
33). CRS is diagnosed and managed by a wide variety of practitioners, including 
primary care physicians, otolaryngologists, pulmonologists and allergologists. 
CRS accounts for billions of dollars spent in healthcare costs, though this is likely to 
underestimate indirect costs due to lost productivity, sickness absenteeism and 
concomitant illnesses like asthma and allergic rhinitis(26, 30, 34).  
In a multicentre European study looking at the natural evolution of aspirin induced 
rhinosinusitis with asthma, Szczeklik and coworkers demonstrated that the age of 
onset of nasal symptoms was in the fourth decade on average and that anosmia was a 
predominant feature in 55% of patients(35). This was followed by bronchial 
symptoms approximately 2 years later and aspirin intolerance developed further on. 
Hastan and coworkers demonstrated in a large cohort of over 50000 subjects that 
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CRS was linked with an increased prevalence of late onset asthma(22). This was 
confirmed by Jarvis et al who in a Global Allergy and Asthma Network of 
Excellence study surveyed 52000 subjects and found an overall age-adjusted 
incidence of asthma in CRS of (odds ratio 3.5, 95% CI: 3.2-3.8)(29).  
Longitudinal 8.8 year follow-up data from the European Community Respiratory 
Health Survey demonstrated that irrespective of atopic status, merely having rhinitis 
led to an increased relative risk of developing lower airways disease of 2·71 (95% 
CI:1·64–4·46)(36). Moreover persistent symptomatology as deemed by the ARIA® 
criteria were also associated independently with the development of lower airways 
disease leading to the conclusion that CRS is an umbrella term for all sinus disease 
but actually which is a constellation of closely associated pathologies manifesting 
varyingly, which are yet to be fully understood.  
 
PATHOGENESIS 
CRS is a multifactorial disease with complex interplay of host and environmental 
factors that are not fully elucidated yet (Figure 1). In a minority of cases CRS is a 
manifestation of a systemic illness such as cystic fibrosis, primary ciliary dyskinesia, 
and hypogammaglobulinaemia, but in the vast majority of cases, CRS is deemed 
idiopathic.  
Genetics 
As mentioned above there are a few disorders like cystic fibrosis and Kartagener’s 
syndrome that are strongly associated with a tendency towards CRS and in particular 
CRSwNP(37). However, supportive data for a genetic ‘sensitisation/predilection’ are 
lacking.  Lockey and coworkers studied 4 members of a Mennonite family to 
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elucidate an autosomal recessive basis for the transmission of aspirin intolerant 
rhinosinustis with asthma(38). Some HLA haplotypes have been implicated in the a 
priori risk of developing nasal polyposis(39). Its is also possible that many genes 
involved in the pathogenesis, course and severity of allergic rhinitis and asthma are 
common to CRS(26). Using genome-wide expression microarrays Stankovic and 
coworkers demonstrated five genes likely to be involved in the pathogenesis of CRS 
and aspirin sensitivity(40). A familiar preponderance has also been demonstrated in 
certain studies. Using a case-control study design Alexiou and coworkers showed in 
a 102 patients, a 13% familial prevalence of nasal polyps as compared to population 
controls(41). However, in the vast majority of idiopathic cases a clear genetic 
component is not defined as evidence by a lack of increased prevalence in 
monozygotic twin studies(9).  
Molecular mechanisms and Endotypes 
There is an increasing interest in identifying disease phenotypes in CRS, e.g. 
CRSwNP, CRSsNP and aspirin intolerance. For e.g. presence of ostiomeatal 
complex obstruction is considered by many to be a surrogate of disease severity and 
overall burden and may predict a worse outcome(42). CRS with nasal polyposis 
(CRSwNP) is a distinct phenotype with a greater burden of symptoms and a higher 
relapse rate after treatment that those without polyposis(10). But merely identifying 
these clinical phenotypes has proven to be of limited value from a long-term 
perspective, as this does not provide a holistic understanding of the cellular 
mechanisms underpinning CRS. Moreover, as yet there are no specific treatments 
tailored for each phenotype. As mentioned before, CRS is an umbrella term for a 
collection of various diseases. There is a growing trend towards ‘endotyping’ as well 
as phenotyping i.e. defining subtypes based on a distinct pathogenetic mechanism or 
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biomarkers(37). Such endotyping may help define future treatment responses, such 
as differential corticosteroid response between CRSwNP and CRSsNP, patients with 
a marked Aspergillus IgG burden, aspirin intolerance and desensitisation. We know 
currently that there are key molecular and cellular differences between the major 
phenotypes of CRSwNP and CRSsNP. In a landmark paper by Van Zele and 
coworkers, characteristic differences were found between CRSwNP, CRSsNP and 
cystic fibrosis polyposis patients in terms of effector cell predominance, Th1/Th2 
polarization and levels of TGF-ß(43).  
Table 1. Characteristics of CRS endotypes 
Endotype) CRSwNP) CRSsNP)
Anatomical*factors* Nasal*polyposis,*blocked*
ostiomeatal*complex*
No*associated*anatomical*
factors*
QoL*and*disease*burden* Worse*QoL*and*symptoms,*
relapses*common,*more*
therapy<recalcitrant*
Better*QoL*and*disease*
burden*
Type*of*cell*mediating*
disease*
Th2*predominant* Th1*predominant*
Cytokines* Raised*IL<5,*eotaxin,*IgE*
Low*TGF<ß*
Raised*IFN<gamma,*TREG*
and*TGF<ß*
Abbreviations:*CRSwNP,*chronic*rhinosinusitis*with*nasal*polyposis;*CRSsNP,*chronic*
rhinosinusitis*without*nasal*polyposis;*QoL,*quality*of*life*
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However, the above diagram may be not be necessarily accurate in all patient 
populations, as recent evidence has shown that there is a considerable overlap in 
these mechanisms in Asian patients(44). More recently, there has been interest in the 
levels of fibrosis in CRSwNP and CRSsNP, whereby in nasal polyps there is lesser 
fibrotic change, upregulation of metalloproteinases such as MMP-7 and MMP-9, 
more tissue oedema and a defect in T cell regulation (Treg)(26, 45). Despite these 
ethnic differences, it is clear that eosinophilic activation and IL-5 induced reduction 
of apoptosis plays a crucial role in the activation of specific adhesion receptors and 
possibly in conjunction with Staphylococcus aureus enterotoxins, which may serve 
as superantigens, induce a cascade of T and B cell activation and amplification of the 
inflammatory cascade(46-48).  
Staphylococcus aureus enterotoxins or ‘Superantigens’ 
It is generally accepted that IL-5 and eotaxin secretion in CRS orchestrates the 
chemotaxis, activation, migration and further release of eosinophilic mediators in 
inflamed tissues and a reduction in cellular apoptosis(49, 50). Staphylococcus aureus 
is one of the commonest bacteria found in patients with CRS and it much more 
commonly found in CRSwNP(37, 51). S aureus elaborates a number of powerful 
factors that are capable of initiating a Th2 response through staphylococcal 
enterotoxins (SE) or other proteins and are capable of strikingly amplify the 
inflammatory cascade in CRS(49, 52). In vitro studies have demonstrated this 
modulatory effect on Th1 and Th2 cytokines (IFN-gamma, IL-2, IL-4, IL-5, IL-10 
and IL-13) when polyp tissue was exposed to SEB(47).  Van Zele and coworkers 
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showed that nasal polyp homogenates in which S aureus enterotoxin specific – IgE 
antibodies were detectable had significantly greater concentrations of IgG, IgG4 and 
IgE than did those without(49). Moreover, it is known that SEA and TSST-1 
(examples of staphylococcal enterotoxins) can induce a rapid polyclonal response to 
multiple allergens, modulate the allergic response by augmenting isotype switching 
and IgE synthesis(53). Further, there may even be a link between eicosanoid 
metabolism and SE with the demonstration of upregulation of cysteinyl leukotrienes, 
leukotriene B4 and lipoxin A4 in polyp tissue from those with an immune response 
to S. aureus enterotoxins as compared to those who were negative for S. aureus 
enterotoxin – IgE(54). This is potentially of interest as increased synthesis of pro-
inflammatory leukotrienes and decreased synthesis of anti-inflammatory 
prostaglandins (PGE2) have been proposed as a mechanism not just for aspirin-
sensitive nasal polyps but also aspirin-tolerant CRSwNP(55). However, while 
multiple direct and indirect data are available to substantiate this rather interesting 
hypothesis, a direct causal link is yet to be clearly established, and the putative role 
of SE in informing therapeutics is to be explored.  
 
Microorganisms and the Immune barrier hypothesis 
Acute rhinosinusitis (ARS) is triggered by infectious organisms, with perpetuated 
inflammation as the underlying basis of the disease, modulated by local anatomical 
and other host factors, which play a role in disease perpetuation, progression and 
recurrence(1). A normal milieu in the host in the form of normal anatomy, histology 
and tissue function essentially precludes recurrent infections, and there is a vicious 
cycle of repeated infections leading to changes in tissue function and cascades of 
inflammation that are responsible for the remitting relapsing nature of the 
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disease(56). CRS is not to be considered to arise from ARS and has a distinctive 
pathophysiology underpinning it. Indeed, the role of microorganisms in CRS is 
unclear at present with a rekindled interest as a result of S aureus enterotoxins as 
described above.  
With the advent of culture-independent techniques, a wider variety of organisms can 
now be detected, although it remains to be seen if there is a clear role within the 
pathological framework of disease(57). In particular, it has been recently reported 
that both bacterial and fungal biofilms are present more commonly in CRS than in 
normal controls(58, 59). These biofilms have also been demonstrated in CRSsNP 
and have been shown to respond to macrolide therapy rather than traditional 
corticosteroid treatment(60). Basically, biofilms may provide a shielded environ for 
a reservoir of microbiota in which they are protected from host defenses and 
treatment, and may play a role in refractory CRS.  
Similarly, the role of fungi in CRS is a matter of continued debate. Fungi are 
ubiquitous in nature and have been detected in the nasal mucosa of both patients with 
CRS and normal subjects(61). Shin and coworkers found that patients with CRS 
showed exaggerated humoral and cellular responses, both Th1 and Th2, to common 
airborne fungi, particularly Alternaria using peripheral blood monocytes(62). Lastly, 
patients with CRS demonstrated excessive eosinophilic inflammatory change in the 
nasal mucosa in the absence of mould-specific IgE reactivity(61). This led to the 
suggestion of a ‘Fungal Hypothesis’ in CRS.  Disappointingly, in a large multicentre 
randomized clinical trial by Ebbens and coworkers, they failed to demonstrate 
efficacy of topical Amphotericin B in patients with CRS using total visual analogue 
scale (VAS) score and nasal endoscopy score as their primary outcome measure(63). 
Similarly, in a prospective randomized controlled trial, Gerlinger and colleagues 
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failed to demonstrate an improvement in postoperative CT scores, clinical 
symptoms, or quality of life measures in CRS using amphotericin B nasal spray(64). 
There is perhaps a broader repertoire of in vitro data to support the role of fungi in 
the aetiopathogenesis of allergic rhinosinustis(65). This along with some restricted 
clinical responses seen still maintain the likelihood that a fungal endotype is 
possible, although a wider role in CRS is currently questionable. Areas of future 
research interest in this arena include immunomodulation of host response and a 
chitin-induced Th2 response secondary to direct colonization or biofilm 
formation(1). Chitin (C8H13O5N)n is a long-chain polymer of N-acetylglucosamine 
and is an abundant polysaccharide type found in the cell walls of fungi, insects, and 
parasitic nematodes. Innate immune host defense against chitin-containing pathogens 
include production of chitinases. There is some evidence that an increased 
expression of acidic mammalian chitinase in chronic rhinosinusitis with nasal polyps 
may influence the Th2 mediated inflammation in the upper respiratory tract(66).  
Lastly, the effect of these microorganisms or allergens is enhanced due to barrier 
breakdown in the form of epithelial tight junctions, which are critical in controlling 
paracellular flux of substances(37, 67). The human nose is constantly exposed to a 
wide variety of environmental insults and acts as a gatekeeper to exogenous irritants 
and noxious stimuli(68). Epithelial tight junctions are delicately regulated by 
complex interactions between a variety of adhesion molecules and represent a 
dynamic ever-changing interface between the human body and its surroundings(67).  
Their disruption represents a key link in the etiologic chain of causation in CRS. 
Similarly, several studies have implicated a reduction in the responsiveness of Toll-
like receptors which are sinonasal epithelial receptors that play a critical role in 
innate and acquired immune responses(69). In particular, upper airway cells are host 
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to TLR2, TLR3, TLR4 and TLR9, which may play a role in mediating host 
inflammation, with consequential derangements contributing to the final common 
pathway of CRS(70). In particular, TLR 2 and TLR9 have been implicated in 
recalcitrant rhinosinusitis and in patients with early polyp recurrence post FESS(71). 
Allergy 
Current international consensus is that the role of allergy in CRS is limited and 
unclear(9, 72). A number of studies have reported an increase in the prevalence of 
atopy in CRS(1, 73, 74).  Friedman reported a 94% prevalence of atopy in his cohort 
of patients undergoing sinus surgery(73). Authors have reported a prevalence of 30-
94% with regard to patients with CRS with positive skin prick tests(72, 75-78). 
There are data contrary to this with authors reporting no increase in the prevalence or 
severity of CRSwNP in patients with allergies(79, 80). A more population-based 
prevalence is reported as much lower in the range of 0.5 to 4%(81-83). In our 
institution, we have a high background prevalence (approximately 50% - see also 
Chapters 3 and 4) of allergic symptoms and atopy in our patient cohort of CRS(84-
86). Interestingly, this is quite similar to a large European survey by GA2LEN in 
52000 people, reported a 56.7% prevalence of allergic symptoms in those who 
fulfilled the EPOS 2012 criteria for CRS(22). 
What is clear is that both diseases share a common denominator of inflammation, 
similar symptomatology, are both demonstrating a rising global trend, and frequently 
co-exist in the same patient. Baroody and coworkers demonstrated the concept of a 
unified inflammatory milieu for nasal and sinus mucosa in two experiments, one of 
which was a double blind, crossover, randomized, placebo-controlled study in 20 
allergic subjects out of season, to show that allergen challenge to the nasal mucosa 
resulted in an allergic response from the maxillary sinus mucosa(87, 88). Lin et al 
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found a higher rate of surgery, increased disease severity and higher medication use 
in CRS patients with concomitant allergic rhinitis(78). These data are similar to other 
authors who have shown an increase in symptom severity in patients with 
concomitant CRS and allergies using validated symptom scores such as SF-36, 
Rhinosinusitis Disability Index and SNOT-20(89-91). Lastly, a systematic review by 
Contreras and coworkers demonstrated a mixed picture with a probable high 
concomitant prevalence of atopy with CRS, but high quality evidence was still 
lacking(72).  
Aspirin sensitivity 
Of note, 5% to 8% of patients with CRSwNP will be intolerant to aspirin 
(acetylsalicylic acid) and non-steroidal anti-inflammatory drugs (NSAIDs) and 
almost invariably have associated asthma. This trio of disorders is often referred to 
as the 'aspirin triad' or 'Samter's triad'(92). It is known by several acronyms and 
names such as aspirin-induced/intolerant asthma (AIA), aspirin-induced/intolerant 
rhinosinusitis (AIR), aspirin sensitive asthma (ASA), aspirin hypersensitivity and 
aspirin exacerbated respiratory disease (AERD).  
A meta-analysis showed that the prevalence of aspirin sensitivity in the general 
population may be as high as 22% if oral aspirin challenge tests are used as the 
diagnostic gold-standard instead of patient history(93). Moreover, there is almost a 
100% cross-sensitivity to common over-the-counter NSAIDs(93, 94). Aspirin 
sensitivity affects about 10% of adults with chronic asthma and in patients with 
aspirin sensitivity, 36% to 96% have nasal polyposis as evidenced by endoscopic or 
radiographic changes(1). 
The pathogenetic mechanisms of AIR are complex and not fully understood yet. 
Common hypotheses include an imbalance in the arachidonic acid pathway causing 
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an overproduction in leukotrienes in genetically predisposed phenotypes(95). It is 
postulated that the inhibition of the COX1 enzyme by aspirin (or related substances) 
leads to subsequent inflammatory cell activation, and the release of both lipid and 
non-lipid mediators(96). A significantly lower generation of PGE2 and COX2 
expression in the nasal and sinus mucosa has been reported(97, 98). This could 
contribute to the development of the severe eosinophilic inflammation characteristic 
of AIR patients. AIR usually presents in the third and fourth decades and is more 
common in females and in non-atopic individuals(9). It may present initially as non-
specific rhinorrhoea and nasal congestion and progresses over the next decade or so 
to aspirin sensitivity, asthma and nasal polyposis(99).  
Typically, the presence of aspirin intolerance makes the upper and lower airways 
disease severe, persistent and treatment resistant(35). Patients with AIR have a 
higher frequency of hospitalisations and emergency department visits than tolerant 
patients(100). Their illness is recalcitrant to medical and surgical treatment and they 
are often either steroid dependent or unresponsive(9). In a pan-European survey of 
AIR, inhaled corticosteroids or oral corticosteroids were used by 80% of afflicted 
patients with a mean daily dose of 8 mg of oral prednisolone(35). Endoscopic sinus 
surgery outcomes are also less successful in AIR patients compared with aspirin 
tolerant patients, with more frequent and earlier relapses(101). 
The diagnosis of aspirin sensitivity relies upon either a clear history of two or more 
aspirin/NSAID induced reactions and/or on aspirin challenge, which can be oral, 
inhaled or intranasal(9). Establishing a diagnosis of aspirin intolerance is important. 
It provides the patient with a host of common drugs that must be avoided, diagnoses 
a particularly severe and recalcitrant form of disease phenotype and allows a choice 
of specific therapy such as leukotriene modifiers or aspirin desensitisation(1).  
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Oral aspirin challenge with placebo control is widely used, but is time consuming (it 
can be three days long), and may provoke severe bronchospasm and anaphylaxis. 
Moreover, a negative oral challenge cannot by itself rule out AIR. Indeed the 
possibility of false-negative responses increases when diagnostic provocation tests 
with aspirin are carried out in asthmatics being treated with corticosteroids or during 
symptom-free intervals(94). However, when endpoints such as a 20% reduction in 
forced expiratory volume in 1 second (FEV1), or characteristic extrathoracic 
symptoms (such as severe rhinorrhoea and nasal congestion), are used oral aspirin 
challenges have a sensitivity of 89% and specificity of 93%(102). 
Inhalation or nasal challenge with lysine aspirin (L-ASA) is becoming the preferred 
method. L-ASA is more soluble than aspirin (40% versus 0.3%), is non-irritant, and 
is well tolerated when inhaled(94). Nasal challenge with L-ASA is similarly 
sensitive and specific (95.7% and 86.7%, respectively), but a negative test does not 
exclude aspirin sensitivity(103). Its negative predictive value is as low as 78.6% and 
an oral challenge is recommended after a negative nasal test(103). Lastly, 
irrespective of challenge results, aspirin sensitivity should always be suspected in 
patients with severe nasal polyposis, especially those with recurrent polyps and 
steroid dependent refractory asthma(9). 
 
Nasal Anatomy – gross, microvascular and molecular anatomy 
There are some purported nasal anatomical factors which have been deemed 
abnormal or are high risk for the development of CRS such as concha bulllosa, 
paradoxical middle turbinate, deviated nasal septum, a displaced uncinate process, 
accessory sinus ostia, and atypical ethmoidal air cells (104). Several authors have 
found no correlation between sinus opacification, nasal symptom scores and normal 
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sinonasal anatomic variants(105-107). Correction of these abnormalities may be 
carried out as part of a more functional sinus surgery for better access.  
The microvascular anatomy of the nose provides a more clear understanding of the 
potential regulatory mechanisms for nasal congestion and decongestion in 
physiology and pathology(108). 
 
Figure 2:Schematic to demonstrate human nasal microvascular anatomy and differential 
adrenoceptor response.  
 
M = nasal respiratory-type ciliated pseudostratified epithelium with goblet cells 
(blue), a-1 = alpha-1 adreceptors, a-2 = alpha-2 adrenoceptors, A = arterioles, C = 
capillaries, S = arterio-venous shunts, V = venous sinusoids, T = throttle veins. The 
nasal mucosa (M) is made of respiratory-type pseudostratified columnar epithelium 
and goblet cells (blue). The arterioles (A) feed an abundant plexus of submucosal 
capillaries (C), the density of which is required to supply nutrients, transport oxygen 
and remove toxins for one of the most metabolically active epithelium in the human 
body. There are however, some ‘anomalies’ when compared to the rest of the upper 
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airways that makes the nose unique(109). The capillaries have extensive 
fenestrations on the epithelial side, allowing water to escape for evaporation acting 
as an air conditioner. There is an extensive unique network of arteriovenous shunts 
(Figure 2 - S) that bypasses the capillary network. This is similar to other highly 
vascular beds like the fingernail bed. Uniquely, the human nose (like other 
mammalian noses) has capacitance vessels or venous sinusoids (V) enclosed in an 
osseous cavernous cover that serve to engorge and expand in response to stimuli and 
cause congestion and decongestion, the so-called nasal cycle(110). It is also likely 
that the shunts and capacitance vessels increase the capacity of the nasal mucosa to 
act as an air conditioner.  
Adrenoceptor Regulation 
Adrenergic receptors mediate the effects of adrenaline and noradrenaline and are 
virtually involved in the regulation of every organ system in the human body. In the 
early 1900s adrenoceptors were identified through tissue response methods. The 
exemplary division of these into alpha and beta-adrenoceptors in the 1960s was of 
critical importance and since then their importance in modern day medicine and 
research is self-evident(111). It was the advent of radioligand binding assays that 
represented the next major advance in the classification and study of 
adrenoceptors(112). Data from these assays and second messenger studies have 
shown that there are atleast six subtypes of alpha adrenoceptors alone(113). Stafford-
Smith and coworkers demonstrated using in situ hybridization of nasal turbinate 
samples the prevalence of alpha2c-adrenoceptors on the venous sinusoids and 
arteriovenous shunts and postulated that a selective alpha2c agonist may be of value 
in providing decongestion whilst avoiding side-effects due to more generic receptor 
effects(114, 115). Corboz and colleagues demonstrated that alpha-2 adrenoceptors 
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predominate on the venular side of the nose while alpha-1 adrenoceptors on the pre-
capillary side(116). This was in keeping with a prior study by Johannssen and 
coworkers that constriction of human nasal mucosal arteries was alpha-1 
mediated(117). This led to the suggestion that a selective alpha-2 agonist could 
potentially influence congestion without affecting nasal mucosal blood flow, which 
is considered to be one of the key links in the chain causing rhinitis 
medicamentosa(118). These studies used oxymetazoline which has an approximately 
5:1 ratio effect on alpha-2 vs. alpha-1 adrenoceptors(113). However, this is in 
conflict with what Ichimura and coworkers have demonstrated previously that the 
predominant adrenoceptor in the nose is an alpha-1 adrenoceptor(119). There may be 
an issue with size of tissues used, incubation techniques and experimental 
methodology, which may account for these effects. The reality is that there are no 
real life studies that have evaluated these effects in vivo and there is a wide chasm 
currently before any of this can be translated into daily practice.  
The human nose is under tonic sympathetic control by post-ganglionic fibres 
emanating from the stellate ganglion in the neck and reaching the nose along arteries. 
Although there is an abundance of adrenergic innervation to these blood vessels 
(predominantly alpha-1), there is also sparse cholinergic innervation to the 
glands(120). While it is likely that a series of complex interactions are responsible 
for the fine regulation of nasal blood flow in health and disease, in simple terms, 
increasing the rate and duration of sympathetic nerve impulses to the nose causes 
vasoconstriction with the reverse effect i.e. decongestion in those who undergo 
cervical sympathectomy. Based on current evidence, the predominant adrenoceptor 
type in the superficial pre-capillary sphincters seems to be the alpha-1 subtype and 
on the deep venous sinusoids, the alpha-2 subtype(116, 121). Thus a selective alpha-
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2 adrenoceptor would potentially have a higher therapeutic index, with a high 
efficacy to safety ratio, by causing contraction of the venous sinusoids but sparing an 
ischaemic effect on the nasal mucosa which has been hypothesized as a potential 
cause of rebound congestion. While one may theorize the existence of significant 
cross-talk between inflammatory mediators and adrenoceptors, the actual evidence in 
CRS is sparse(122). Kunkel!and!coworkers!proposed!a!reduction!in!the!numbers!of!beta6adrenergic!receptors!in!the!nasal!mucosa!of!patients!with!nasal!polyps!and!allergic!rhinitis!compared!to!healthy!controls,!raising!the!possibility!of!the!human!nose!being!a!mirror!to!the!bronchial!mucosa(123).!Indeed, in a study by 
Van Megen and coworkers in allergic rhinitis (not CRS), no significant change in the 
nasal alpha-adrenoceptor affinities or densities was demonstrated when compared to 
healthy controls(124). Moreover, animal studies may not be truly translatable into 
human subjects readily, given the difference in adrenoceptor profiles, for e.g. pig 
nasal mucosa seems predominantly under alpha-2 adrenoceptor control as opposed to 
the human nasal mucosa(125). 
 
The link between the upper and lower airways 
Some!lessons!can!be!extrapolated!from!research!performed!in!the!lower!airways.!This!is!due!to!the!fact!that!rhinitis!and!asthma!are!clinically!overlapping!manifestations!of!a!single!unified!airway!disease!which!share!many!pathological!and!epidemiological!characteristics,!particularly!in!allergic!rhinitis(2,!126).!Given!that!the!nose,!sinuses!and!lower!airways!are!all!lined!by!similar!ciliated!pseudostratified!columnar!epithelium,!resting!upon!a!rich!submucosa!of!vessels,!mucous!glands,!fibroblasts,!inflammatory!cells!and!nerves,!this!is!hardly!surprising.!Moreover,!similar!inflammatory!mechanisms!
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underpin!both!disease!processes,!with!a!Th2!driven!inflammatory!cellular!cascade!releasing!cytokine!mediators!such!as!IL64,!IL65!and!eotaxin!found!in!both!nasal!and!bronchial!mucosa(127,!128).!Indeed,!treating!upper!airway!inflammation!has!been!shown!to!have!a!downstream!effect!and!improve!lower!airway!outcomes!including!airway!hyper6responsiveness!and!pulmonary!function(129).!This!link!between!upper!airway!inflammation!and!bronchial!hyperreactivity!is!not!limited!to!merely!allergic!rhinitis,!however,!and!there!is!a!risk!of!developing!asthma!with!any!rhinosinusitis!irrespective!of!the!presence!of!atopy.!In!a!recent!large!community6based!study!in!Europe!by!Global!Allergy!and!Asthma!European!Network!there!was!a!strong!demonstrable!association!between!CRS!and!asthma!(adjusted!OR:!3.47;!95%!CI:!3.2063.76)!across!all!age6groups.!The!association!with!asthma!was!stronger!in!those!reporting!both!CRS!and!allergic!rhinitis!(adjusted!OR:!11.85;!95%!CI:!10.57613.17)(29).!
Asthma was historically thought to be associated with an intrinsic defect of β2-
adrenoceptor function in airway smooth muscle that tipped the balance towards 
bronchoconstriction. Since then, there has been a shift in thinking to a more 
inflammation based approach in asthma, and the upper airways have similarly 
followed suit(2, 130). Despite this shift, there remains a reasonable body of evidence 
for a neural basis of disease with regard to beta-adrenergic receptor polymorphisms 
in asthma, although as mentioned before a similar understanding is currently lacking 
in rhinology. Of particular interest is that link between the neural control and 
inflammatory processes which are yet to be fully elucidated. In asthma, it has been 
recognized that genetic factors, evidenced by greater incidence rates in family 
members of asthmatics, include polymorphisms of a number of genes involved in 
atopy, airway inflammation and bronchial smooth muscle tone including the beta2-
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adrenoceptor(131). There is some evidence in the literature that this may influence 
treatment dosages of corticosteroids(132). Palmer and coworkers demonstrated that 
the arginine-16 genotype of the beta-2-adrenoceptor predisposes to exacerbations in 
asthmatic children and young adults, particularly in those exposed to regular 
salmeterol(133). This may be explained by salmeterol-induced downregulation, 
impaired receptor coupling, and associated dampening of the response.  
More recently, a landmark study by Hanania and coworkers showed that chronic 
administration of an antagonist at the beta-adrenoceptor in asthma, actually causes 
something unexpected, and they start acting as agonists instead and upregulate these 
receptors (134, 135). More importantly, this caused a downstream decrease in 
bronchial hyperreactivity using methacholine challenge which is a surrogate for 
lower airwars inflammation. This was a clear demonstration of how tweaking neural 
networks could potentially influence airway inflammation. If this held true in the 
upper airways, what this could mean was that the chronic administration of an alpha-
adrenoceptor antagonist in AR or CRS could help reduce nasal hyperreactivity. 
Short and coworkers, however, in a double blind randomized clinical trial could not 
demonstrate an effect of chronic dosing of propranolol on methacholine challenge in 
asthmatics(136). Despite the above conflicting results, this remains an area of 
potential growth and further studies in the nasal mucosa using an alpha-receptor 
blocker such as prazosin might have an influence on nasal mucosal reactivity, which 
is a ubiquitous feature of rhinosinusitis.  
Moreover, alpha-agonists are one of the most efficacious drugs in relieving 
congestion which is a principal symptom of CRS and one that impairs QoL more 
than any other(1). However, their use is currently restricted due to the development 
of tachyphylaxis at the receptor manifesting as decreased efficacy and more 
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worryingly the development of rebound congestion i.e. rhinitis medicamentosa(137). 
In the lung, it has been shown by Tan and coworkers that administration of a single 
dose of oral corticosteroid will rapidly reverse beta-adrenoceptor subsensitivity by 
upregulating their concentrations dramatically in the airway smooth muscle 
cells(138). We also know that alpha adrenoceptor downregulation is a rapid 
phenomenon and more than 50% of receptors will downregulate with a half-life of 
2.5 hours(139). We therefore explore the assumption that corticosteroid 
administration in the nasal mucosa might do the same and prevent or delay the onset 
of tachyphylaxis and rebound congestion. This is one of the major themes explored 
in this thesis.  
 
TREATMENT OPTIONS 
The mainstay of treatment for CRSwNP and CRSsNP is medical with surgery 
playing a role in providing improved access to medical therapy, dealing with severe 
or recalcitrant disease, steroid-resistant disease, AIR, and last but not least dealing 
with complications of CRS such as mucocele formation, intraorbital and cranial 
complications(1). Of course, surgery represents an extremely effective treatment 
option and has been shown to improve outcomes, quality of life scores and prevent 
morbidity(37, 140). Dalziel and coworkers performed a systematic review and 
metaanalysis of more than 10000 patients spanning two decades concluded that the 
vast majority of patients derived benefit from functional endoscopic sinus surgery 
(FESS) and open procedures with a very low complication rate (1.4% for 
FESS)(141).  In a large UK based prospective cohort study titled the National 
Comparative Audit in CRS, significant improvements in SNOT-22 scores were 
demonstrated up to 3 years post-surgery with greater benefit in those with CRSwNP 
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than CRSsNP(142). However, revision surgery was indicated in 3.6% of patients at 
12 months and 11.8% at 36 months(142, 143). A randomized trial by Ragab and 
coworkers comparing long-term medical management with surgical treatment in 
patients with both CRSwNP and CRSsNP using a vast array of objective (polyp 
scores, NO, PNIF and mucociliary clearance) and subjective measures such as VAS, 
SNOT-20, SF-showed that both treatments significantly improved almost all 
parameters of CRS (P <.01), with no significant difference between groups(144). 
In summary, surgery and medical therapy must be considered complementary in 
CRS. 
 
Corticosteroids 
The mainstay of treatment for CRS remains long-term intranasal corticosteroids 
(INCS)(1, 9). There is an extensive evidence in this regard, which has been 
previously summarized, systematically reviewed and meta-analysed(1, 145, 146). 
INCS have demonstrated unparalleled efficacy based on subjective and objective 
outcome measures such as polyp size, endoscopy score, symptoms score, nasal 
airway patency measures such as PNIF; improved QoL; reduced surgical events and 
improved post-surgical outcomes(1, 9, 145). They are also known to significantly 
improve ocular symptoms in those who have allergic CRS(147). No evidence exists 
currently for the recommended use of one INCS over another in terms of efficacy. A 
twice-daily dosing regime seems more effective than once daily administration(148). 
There is also a significant effect of the technique of administration on the efficacy of 
nasal based therapy and patient education plays a key role in this illness(9, 149). The 
predicament with chronic maintenance treatment with INCS is the slow attrition of 
efficacy as evidenced by the chronic remitting relapsing nature of CRS(150). This 
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may be hypothesized to occur due to a lack of effect of INCS on the ostiomeatal 
complex and sinus drainage requiring multiple medical polypectomies(9). Clearly, 
this is the reported experience of many practitioners treating CRS, however, 
evidence in favour of using an initial oral corticosteroid induction was lacking until 
recently, and these data have been presented later in this thesis(85). 
In particular, there is a remarkable lack of safety data in the literature on INCS in 
CRS patients. INCS are highly lipophilic compounds and this diminishes the 
solubility of these compounds in the water-dominant nasal mucosa, reducing direct 
systemic absorption from the nasal cavity. Indeed, the reported systemic 
bioavailability of INCS in the literature varies between 1-50% and clearly with ease 
of availability over-the-counter, there is a risk of systemic adverse effects(151, 152). 
This assumes greater importance as many patients with CRS have associated asthma 
and are on inhaled corticosteroids and in patients with AIR or steroid-refractory 
disease; these factors clearly are additive in terms of the overall steroid burden(9, 
81). It is also well-recognised that in real life, it is uncommon for patients to have 
their inhaled and intranasal corticosteroids tapered or fine-tuned frequently. Indeed, 
in the experience at our institution step-down of therapy is rarely achieved, 
particularly in the community or even secondary care(153). So far most studies in 
CRS have focused on reported symptoms such as epistaxis, although the EPOS 
guidelines conclude that the existing literature in INCS has failed to show any 
significant systemic adverse effects(1). This assumption in the current guidelines 
must be taken with a note of caution. Most data in the literature is in the form of 
systemic detection after single pass metabolism. For example a study by Daley-Yates 
assessing systemic bioavailability of four consecutive 800 µg doses intranasal 
fluticasone aqueous spray given over 24 h in healthy volunteers concluded that even 
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at 12 times the normal dose was safe and that drops were 8 times less detectable than 
spray(154). This is likely to be an incorrect assumption, as drugs such as fluticasone 
are highly lipophilic and are mainly stored in the adipose tissue of the body due to a 
large volume of distribution and may have prolonged systemic effects despite a lack 
of detection in the intravascular compartment(153). Vargas and coworkers claimed 
that a lack of effect after 4 weeks of high dose fluticasone on a 250 µg ACTH 
stimulation test may be explained by the known insensitivity of this test, as 250 µg 
represents a supraphysiological dose of ACTH, with much lower doses of ACTH 
(i.e. 0.5–1.0 µg) being as effective in producing a stimulated cortisol response(155).  
Knutson and coworkers showed in healthy volunteers receiving intranasal 
fluticasone spray 200 µg daily for 1 week followed by 400 µg daily for a second 
week, that there was a 37% fall in 0800 h serum cortisol, a 24% fall in 24-h urinary 
cortisol, a 45% fall in serum osteocalcin as well as a 28% fall in peripheral blood 
lymphocytes glucocorticoid receptor mRNA expression, all of which were highly 
significant effects (P < 0.001)(156). Wilson and coworkers have shown in a study on 
healthy volunteers, that administration of intranasal fluticasone spray 200 µg daily 
compared with placebo resulted in significant HPA-axis suppression in terms of a 
43% reduction of overnight urinary cortisol excretion, but not triamcinolone spray 
220 µg(157). In summary, not only in children, but also in adults, practitioners must 
be aware that efficacy and safety monitoring must go hand in hand and that in CRS 
there is a potential for significant additive steroid burden.  
There is evidence of short-term efficacy for oral corticosteroids in CRSwNP with a 
systematic review of 3 clinical trials by Martinez-Devesa and coworkers, but no 
long-term or frequent use data existed until this thesis data(158). 
Antibiotics 
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There is little evidence to support the routine use of short-term antibiotics in CRS(1, 
37). Two short-term studies exist in terms of using staphylococcal specific antibiotic 
treatment based on the SE superantigen hypothesis. The study by Schalek and 
coworkers evaluating patients undergoing FESS randomized to receive a post-
operative 3-week course of oral anti-staphylococcal antibiotics in CRS did not show 
any additive benefit at 3 or 6 months in terms of endoscopy score or SNOT-20 QoL 
outcome(159). Van Zele and coworkers in another RCT looking at a 3 week course 
of oral Doxycycline 100mg daily for 3 weeks showed significant improvements in 
polyp size, nasal secretions and nasal inflammatory marker reduction but not 
QoL(160). 
Most of the long-term data is in macrolide antibiotics due to their putative 
immunomodulatory effects(161). Macrolide antibiotics have traditionally been used 
for their antibiotic effects in acute rhinosinusitis and in exacerbations of chronic 
rhinosinusitis(162). In this regard they are as efficacious as other penicillin and non-
penicillin antibiotics(1). However, recent years have seen an increasing interest in 
their anti-inflammatory actions(163). The first such report, was in patients suffering 
from diffuse panbronchiolitis experiencing marked improvement in their symptoms 
with low dose macrolide therapy, by Kudoh et. al.(164). Since then, many in vivo 
and in vitro studies have has shown similar effects in cystic fibrosis, asthma, chronic 
rhinosinusitis, rheumatoid arthritis, cancer and coronary artery disease(165). It is to 
be noted that this is not a down-regulation of the immune system, and there is no 
evidence of immunosuppression(166). In fact, it is broad-based modulation of the 
biological inflammatory response without jeopardizing the host ability to combat 
infection. It is also independent of their anti-microbial activity; macrolides have 
shown excellent clinical efficacy even in the presence of resistant microorganisms at 
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lower than anti-microbial doses. In cystic fibrosis for instance, studies have shown a 
positive effect including a marked reduction of cytokine levels and significant 
improvement in lung function(167). Macrolides decrease pro-inflammatory cytokine 
secretion (IL-5, IL-8, GM-CSF etc.), inhibit neutrophil chemotaxis, adhesion, 
oxidative burst and increase apoptosis(166). They accumulate intracellularly and 
mediate a variety of effects presumably through the key proinflammatory 
transcription activator NF-κB unlike glucocorticoids(168).  
The first clinical study in the English literature to show benefit in CRS was by 
Hashiba and Baba(169), they showed a 71% improvement in symptoms after 12 
weeks of clarithromycin (CLARI) 400 mg daily. In another longitudinal study using 
erythromycin 250 mg bid or CLARI 250 mg od, 70% of patients experienced 
significant improvement in their symptom scores, saccharine clearance time and 
nasal endoscopy grading(170). It is estimated clinically that the anti-inflammatory 
effect of macrolides is present at low doses (half of the anti-infective dose), and that 
it takes longer to manifest than the anti-microbial effect (50% by 4-6 weeks and full 
effect by 12 weeks)(171). Also, there seems to be a proportion of patients do not 
respond to therapy and this is usually apparent by 3 months. While this lack of 
response is poorly understood, indicators of good treatment response include normal 
IgE levels, High tissue IL-8 levels, small polyp size(163, 166). 
Researchers have also found that macrolides reduce the levels of some tissue 
cytokines such as IL-8, a critical cytokine in the pathogenesis of CRSwNP(172, 
173). IL-8, a potent neutrophil chemoattractant, is elevated in patients with CRS as 
opposed to allergic rhinitis (AR) and may be a key factor in the formation of NP(1). 
Indeed, in a prospective study patients with NP treated with low dose macrolide 
therapy, treatment responders experienced a significant fall in IL-8 levels as 
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compared to non-responders(173). They also had significantly higher baseline IL-8 
values (231.2 vs. 88.1 pg.mL-1, P<.005). Macrolides inhibit the production of 
superoxide and other free radicals by neutrophils in a dose dependent manner(174). 
Macrolides also reduce the activity of inducible nitric oxide synthase (iNOS), an 
enzyme that produces NO, a potent mediator of inflammation in the upper 
airways(165). In a comparative in vitro study, CLARI and prednisolone both reduced 
the levels of IL-5, IL-8 and GM-CSF in nasal epithelial cells(161).  
Polyps can be classified pathologically into neutrophil predominant or eosinophil 
predominant. The majority of evidence points to a modulation of neutrophilic 
inflammation with minimal effect on eosinophil driven inflammation(168). This is 
surprising, as in vitro studies show that macrolides have significant effects on 
eosinophils and mediators such as IL-5, ECP, eotaxin, GM-CSF(161). Nevertheless, 
the presence of atopy and high IgE levels have been shown to reduce treatment 
efficacy(175, 176), however, the evidence for excluding such patients is weak and 
needs further verification. Macrolides have even been shown to reduce bone 
remodeling which may have consequences for patients with CRSwNP with regard to 
their ostiomeatal complex obstruction(177).  
There is only one randomized clinical trial looking at the effect of macrolides in 
CRS, however patients with nasal polyposis were excluded(176). As such this limits 
its clinical applicability as it is in this group that macrolides are most effective. 
Moreover, they authors looked at patients when they were steroid naive. In clinical 
practice, intranasal steroids form the mainstay of treatment and as such it seems 
unlikely that macrolides will progress to becoming first-line agents for treating this 
condition.  
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Bronchial asthma is a comorbid condition of CRS and in some centres more than 
50% patients have lower airway involvement(1). Around 10% patients with asthma 
are estimated to have nasal polyposis, the figure increasing to 40% in patients with 
aspirin sensitivity(99). There are no clinical trials looking at the effect of long term 
low-dose macrolide therapy on lower airway outcomes in chronic 
rhinosinusitis(178). Macrolides are known to have a variety of effects on the lung 
such as decrease in bronchial hyperresponsiveness(179), sputum eosinophil 
counts(180), decrease in nighttime symptoms and improvement in airway 
calibre(163). Finally, it is unclear as to how long this immunomodulatory effect lasts 
for, i.e. is there evidence of a more lasting disease modification than observed with 
steroids. 
 
Aspirin intolerant patients 
Prevention 
Patients should be warned to avoid all drugs with COX-1 inhibitor activity. Although 
selective COX-2 inhibitors and paracetamol appear to be safe, the first dose should 
preferably be administered in hospital under monitoring. The role of avoiding 
preservatives, additives and high salicylate foods is controversial, with some benefit 
reported in open studies(9). 
 
Leukotriene pathway modification 
There is evidence that leukotriene modifiers like montelukast ameliorate nasal 
symptoms, decrease nasal response to an aspirin challenge and reduce the need for 
corticosteroids(181-183). In an uncontrolled prospective study of 678 patients with 
AIR, leukotriene modifiers alone or in combination blocked lower respiratory tract 
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reactions rather than upper respiratory symptoms during aspirin challenge in some 
patients. There was no change in the overall rate of positive challenge results(184). 
Leukotriene modifiers are only partially effective and patients often experience 
breakthrough nasal and bronchospasm despite treatment(185). 
 
Aspirin desensitisation 
Aspirin desensitisation is an important therapeutic option for patients who have 
inadequately controlled AIR and/or asthma despite treatment with topical 
corticosteroids and leukotriene-modifying drugs. Aspirin desensitisation reduces the 
reactions to aspirin by repeated and increasing exposure to prudent daily doses until 
all reactions cease. Just like provocation testing, desensitisation can be performed via 
the oral, endonasal or inhalational routes. 
Aspirin desensitisation has been described as a treatment modality since 1922(186). 
In 1977, Bianco et al tried the bronchial provocation test with L-ASA in asthmatic 
patients intolerant to aspirin, and observed the existence of a refractory period post-
challenge(187). At the end of the trial (within 20 days), all patients tolerated 500 mg 
of aspirin by mouth. Several author groups have since reported successful 
desensitisation with good clinical efficacy, a low risk-profile and high cost-
effectiveness(188). There is some evidence that desensitisation may be more 
effective for rhinosinusitis symptoms than for lower airway symptoms, but overall 
patient hospitalisations and emergency department visits are reduced(189). 
 
A typical oral regime will consist of gradually increasing doses of oral aspirin, and 
desensitisation takes a few days to achieve. Different authors have recommended 
various regimes and dosages ranging from 100 mg to 1300 mg of oral aspirin so as to 
 49!
maintain a reduction of polyp size, improvement in olfaction and need for revision 
surgery, and improvement in lower airway outcomes(190-192). The European 
Network of Aspirin-Induced Asthma (AIANE) have described these procedures used 
to obtain desensitisation as 'adaptive deactivation' to distinguish them from the 
desensitisation obtained by specific immunotherapy in allergic asthma(94). 'Rush 
deactivation' is obtained in two days by administering L-ASA until induction of 
tolerance. 'Individual dose titration' is a combination of inhalation and oral 
administration of aspirin, and complete tolerance (which means that a single dose of 
500 mg of aspirin is safely tolerated) is generally induced in 12 days. 
Endonasal desensitisation has also been successfully carried out using the topical 
application of L-ASA for the specific treatment of AIR(193, 194). One author group 
have reported a lack of efficacy with a regimen of 16 mg of topical L-ASA or 
placebo instilled intranasally every 48 hours for six months(195). However, the same 
group reported improvements in polyp scores, peak nasal inspiratory flow rates and 
nasal nitric oxide levels using an endonasal regimen of 30 mg/ml L-ASA to each 
side in a dose ramp from 2 mg/day, increased every two or three days up to a 
maximum of 54 mg/day(196). Endonasal desensitisation may be sensitive to local 
factors such as nasal polyp size, mucociliary clearance, or to the concentration or 
regime of L-ASA. 
 
Initial desensitisation by any route must be followed by maintenance dosing, as this 
deactivated state is only sustained for two to five days after cessation of aspirin. 
After this, one can ingest aspirin or NSAIDs on an indefinite basis by taking a 
maintenance dose of aspirin without any serious adverse effects in many cases(197). 
With appropriate monitoring equipment and adequately trained personnel, this can 
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be done as an outpatient regimen(198). It is important to note that if doses of aspirin 
are missed for any reason for more than 48 hours, then a repeat graded 
desensitisation will need to be done, or else severe reactions may be provoked. 
Inpatient desensitisation has been recommended for patients with the following risk 
factors: beta-blocker use, recent myocardial infarction, severe asthma, history of 
severe or life threatening aspirin or NSAID reaction, or any medical condition or 
drug treatment regimen that would make the management of severe asthma or 
anaphylactoid reaction difficult(198). Pre-treatment with a cysteinyl leukotriene 
modifier such as montelukast, zileuton (or both) significantly reduces the incidence 
and severity of any aspirin-induced bronchospasm(184). 
With oral and inhaled desensitisation, there is a small but pertinent risk of 
anaphylactoid and bronchospasm. Full cardiopulmonary resuscitation equipment 
must be available in the centre conducting desensitisation, and the patient must be 
under the supervision of a practitioner with advanced life-support training for two to 
three hours. The risks of desensitisation also include cutaneous reactions and 
gastrointestinal symptoms (dyspepsia, gastritis or haemorrhage). These are observed 
in about 20% of patients treated with aspirin(1, 189). There should be a protocol for 
dealing with aspirin-induced reactions; for example, ocular reactions which can be 
treated with topical antihistamines, gastrointestinal symptoms with proton pump 
inhibitors or H2 blockers, urticaria/angioedema with adrenaline and steroids, and 
bronchospasm with inhaled beta agonists(96). Oral aspirin desensitisation followed 
by maintenance daily dosing may cause significant side effects, including 
gastrointestinal bleeding at high doses. There is some evidence to suggest that oral 
doses as low as 100 mg daily may be effective for maintenance therapy and this 
 51!
could potentially circumvent some of the adverse effects associated with currently 
recommended doses of 300 mg(101). 
 
Other medical treatments 
Antimycotics and their lack of efficacy have been discussed in this thesis previously 
in the section on microorganisms in the pathogenesis of CRS. There is good 
evidence for the use of nasal saline lavage as an adjunctive therapy in CRS, with a 
good safety and economic profile(1, 199). There is also some evidence for the 
addition of mupirocin to the lavage solution for extensive crusting(200). 
Antihistamines cannot be currently routinely recommended in CRS alone, but may 
have a role in concomitant AR in a steroid-sparing capacity(1). The issues with nasal 
sympathomimetic decongestants have been dealt with earlier and will be covered in 
the specific chapters. 
 
FOCUS OF THIS THESIS 
Based on the literature review so far, several foci worthy of further exploration have 
been identified. I propose: 
1. To evaluate the role of the ostiomeatal complex in CRSwNP and to construct 
a non-invasive outcome measure that is portable, cheap and reproducible. We 
propose therefore to measure the effect of systemic steroid therapy on the 
paranasal sinus ostiomeatal complex in CRS using humming nasal nitric 
oxide as a surrogate endpoint, with a custom built nasal mask adapter. 
2. To assess if an initial burst of oral steroid therapy can augment and maintain 
long-term intranasal steroid efficacy in chronic rhinosinusitis with nasal 
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polyposis using a powered randomized double-blind placebo controlled 
parallel trial design in patients with moderate to severe CRSwNP. Critically, 
for the first time in the literature to assess a panoply of safety parameters 
including adrenal suppression and bone turnover in the medium to long-term 
3. To evaluate in our cohort of patients with CRS what the prevalence of an 
aspirin-intolerant endotype was, using a nasal lysine-aspirin challenge, and to 
assess if it predicted a more severe phenotype of CRS i.e. assess if the 
endotype informed the phenotype so as to plan future trials in refractory 
patients and consider desensitisation. 
4. To optimise and extend the duration of use of nasal sympathomimetic 
decongestants by evaluating tachyphylaxis of response to nasal 
oxymetazoline and its reversal by fluticasone. This was to assess a hitherto 
unexplored paradigm in rhinology by using a double-blind randomized 
placebo-controlled crossover design to (a) Establish if tachyphylaxis and 
rebound congestion occurs after use of oxymetazoline nasal spray (b) 
Demonstrate if reversal of effect can be achieved by intranasal fluticasone 
propionate and (c) Dissect out the relative α1-/α2-adrenoceptor components 
of tachyphylaxis using the α1-antagonist prazosin. I also aimed to construct a 
custom-made framework for using laser Doppler flowmetry in the human 
nose. 
5. To perform a comparative evaluation of nasal blood flow and airflow in the 
decongestant response to oxymetazoline in the human nose so as to place 
laser Doppler flowmetry in the context of known and commonly used airflow 
measures of disease and to guide future research and power calculations. 
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Chapter 2: Methods 
An overview of methods common to all chapters is described in this section. Specific 
methodology relevant to each study has been described in the respective chapter.
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Objective outcomes 
Peak Nasal Inspiratory Flow Rate (PNIF) 
 
PNIF was measured using an In-checkTM flow meter (Clement Clarke International 
Ltd, Harlow, UK). After blowing their nose, horizontal positioning of the meter and 
correct restoration of the reading to zero, participants inspired forcefully from 
residual volume to total lung capacity with their mouths closed. All measurements 
were made whilst in a sitting position with a good seal around a purpose built 
facemask. The best of three consecutive readings were recorded. Participants were 
trained how to use it properly at baseline prior to inclusion in the study and 
technique assessed and reviewed as indicated in the preceding visit plans. The 
participants were handed PNIF diaries to record at home if required in the study. 
Recordings were made prior to the morning dose of the investigational medicinal 
product and once again before the evening dose. The best of 3 readings were taken 
with the 2 highest within 10 L/min of each other.  
Holmstrom and coworkers showed a highly significant correlation between PNIF 
and nasal airways resistance before and after allergen provocation testing(201). More 
recently, PNIF has been shown to correlate with nasal symptoms in patients with 
CRSwNP(202, 203). Peak nasal inspiratory flow has been shown to be more 
sensitive than acoustic rhinometry or rhinomanometry in evaluating nasal responses 
to provocation testing and correlates well with mucosal changes(204, 205). 
Furthermore it is portable, easy to perform and independent to the effects of the nasal 
cycle; the most common reason for false-positive results in nasal patency 
studies(206). Moreover, normative values have now been published for an adult 
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Caucasian population, allowing for assessment of deviation from standardised values 
and standard deviation in the subject populations(207). 
 
Nasal mucosal blood flow using Laser Doppler Flowmetry 
 
Nasal blood flow was measured using single point laser Doppler flowmetry 
(LDF)(208). Laser Doppler Flowmetry is a well-established technique for the non-
invasive evaluation of microcirculation in man(209). A custom built PF-5 needle 
probe attached to the MBF3D™ monitoring system (Moor Instruments, UK) to 
estimate mucosal blood flow(210).  
 
This probe has a right-angled tip with a red or near-infrared low power Helium-Neon 
laser light emitting diode which uses the coherent properties of laser light to monitor 
the mean velocity and density of the moving red blood cells in a unit of tissue(210). 
The light that is scattered back off moving red blood cells, undergoes Doppler shifts 
in frequencies, the amplitude of which is proportional to the velocity and density of 
red cells. The major advantage over other techniques such as 133Xenon clearance, 
hydrogen clearance or photoplethysmography is that it gives a continuous signal that 
is responsive to subtle changes in vascular fluctuation(211). In the nose, Olsson and 
coworkers have shown that up to a distance of 3.5 mm between the probe and the 
mucosa, there is no change in the output signal(212). The reproducibility using the 
coefficient of variation with laser Doppler flowmetry is purported to be around 
10%(213).  
The depth of tissue penetration varies according to the optical properties of the tissue 
e.g. 1-2 mm for the skin and up to 6 mm for the gastrointestinal tract(208). 
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Moreover, in the nasal mucosa, Laser Doppler Flowmetry tends to measure the more 
superficial mucosal blood flow as opposed to other techniques such as Xe133. 
However, since its depth of penetration is unknown in the nasal mucosa, this is not 
proved beyond doubt. For example in the skin microcirculation of the fingernail bed, 
laser Doppler flowmetry was found to reflect flow in other vessels than simply the 
superficial capillaries(214). Thus it is entirely feasible, that in the nose, which has a 
similar extensive array of arteriovenous shunts just underneath the superficial 
mucosa, laser Doppler flowmetry (LDF) measures more than just the superficial 
capillary flow i.e. also captures partly or in total, the arteriovenous shunt flow. The 
Moor® instrument model has been shown to have higher signal to noise ratio than 
the Periflux® model(208).  
In our study, the probe was positioned gently on the nasal mucosa of the inferior 
turbinate (the position marked and used at each subsequent visit) using a 2.7 mm 30° 
endoscope (Karl Storz-Endoskope; Tuttlingen, Germany). Horizontal head position 
and immobilisation was achieved with a custom-made head strap and chin-stabilizer. 
Olsson and coworkers have used a fixed skull-cap in a supine position to measure 
nasal blood flow using LDF(212). We decided to use an upright position using a 
custom built stable support system with a strap for the head as demonstrated in the 
figure. We felt this was more likely to be tolerated by patients on repeated visits and 
allowed us to visualize the nasal mucosa using the endoscope and administer 
medications easily. A further modification we made was there was a parallel holder 
for the nasal rigid endoscope along with the laser probe, which meant that we could 
always view the tip of the probe as it entered the nares. This ensures that our subjects 
felt comfortable during this procedure. A micromanipulator with an x-y-z axis 
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translator was used for fine adjustment of probe position. An average of 5 minutes of 
reading was taken after an initial stable tracing of 3 minutes was achieved.
 
!
Figure 3. Custom built table framework for laser Doppler flowmetry with PF-5 probe 1 of 2. 
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Figure 4. Custom built table framework for laser Doppler flowmetry 2 of 2. 
 
Nasal endoscopy 
 
Nasoendoscopy was performed using a 2.7 mm 30° endoscope (Karl Storz-
Endoskope; Tuttlingen, Germany) with an integrated endoscopy camera system 
(LCH 01-D, Xion Medical, Berlin, Germany) and where required, standard video 
sequences were stored on a computer. These were later independently reviewed in a 
blinded fashion as per the study protocol. Where present, nasal polyps were graded 
using the system of Lildholdt et al.(828): the degree of nasal polyps was classified in 
relation to the turbinates in four steps (0 – 3), where 0 is no polyposis, 1 is ‘mild’ 
polyposis (small polyps not reaching the upper edge of the inferior turbinate), 2 is 
‘moderate’ polyposis (medium polyps between the upper and lower edges of the 
inferior turbinate) and 3 is ‘severe’ polyposis (large polyps reaching the lower edge 
of the inferior turbinate). 
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Sensitivity testing 
 
Skin prick allergy sensitization testing was used for establishing sensitization as an 
inclusion/exclusion criteria or for characterization of atopic status. Standardized skin 
prick testing has been shown to be highly precise and reproducible and in the 
presence of a right symptomatology supports the diagnosis of allergic 
rhinosinusitis(215-217). Subjects were asked to withhold antihistamines and 
leukotriene receptor antagonists for at least 4 days prior to the test. Allergen drops 
(Bencard Testing Solutions: Welwyn Garden City, UK) were applied to the forearm; 
they were then pressed into the skin using disposable lancets. A standard protocol 
was used; the forearm was then marked using an adhesive strip of numbered tape, 
with markers 2cm apart. A positive response was defined as any wheal with a 
diameter that was 3mm greater than the negative control, at least 15 minutes after 
skin prick. A positive (histamine) control was used to exclude false negatives due to 
medication use, and a negative (excipient) control used to exclude false positives due 
to intrinsic skin hypersensitivity or diluent sensitization. Since the correlation of 
wheal measurements with allergic disease activity is poor, the test was not used in a 
quantitative manner i.e. reactions were recorded as present or absent. 
Serum total IgE levels were measured in some studies using radio-immunoassays or 
enzyme immunoassays(218). Adult total serum IgE levels above 100 to 150 KU⋅L-1 
are considered above normal, but the finding is non-specific, associated with other 
allergic, parasitic and unrelated diseases. Further cytological or histological markers 
of disease inflammation or surrogates of the allergic process may be assessed using 
mucus brushings or scrapings or even biopsies(209). More recently, there has been 
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an increased interest in serum/nasal EDN as a marker of eosinophils as the major 
effector cells (as opposed to the Th2 cells directing the process) of allergic 
inflammation(219).  
Nasal scrapings are a pain-free and well established method of collecting cells from 
the nasal mucosa for looking at inflammatory processes(220). The Rhino-Pro nasal 
curette (Arlington Scientific, Inc., Utah, USA) was used for this purpose. Patients 
remain in the seated position. Adequate lighting in the form of a head-lamp and a 
Thudicum’s nasal speculum was used to gently open the nares. Under direct 
visualisation a small scrape was taken from the middle of the inferior turbinate. 
Briefly, after scraping, the curette was immersed in a 10-ml tube containing 
phosphate-buffered saline; the fluid recovered was centrifuged at 220 g per min for 
10 min, and the pellet resuspended in PBS (2 ml). Cell suspensions were filtered to 
reduce the quantity of mucus, and cytospin slides were prepared. Samples were 
stained with Diff Quik stain and analyzed using an optic microscope. The number of 
inflammatory cells was expressed as a mean of 10 fields at 100 times magnification.  
An open cell Polyurethane Foam Sampler (28 x 18 x 6 mm) with a fluid retention 
capacity of ~2.5 ml or an IVALON® 4000 (Ivalon surgical products, San Diego, 
USA) sinus pack was placed in the nasal floor posterior to the mucocutaneous 
junction for 10 minutes as described in literature(209). The secretions were 
immediately placed on ice. Following removal, cellular elements were separated 
from the liquid phase by centrifugation at 500xg for 5 minutes at 4°C. The cell-free 
supernatants were homogenized by ultrasonification at 160 watts for 5 minutes. The 
amount of liquid is measured volumetrically. Then aliquots of 100 µL are stored at –
20°C for further processing. Nasal secretions were diluted 1:10 and cytokines 
analysed on a Bio-PlexTM Suspension Array System (Bio-Rad Laboratories, Hemel 
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Hempstead, UK) for a variety of Th1 and Th2 cytokines including IL-5, IL-8 and 
GM-CSF. We also measured IgE to Staphylococcus aureus enterotoxins (A, B, 
TSST-1), IgG (1-4 isotypes) to Aspergillus and Alternaria species with the 
fluorescence immunoassay (ImmunoCAP 250, Phadia Ltd., Milton Keynes, UK). 
Nasal polyp biopsy was taken under topical anaesthesia in the form of Lignocaine 
Hydrochloride. It is a painless procedure commonly performed in the outpatient 
clinic. Nasal tissue specimens were weighed, and 1 mL of 0.9% NaCl solution added 
for every 0.1g of tissue. The tissue was homogenized with a mechanical 
homogenizer at 1811 x g for 5 minutes on ice. After homogenization, the suspension 
was centrifuged at 3000 rpm for 10 minutes at 4°C and the supernatants separated 
and stored at –80°C until analysis(43).  
Acoustic Rhinometry 
 
Acoustic rhinometry was measured using an AI Executive acoustic rhinometer (GM 
Instruments, Ashgrove, Kilwinning, UK) according to the consensus report on 
acoustic rhinometry and Rhinomanometry issued by the Standardisation Committee 
on Objective Assessment of the Nasal Airway, I.R.S. and E.R.S.(221). A probe was 
inserted 0.5cm into each nostril to obtain a sufficient acoustic seal without distorting 
the nasal anatomy. Participants will hold their breath during the procedure and a 
probe-stand was used in order to ensure correct positioning of the probe. Correct 
environmental controlling will be done as outlined in the departmental standard 
operating procedure manual, which is in concordance with the European guidelines. 
For mucosal changes the volume 2-5cm seems to be an important variable and 
measurements were made of the minimal cross-sectional area (MCA) at the nasal 
valve (approximately 2cm from the nasal orifice) as outlined in a previous 
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study.(204) The total minimum area was taken to be sum of the measurement from 
the right and left nostrils. 
Active Anterior Rhinomanometry 
 
Anterior rhinomanometry was performed according to the consensus report on 
acoustic rhinometry and Rhinomanometry issued by the Standardisation Committee 
on Objective Assessment of the Nasal Airway, I.R.S. and E.R.S.(221). This was used 
to calculate the total nasal airways resistance using the formula 
€ 
1÷ R = (1÷ R1) + (1÷ R2) . NAR was measured at 150 Pa and tidal breathing using an 
NR6 rhinomanometer (GM instruments, Kilwinning, UK). In subjects free from 
signs of nasal disease, mean total resistance has been reported to be around 0.23 Pa 
cm-3s-1, ranging between 0.15 and 0.39 Pa cm-3s-1(222). Reproducibility of 
rhinomanometry is variable in the literature and depends on the machine, variation 
related to subject technique, and variation caused by changes in airway size and 
shape because of individual differences, and requires serial measurements to be truly 
useful. Jones and coworkers have found a high correlation between NAR, as 
measured by anterior rhinomanometry and PNIF and also subjective nasal 
congestion(202).   
Nasal Nitric Oxide 
 
Nasal nitric oxide was measured at the same time of the day using a 
chemoilluminescence analyzer (NIOXTM, Aerocrine AB, Stockholm, Sweden) under 
standard conditions using one of three techniques: First, the standard aspiration 
technique recommended by the ATS/ERS guidelines(223) using a unilateral nasal 
olive, breathholding and velum closure at a flow rate of 0.05 L.s-1; Second, single-
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breath exhalation without phonation (quiet measurement)with a tight fitting nasal 
mask at a flow rate of 0.2 L.s-1 with a sustained plateau of at least 8 seconds and 
mean values calculated as average of last 70% of exhalation(224); Third, patients 
exhaled as described above but with nasal humming for at least 6 seconds. Patients 
were trained to hum at frequencies close to a 128Hz tuning fork with the mouth 
closed and given at least 3 satisfactory trials prior to the final measurements(225). 
Three technically adequate measurements were made with each technique. Each 
humming manoeuvre was separated by 5 minutes intervals for the sinus NO to 
recover(225). Maniscalco and coworkers also validated the handheld MINO ® 
(Aerocrine AB, Stockholm, Sweden) electrochemical analyser against a more 
standard chemoilluminescence analyzer (NOA, Sievers) and demonstrated good 
agreement between the two techniques in 30 subjects (15 rhinitis and 15 healthy 
volunteers)(226). Given that the supra-velar airway can generate nitric oxide in 
several parts per million as opposed to parts per billion in the lower airways, 
measurement techniques are yet to be fully standardized and nasal NO remains a 
strictly research tool so far(223). It is yet to be fully understood how much the nasal 
mucosa contributes to the NO production vis-à-vis the paranasal sinuses. While it is 
possible that in CRS resulted impairment of the ciliated epithelium of the paranasal 
sinuses, which reduces its normal ability to express iNOS and produce NO decreases 
nNO levels, the more likely explanation is that the dominant factor in nasal NO 
measurements is the paranasal sinus NO(227, 228). What this means is that, rather 
than a measure of nasal mucosal inflammation as thought until recently, it is likely 
that nasal NO is a surrogate of the patency of the ostiomeatal complex(229). Boot 
and coworkers established the reproducibility of nNO with a coefficient of variation 
(CV) at day 1 of 16% and day 7 of 21%(209).  
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Subjective outcomes 
Total Nasal Symptoms score (4-point scale) 
The TNS-4 score is the sum of scores for nasal run, blockage, itch and sneeze, each 
measured on an ordinal scale of 0, 1, 2 or 3 representing no symptoms, mild, 
moderate or severe symptoms respectively.  This results in an integer score for 
global TNS of 0 to 12. We have published minimal important differences for this 
score previously as 0.55 units(230). 
Mini Rhinoconjunctivitis Quality of Life Questionnaire 
The Mini RQLQ(231) is a self completed, rhinoconjunctivitis specific quality of life 
questionnaire.  It has 14 items across 5 domains (activities, practical problems, nose, 
eye and other symptoms).  Each item is scored for the preceding week on a scale 
from 0 (not troubled) to 6 (extremely troubled).  The overall (and domain) scores are 
the mean of all (all domain) scores. The mini-RQLQ retains a strong association with 
the RQLQ (r=0.91), and has been shown to be more reliable (interclass correlation 
coefficient [ICC] 0.93), and responsive to change.  It also has good construct validity 
(correlation with symptoms scores, the SF-36, a feeling thermometer and standard 
gamble(232, 233)). The MID has been published for this outcome and although this 
isn’t a strictly CRS related outcome, the extensive use in the rhinitis literature and 
construct and content validity in the variety of patient populations makes it a suitable 
patient reported outcome measure. The only caveat is that olfactory outcomes must 
be assessed separately similar to the SNOT-20(234). 
 
Sino-nasal Outcomes Test – 20 
This easy to administer disease specific questionnaire was devised after modification 
of the cumbersome RSOM-31(235). Participants are asked to score a list of 20 
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symptoms and social and emotional parameters. They are also requested to indicate 
the 5 most important items on the score sheet. Thus a total score and a domainal 
score is obtained. The list include the need to blow the nose, sneezing, runny nose, 
cough, postnasal discharge, thick nasal discharge, ear fullness, dizziness, ear pain, 
facial pain/pressure, difficulty falling asleep, waking up at night, lack of a good 
night’s sleep, waking up tired, fatigue, reduced productivity, reduced concentration, 
frustrated, restless/irritable and being sad and embarrassed. The possible range is 0 to 
5, with a higher score indicating a greater rhinosinusitis-related health burden. This 
tool role is gaining increasing approval with robust psychometric and clinimetric 
reliability, validity and reasonable responsiveness(236). However, many agree that 
the omission of nasal congestion and hyposmia limits the utility of this measure and 
in the National Comparative Audit of Surgery for Nasal Polyposis and Chronic 
Rhinosinusitis conducted by the Royal College of Surgeons of England a modified 
SNOT-22 was used(142). 
 
Visual Analogue Scale Scoring 
This global score of disease severity is validated in the adult population with 
CRS(1). The disease can be divided into mild, moderate and severe based on a total 
severity scale score of 10cm as follows: mild = 0-3, moderate = 4-7 and severe = 8-
10. To evaluate the total severity, the patient is asked to indicate on a VAS the 
answer to the question: How troublesome are your symptoms of rhinosinusitis? With 
minimum and maximum anchors as ‘not troublesome at all’ and ‘worst thinkable 
troublesome’. A VAS > 5 affects the patient quality of life.  
 
Olfactory testing 
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In a multicentre study across 10 European countries Szczeklik and coworkers 
evaluated the natural history of CRS and found that up to 55% of patients had an 
impaired sense of smell(35). This is particularly important, as hyposmia constitutes a 
primary symptom of CRSwNP and has a significant impact on quality of life(1, 237, 
238). CRSwNP causes olfactory impairment due to mechanical obstruction, 
sensorineural defects secondary to mucosal inflammation and stem cell loss(239). 
When treated with topical steroids alone, improvement in the patient’s sense of smell 
often ‘lags behind’ the improvement in nasal obstruction(240), possibly due to 
limited access to the olfactory cleft. Thus assessment of olfaction is critical in the 
complete assessment of CRSwNP. As mentioned previously, validated quality of life 
tools such as SNOT-20 lack a domain for the assessment of the sense of smell(236). 
Although SNOT-22 has been designed to overcome this and used in large-scale 
cross-sectional observational studies(142), it is not validated in CRS and its 
responsiveness to treatment is unknown.  
The University of Pennsylvania Smell Identification Test (UPSIT) is a 40-item 
validated self-administered test with a test-retest reliability of 0.94(241). It has 
normative values based on over 4,000 persons. The categories of dysfunction include 
mild, moderate, severe and total. It has an inherent ability to detect malingering. 
Unfortunately, some smells are not relevant to the UK (e.g. skunk), the test is 
expensive to administer and is time consuming. Hence we chose to use a 
combination of the Pocket Smell Test® which is a 3-item, forced choice, short 
derivative of the UPSIT® to assess olfaction in our study (Sensonics, Inc. New 
Jersey, United States)(242) along with a 10-point visual analogue scale(1, 6). This 
test has been validated in neurological disorders and has been used to validate other 
short olfaction testing(243, 244). 
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Safety Outcomes 
 
There are remarkably little medium to long-term controlled data in rhinology with 
regards to systemic safety data (when compared to efficacy data) in adults. This is 
surprising, given the rampant use of highly lipophilic drugs, such as intranasal 
corticosteroids, when measuring the concentration in the water soluble plasma 
compartment is only looking at a relatively small portion of the systemically 
available drug, which has a large total volume of distribution(245). Not only will this 
underestimate the total body exposure, but also ignore the prolonged elimination 
half-life with systemic tissues acting as slow-release reservoirs. This may lead to an 
apparent discrepancy in bioavailability after a single dose and systemic bioactivity at 
steady-state. Thus studies measuring plasma concentrations after single doses for 
intranasal corticosteroids may underestimate the potential for systemic adverse 
effects in the steady state(245). Hypothalamic-pituitary-adrenal axis activity has 
been shown to be one of the most sensitive markers of systemic bioactivity(155). 
Indeed, the measurement of overnight urinary cortisol-creatinine excretion has been 
shown to be as sensitive as an integrated 24-hour plasma or urinary free cortisol 
collection and is more sensitive than a spot measurement of 8 a.m. plasma cortisol 
levels(246, 247).  
Overnight urinary cortisol: creatinine ratio 
At 22:00 hours on the night before each visit, subjects emptied their bladders and 
then collected all urine produced until 08:00 hours the following morning. Cortisol 
(Diastorin, Wokingham, UK) and creatinine (Cobas-Bio, Roche Diagnostics, Basel, 
Switzerland) were assayed and ratios calculated to determine the overnight urinary 
 68!
cortisol: creatinine ratio (OUCC), a sensitive marker of drug effects on the HPA 
axis(246). The coefficients of variation within and between assays were 9% and 
6.2% respectively, for cortisol; and 2.9% and 4.6% for creatinine. Each participant’s 
samples were processed within a single assay. The assay has no cross reactivity with 
fluticasone propionate. 
Similarly, there are no long-term controlled data in the literature evaluating markers 
of bone turnover. The bone mass at any given time of life represents a complex 
interplay of genetic loading and other risk factors such as age, ethnic origin, sex, 
body size, diet, use of alcohol and tobacco, physical activity, thyroid status, and sex 
hormone status(248). 
Chapter 3 is the first and in our knowledge the only randomized clinical trial to 
include a comprehensive safety data profile within its portfolio. 
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Chapter 3: Re-establishing 
ostiomeatal complex drainage: a 
prospective study 
 
Aims: To evaluate the effect of systemic steroid therapy 
on the sinus ostiomeatal complex in chronic 
rhinosinusitis using humming nasal nitric oxide as a 
surrogate endpoint. 
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Introduction 
Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a common chronic 
inflammatory disorder with significant morbidity, major healthcare costs and a high 
socioeconomic burden(26). The course of CRSwNP is characterized by multiple 
relapses and short courses of oral steroids are frequently used as rescue therapy to 
relieve inflammation, reduce polyp size and improve physiologic sinus drainage. A 
fundamental role in the pathogenesis and perpetuation of CRSwNP is attributed to 
blockage of the paranasal sinus outflow tracts due to inflammation and eventually 
hyperostosis. However, it is often difficult to determine clinically if systemic steroids 
improve sinus ostial patency, and if this occurs concurrently with other outcomes 
such as endoscopic polyp score, symptoms and nasal airflow. 
Nitric oxide (NO) is an important regulatory molecule and is produced in the 
respiratory tract by a variety of sources such as endothelium, epithelial cells, smooth 
muscle and inflammatory cells, with highest measured concentrations in the 
paranasal sinuses(249). NO is a sensitive non-invasive marker of inflammation and 
ciliary dysfunction and has played an increasingly important role in lower airway 
conditions such as asthma; however its niche in the diagnosis and management of the 
upper airway has not been firmly established. Moreover, in patients with CRSwNP 
despite higher levels of inflammation compared to uncomplicated allergic rhinitis, 
paradoxically low levels of nasal NO have been demonstrated due to sinus ostial 
obstruction and perhaps contributed to by mucociliary dysfunction(229). Conversely, 
following medical or surgical treatment for CRSwNP levels of nasal NO have been 
shown to increase significantly(250, 251). 
Having the patient hum at optimal frequencies with the mouth closed during 
expiration has been shown to induce a large increase in nasal nitric oxide levels, and 
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it has been proposed that this reflects rapid gas exchange between the nose and 
paranasal sinuses i.e. sinus ostial patency(252). To our knowledge, there are no 
studies in the literature evaluating the effect of systemic steroid therapy on the 
humming fraction of nasal nitric oxide in nasal polyposis. This is crucial, as NO 
measurement may fill a niche in patient management that radiography, including CT 
imaging, cannot due to cost and radiation exposure. Moreover, NO measurements 
are quick, non-invasive, harmless and can be done through portable 
chemoilluminescence analyzers(226). Additionally, humming NO as opposed to 
other methods of measuring NO may be more sensitive at detecting a treatment 
response as it may boost the signal for detection particularly in severely obstructed 
patients. 
We hypothesized that a short course of oral steroids would increase the humming 
fraction of nasal nitric oxide as compared to baseline values as a surrogate of sinus 
ostial patency. We also aimed to evaluate if the humming NO is a stronger indicator 
of this increase than other methods of measuring NO, and if it correlates to 
improvements in clinical parameters for sinonasal disease. 
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Methods 
Participants and Settings 
Non-smoking, adult patients with CRSwNP, with or without asthma and a 
nasoendoscopic polyp grade (2.7 mm 30° endoscope Karl Storz-Endoskope; 
Tuttlingen, Germany) of 2 or above as deemed by the Lildholdt grading system(253), 
and normal serum aspergillus IgE and IgG levels were included. Patients were 
excluded with known aspirin sensitivity, systemic steroid treatment during the prior 
three months, sinus surgery within 1 year, acute upper respiratory tract infection 
within 1 month, antibiotics taken within 1 month, nasal airway obstruction due to 
septal deviation >50%, pregnancy and lactation were excluded. These patients are 
seen in our joint surgical and medical rhinology clinic and are routinely treated with 
a 2-week course of oral prednisolone 25mg/day followed by intranasal 
corticosteroids as part of their routine clinical care.  In our clinic, we also regularly 
measure peak nasal inspiratory flow, quality of life and nitric oxide as part of routine 
practice, to which we added the measurement of humming NO. Institutional review 
board approval was therefore not necessary as the Tayside Committee for Medical 
Research Ethics gives standing approval as part of patients’ routine clinical care. No 
alterations were made to their regular medications.  
Measurements 
Peak nasal inspiratory flow (PNIF)(204, 205, 230), Sinonasal Outcomes Test-20 
(SNOT-20)(236), global visual analogue scale (VAS) score (answering the question 
“How troublesome are your overall symptoms of rhinosinusitis?” 0 being ‘Not 
Troublesome’ and 100 mm being ‘Worst Thinkable Troublesome’)(13), hyposmia 
VAS(6) ( 0 was ‘No Sense of Smell’ and 100 mm was ‘Excellent Sense of Smell’) 
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were measured before and after their routine treatment. Similarly, nasal nitric oxide 
was measured at the same time of the day using a chemoilluminescence analyzer 
(NIOXTM, Aerocrine AB, Stockholm, Sweden) under standard conditions using three 
techniques: First, the standard aspiration technique recommended by the ATS/ERS 
guidelines(223) using a unilateral nasal olive, breathholding and velum closure at a 
flow rate of 0.05 L.s-1; Second, single-breath exhalation without phonation (quiet 
measurement)with a tight fitting nasal mask at a flow rate of 0.2 L.s-1 with a 
sustained plateau of at least 8 seconds and mean values calculated as average of last 
70% of exhalation(224); Third, patients exhaled as described above but with nasal 
humming for at least 6 seconds. Patients were trained to hum at frequencies close to 
a 128Hz tuning fork with the mouth closed and given at least 3 satisfactory trials 
prior to the final measurements(225). Three technically adequate measurements were 
made with each technique. Each humming manoeuvre was separated by 5 minutes 
intervals for the sinus NO to recover(225).  
Statistical Analysis 
Ours was a prospective cohort study with a follow-up duration of two weeks. Each 
outcome was assessed for normality using the Shapiro-Wilk test and by visual 
inspection of histograms and Q-Q plots, with consideration of previous datasets and 
literature. Non-Gaussian data (Nitric oxide) were log-transformed prior to analysis to 
normalize the distribution. A correction for exhaled lower respiratory nitric oxide 
levels was applied by subtracting respective tidal nitric oxide levels(254). Outcome 
comparisons before and after treatment were made using paired Student’s t-tests and 
mean differences (or geometric mean fold change for logtransformed variables) with 
a significance level set at P < 0.05. Secondary analyses included area under the curve 
for exhaled and humming NO and standardized response means (SRM) for all three 
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methods of measuring NO. The area under the curve (AUC) for quietly exhaled 
nitric oxide and humming nitric oxide were calculated at time-points 0, 2, 4 and 6 
seconds from the start of exhalation using a linear trapezoidal rule. AUC 
comparisons were made pre and post-treatment and are more sensitive than average 
measurements. SRM is defined as the ratio of the mean change in scores to the 
standard deviation of the change and is a relative measure of effect size and 
responsiveness. It allows the expression of the signal of change in an outcome 
relative to its variability(255). Lastly, a correlational analysis was performed 
comparing the three methods for NO estimation with all other outcomes and Pearson 
correlation coefficient was calculated.  
All analyses were performed with SPSS version 15, Chicago, IL, USA. 
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Results 
Baseline characteristics for all patients are presented in the following table (Table 1). 
 
Table 2: Baseline characteristics. 
No. Age 
(years) 
Sex Rhinosinusitis 
Duration 
(years) 
Rhinosinusitis 
Medications 
Intranasal steroids and 
dose prior to study 
(µg) 
Asthma 
1 52 M 36 S, L BUD 256µg/day Y 
2 44 M 15 S FP 400µg/day Y 
3 64 F 29 S BDP 200µg/day Y 
4 50 M 13 S BDP 100µg/day N 
5 49 F 26 S BDP 100µg/day N 
6 69 M 27 S FP 200µg/day Y 
7 35 F 11 S, L, A 
S 
 
FP 400µg/day Y 
8 45 F 16 S BUD 128µg/day N 
9 41 M 6 S, L MF 200µg/day Y 
10 38 M 11 -  Y 
11 45 M 17 S MF 200µg/day N 
12 55 M 16 S, A MF 200µg/day Y 
Mean 
(SEM) 
49 (3)  18.5 (2.5)    
Abbreviations: ICS, inhaled corticosteroids as µg of CFC-beclometasone equivalent units; FEV1 %, 
forced expiratory volume in 1 second % of predicted value; S, intranasal corticosteroids; L, 
leukotriene modifiers; A, antihistamines; BUD, Budesonide; FP, Fluticasone propionate; BDP, 
Beclometasone dipropionate 
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Effects of oral prednisolone on all outcomes is shown in the following Table 2 and 
Figures 2, 3, and 4.  
Table 3: Outcomes pre and post oral steroid. 
Variable Pre-steroid (95% 
CI) 
Post-steroid (95% 
CI) 
Mean difference (95% 
CI, P) 
SNOT – 20 (units) 2.6 (2.1 to 3.1) 1.1 (0.7 to 1.4) 
–1.57 (–2.03 to –1.10, 
<.0001) 
Global VAS score (0-
100mm) 
64.1 (51.6 to 
76.8) 
24.9 (12.9 to 
36.9) 
–39.2 (–48.9 to –29.6, 
<.0001) 
Hyposmia VAS score(0-
100mm) 
20.4 (11.0 to 
29.8) 
67.7 (5.7 to 80.8) 
47.3 (31.3 to 63.4, 
<.0001) 
Endoscopic polyp 
grading (0-6) 
4.7 (4.0 to 5.3) 2.5 (1.5 to 3.5) 
–2.2 (–2.8 to –1.5, 
<.0001) 
PNIF (L.min-1) 
112.5 (78.1 to 
146.9) 
157.5 (132.1 to 
182.9) 
45.0 (33.3 to 56.6, 
<.0001) 
Aspiration NasalNO 
(ppb)† 
341.5 (254.2 to 
458.7) 
503.6 (376.2 to 
674.3) 
1.5 (1.1 to 1.9, 0.006)‡ 
Exhaled  NasalNO (ppb)† 11.2 (5.9 to 21.1) 
23.9 (17.1 to 
33.3) 
2.1 (1.2 to 3.9, 0.02)‡ 
Humming  NasalNO 
(ppb)† 
31.2 (15,6 to 
62.8) 
152.9 (91.7 to 
255.1) 
4.9 (2.2 to 10.7, 0.001)‡ 
Abbreviations: CI, confidence interval; SNOT, sino-nasal outcomes test; VAS, visual analogue 
scale; PNIF, peak nasal inspiratory flow rate; NO, nitric oxide. Nasal NO values shown are 
corrected for tidal NO levels and measurements were taken at a flow rate of 0.2L.s-1. 
* Data are presented as arithmetic mean (95% CI) unless otherwise indicated.  
† Geometric mean (95% CI) 
‡ Geometric mean fold ratios (95%CI). 
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Figure 5: Outcomes pre and post oral steroids. 
 
Figure 1. Scatter plots showing individual values for Sinonasal Outcomes Test 20 
(SNOT-20), visual analogue scale for hyposmia (mm), peak nasal inspiratory flow 
rate (L.min-1) and endoscopic polyp grading before and after treatment with oral 
prednisolone 25mg per day for 2 weeks in patients with nasal polyposis. Horizontal 
bars represent arithmetic means. Treatment with systemic steroid resulted in global 
improvement in all subjective and objective outcome measures. P-value corresponds 
to the results of comparing means for pre- and post-treatment for each parameter. 
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Figure 6: Nasal NO using different methods pre and post oral steroids. 
 
 
Figure 3. Scatter plots showing individual values for nasal nitric oxide measured by 
aspiration, quiet exhalation and humming exhalation before and after treatment with 
oral prednisolone 25mg per day for 2 weeks in patients with nasal polyposis. 
Horizontal bars represent geometric means. Treatment with systemic steroid resulted 
in improvement in all three outcomes with the greatest improvement by the 
humming method. P-value corresponds to the results of comparing means for pre- 
and post-treatment for each parameter.
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Figure 7: Time profile curve for exhaled and humming nasal NO pre and post oral steroids. 
 
 
Figure 4. Time-profile for quietly exhaled fraction of nasal nitric oxide (NO) and 
humming fraction of nasal NO before and after treatment with oral prednisolone 
25mg per day for 2 weeks in patients with nasal polyposis. Values denoted are 
arithmetic means and represent the total (uncorrected nasal and tidal values) exhaled 
and humming NO measured at a flow rate of 0.2L.s-1.  
* denotes significant difference (P < 0.05) between exhaled and humming fractions 
after (but not prior to) treatment with oral prednisolone 25mg per day for 2 weeks in 
patients with nasal polyposis.
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In this study, SNOT-20 scores improved at 2 weeks i.e. post-steroid as compared to 
baseline by a mean difference (95% CI, P) of 1.6 (1.1 to 2.1, <.0001) units. The 
minimal important difference is 0.8 units making this clinically significant. Global 
VAS scores and hyposmia VAS scores improved by 39.2 (29.6 to 48.9, <.0001) mm 
and 47.3 (31.3 to 63.4, <.0001) mm respectively. PNIF increased by 45 (33.3 to 
56.6, <.0001) L.min-1 and endoscopic polyp score shrunk by a median (IQR) of 2 
(1.75 to 2.25, <.0001) units. 
Nasal NO measured by aspiration, exhaled and humming techniques increased post-
treatment as compared to baseline as geometric mean fold ratio (95% CI, P): 1.5 (1.1 
to 1.9, .009), 2.1 (1.2 to 3.9, .02) and 4.9 (2.2 to 10.7, .001), respectively. 
The difference in the AUC of humming NO vs. quiet exhaled NO was mean 
difference (95% CI) 21.7 (–355.5 to 398.9) ppb.s-1 at baseline and increased to 770.2 
(393.3 to 1147) ppb.s-1 post-steroid. The standardized response means were as 
follows for the three methods: aspiration = 0.97; exhalation = 1.05 and humming= 
1.61. 
The aspiration NO technique did not correlate significantly with any outcome. Quiet 
exhalation method showed significant correlation only with PNIF (R = 0.71, P = 
0.01). Humming NO correlated significantly only with hyposmia VAS (R = 0.59, P 
= 0.04)  
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Discussion 
In the present cohort study we have shown for the first time that treatment with oral 
prednisolone in patients with nasal polyposis results in an increase in the humming 
fraction of nasal NO (Figures 6,7). We have also shown that compared to the 
aspiration and expiration without humming techniques for measuring nasal NO, 
humming accentuated the difference in NO levels between pre- and post-treatment. 
Lastly, increases in NO levels with treatment occurred concomitantly with 
improvements in an array of clinical parameters including polyp size, symptoms and 
nasal airflow. Whilst it has been shown previously that oral steroids improve nasal 
symptoms, quality of life and sinus opacification scores on imaging, their effect on 
humming NO as a surrogate of sinus ostial  patency has not been assessed(256). 
Ragab and coworkers showed that aggressive medical treatment for CRSwNP 
including initial oral steroids followed by topical steroids resulted in a significant 
increase in nasal NO over the 12 month follow-up period(144, 250). Delclaux and 
coworkers similarly showed an increase in nasal NO flux after treatment with oral 
and topical steroids and nasal washes(251). Until now, no one has evaluated 
humming NO as a surrogate of sinus ostial patency or compared it to other methods 
of NO estimation. Maniscalco and coworkers have demonstrated the absence of a 
nasal NO peak during humming in patients with CRSwNP with endoscopic findings 
suggestive of sinus ostial obstruction(257). Lundberg and coworkers have shown 
that in patients with CT scan findings of sinus ostial obstruction, there was an absent 
humming peak (vs. controls)(252). In the same paper, they claimed that humming 
NO peak levels recovered post surgery but these data were not shown. CT scans are 
considered crucial by many authors in the assessment of sinus ostial patency(6). 
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While CT may be valuable in the anatomical assessment of paranasal sinuses and 
their outflow tracts, they lack functional value in evaluating sinus ostia patency (e.g., 
an obstructed looking ostium on CT scan may be functionally patent or vice versa). 
High percentages of incidental radiologic findings are found in healthy individuals, 
normal nasal cycle may induce changes in the nasal mucosa, and radiological 
abnormalities correlate poorly with patient's symptoms and clinical outcomes(258). 
Moreover, in routine clinical practice in the UK, CT scans are not performed unless 
osseus/intracranial complications are suspected or as a staging/roadmap prior to 
surgery. Repeated CT scans cannot be justified in clinical practice due the high 
radiation risk, especially in nasal polyposis which has a remitting and relapsing 
course over many decades and may require many rescue courses of oral steroids -
mean duration of symptoms in our study was 18.5 years (150). On the other hand, 
humming nasal NO is a quick and non-invasive technique to evaluate ostiomeatal 
patency(252). Indeed, recent advances in portable hand-held electrochemical 
analyzers have made it possible for these measurements to be made even in the 
community where most patients with CRSwNP are managed(1, 226). We believe 
that humming NO and CT scans provide complementary information assessing both 
functional and anatomical aspects of the disease respectively.  
Ours is also the first study to evaluate the exhalation technique to measure nasal NO 
in medical therapy for CRSwNP. International guidelines currently recommend the 
aspiration method for measuring nasal NO(223). The nasal aspiration technique is 
advantageous with regard to velum closure and therefore not needing correction for 
tidal NO values. It is plausible that the correction for tidal NO is a factor influencing 
variability in our study. In a study by de Winter–de Groot and coworkers, the 
humming and breath holding methods showed the lowest variability and highest 
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short term and long term reproducibility with humming performing better than 
breath-holding(259). However, these findings were from studies conducted in 
healthy volunteers, patients with CRSwNP prefer exhalation technique due to the 
prolonged breath-holding with the former method, often accentuated by the fact that 
many of them have concomitant lower airway dysfunction. Moreover, we calculated 
the standardized response means (SRM) for all three nasal NO techniques as; 
aspiration method, 0.97; exhalation, 1.05 and humming, 1.61. SRMs are highly 
informative measures calculated by dividing the mean change in an outcome by the 
standard deviation of the difference, i.e. it is a measure of effect size or 
responsiveness. Because the denominator examines response variance, it provides a 
sensitive indication of ‘signal-to-noise’ ratio. It is readily apparent that humming 
nasal NO is the most responsive followed by exhalation and lastly aspiration.  
We recognize the limitations of our study. Ours was an open label study in a small 
group of selected patients without a parallel control group. However, it represents 
real patients in actual clinical situations, and the global improvement in PNIF, 
quality of life, symptoms, olfaction and polyp scores (Table 2 and Figure 6) shows 
an adequate effect size. Interestingly, humming nasal NO correlated significantly 
with improvement in smell (R = 0.59, P = 0.04) and quiet exhalation correlated with 
PNIF (R = 0.71, P = 0.01). It is likely that the small numbers in our study reduced 
the statistical power  to tease out further correlations. Even so, it is interesting that 
humming NO improves in parallel with one of the most disabling symptoms of 
CRSwNP i.e. the loss of sense of smell. Further larger controlled studies may be able 
to differentiate humming responders and non-responders and possibly see if an 
improvement in the sense of smell can be predicted based on baseline humming NO 
or change in NO after the initial oral steroid bolus. Humming NO may also be useful 
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in predicting which patients are candidates for long-term medical therapy without 
surgery. Conversely, lower humming NO could be used for early detection of relapse 
of disease or non-response to treatment. Humming NO may also be a useful 
objective investigational tool in future research trials evaluating sinusitis and allergy 
treatments in patients with CRS and may obviate the need for CT scans in some 
patients. 
In summary, we have shown that treatment of patients with CRSwNP using 
prednisolone 25mg/d for 2 weeks is associated with an increase in NO levels 
utilizing the nasal humming during expiration technique. Compared to the aspiration 
and expiration without humming techniques for measuring nasal NO, the nasal 
humming technique accentuated the difference in NO levels between pre- and post-
treatment, which implies that it is likely the most sensitive method for detecting 
improvements in sinus ostial patency. Lastly, increases in NO levels with treatment 
occurred concomitantly with decreases in nasal polyp size and symptoms (measured 
by the SNOT-20 questionnaire and the global and hyposmia visual analogue scales), 
and increases in peak nasal inspiratory flow. Further long term randomized studies 
are needed to evaluate the utility of humming nasal NO in the treatment algorithm of 
CRSwNP in the community during sequential step down from systemic to topical 
steroids, as well as postoperative improvement or relapse after endoscopic sinus 
surgery.
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Introduction 
Chronic rhinosinusitis (CRS) is a common chronic disorder in the developed world 
affecting 32 million people (16.3% of the population) in the United States and 15% 
of the European population(26). Annual healthcare costs for CRS have been 
conservatively estimated at $6 billion, though this is likely to underestimate indirect 
costs due to lost productivity, sickness absenteeism and concomitant illnesses like 
asthma(26, 30, 34). Indeed, using the SF-36 questionnaire it has been shown that 
patients with CRS report lower quality of life scores than patients with congestive 
heart failure, angina, COPD and back pain(28). CRS and asthma may represent 
different aspects of the same inflammatory disease continuum and coexist 
frequently(260). Patients with concomitant CRS and asthma are more likely to have 
unstable lower airway disease with multiple exacerbations and a more severe 
phenotype of CRS(261). While the link between CRS and asthma has been 
investigated, its putative associations with chronic cough syndrome, depression and 
even lung malignancy are less well appreciated(30-33). CRS is diagnosed and 
managed by a wide variety of practitioners, including primary care physicians, 
otolaryngologists, pulmonologists and allergologists. It is one of the most common 
reasons for presenting to primary care and accounts for 21% of all adult antibiotic 
prescriptions in the US, despite a lack of evidence for efficacy(25, 26). 
CRS with nasal polyposis (CRSwNP) is a distinct pathological subtype with 
a greater burden of symptoms and a higher relapse rate after treatment that those 
without polyposis(10). Intranasal corticosteroids are recommended as the treatment 
of choice for maintenance in CRSwNP(13). However, the typical course of the 
illness is marked by frequent relapses requiring either endoscopic sinus surgery or 
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rescue pulses of oral corticosteroids which are often referred to as ‘medical 
polypectomies’(9). We hypothesize this is partly attributable to the fact that topical 
therapies cannot effectively penetrate the ‘ostiomeatal complex’ (the outflow tract of 
the paranasal sinuses) and therefore fail to re-establish physiological sinus drainage. 
Surgical treatment temporarily relieves ostiomeatal complex blockage, but is not 
curative and serves primarily to facilitate penetration of topical steroid therapy i.e. 
establishing an access route. Moreover, with the potential for orbital and intracranial 
complications, surgery should be reserved for those who are refractory to maximal 
medical therapy(13). In our clinical experience, a short course of oral steroids, or  
‘medical polypectomy’, improves long-term efficacy of topical therapy, however, 
there are no robust data to support this. Moreover, despite the high prevalence of 
concomitant asthma and use of inhaled corticosteroids, there are no data on long-
term systemic steroid burden in these patients. 
Both surgery and medical polypectomy are thought to improve sinus drainage via the 
ostiomeatal complex allowing better access to maintenance topical 
corticosteroids(262). Indeed, long-term therapy with intranasal corticosteroids alone 
leads to a steady loss of symptom control, in particular hyposmia, which is a key 
symptom in CRS(1, 150). 
Current American and European management guidelines for CRSwNP do not 
acknowledge the need for a sequential approach encompassing induction and 
subsequent maintenance corticosteroid therapy(1, 6, 9, 30). Instead, existing 
treatment algorithms advocate the use of initial intranasal corticosteroid therapy, 
especially for primary care physicians and non-specialist practitioners, and 
recommend the use of oral corticosteroids only in refractory cases in secondary 
care(25). There is an unmet need to establish a standardised, long-term approach to 
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management, which maximises the benefits of corticosteroid therapy without undue 
adverse side effects. There are, however, no randomized clinical trials evaluating the 
medium to long-term efficacy of medical treatment regimes for CRSwNP. Little is 
known about treatment safety, in particular the effects on adrenal function and bone 
turnover in the medium to long-term. This is especially important, due to the high 
concomitant prevalence of asthma and concurrent therapy with inhaled 
corticosteroids. In addition, cellular steroid resistance has been reported in CRS; the 
illness being especially recalcitrant to therapy in patients with asthma and aspirin 
intolerance(101, 263). It is not known which local or systemic factors may predict 
response to treatment(264). Emerging evidence suggests a possible role for 
staphylococcus aureus enterotoxins (SAE)(50). These act as superantigens in the 
pathogenesis and disease modification of CRSwNP by orchestrating polyclonal IgE 
activation and stimulating eosinophil recruitment(13). These superantigens have also 
been shown to alter corticosteroid sensitivity and glucocorticoid receptor 
expression(265). There are no randomized clinical trials to examine the influence of 
systemic corticosteroids on multiclonal IgE activation induced by SAEs. 
On this basis, we conducted the first randomized clinical trial evaluating the medium 
to long-term efficacy and safety of a treatment regime consisting of initial systemic 
induction with oral prednisolone followed by sequential maintenance therapy with 
intranasal corticosteroid as drops and spray. We hypothesized that the initial 
‘medical polypectomy’ would provide greater and sustained improvement in nasal 
function, systemic inflammation and quality of life parameters in the medium to 
long-term after sequential step down to topical corticosteroids. We also evaluated a 
host of other clinical, molecular and histological factors as predictors of treatment 
response.
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Methods 
DESIGN OVERVIEW 
We conducted a parallel randomized controlled trial of oral prednisolone versus 
placebo for an initial 2 weeks, followed in both groups by 2 months of fluticasone 
nasal drops followed by fluticasone nasal spray for 4 months for the treatment of 
CRS with NP. 
SETTING AND PARTICIPANTS 
Non-smoking adults with CRS with NP, with or without asthma, were recruited from 
a single-centre specialty clinic in Tayside, Scotland, where patients were referred for 
assessment by their primary care physician. Diagnosis of CRS with NP was made by 
ENT specialists according to the European Position Paper on Rhinosinusitis and 
Nasal Polyps 2007 criteria (13) and suitability was confirmed in each case as 
follows: On nasoendoscopy, participants were required to have bilateral nasal 
polyposis of grade 2 or above using the Lildholdt grading(266) and at least two of 
the following symptoms for >12 weeks; anterior and/or posterior nasal discharge, 
nasal obstruction and decreased sense of smell. Exclusion criteria included: 
treatment with oral corticosteroid within three months, sinus surgery within one year, 
recent upper respiratory tract infection, mechanical nasal airway obstruction due to 
septal deviation >50%, pregnancy and lactation. The study had Institutional Review 
Board approval from the Tayside Committee on Medical Research Ethics. All 
participants gave written informed consent.  
RANDOMIZATION AND INTERVENTIONS  
An independent off-site clinical trials pharmacist (Pharmacy Production Unit, 
Western Infirmary, Glasgow, United Kingdom) used a computer-generated random 
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allocation sequence to randomise the trial using block randomisation with block size 
of 4. The same pharmacist masked and blinded the prednisolone 25 mg tablet and an 
identical placebo tablet to double-blind the study from the investigator and 
participants. These were administered using sealed opaque envelopes at the research 
unit. 
Following a screening visit, suitable subjects entered a two-week run-in, where 
treatment for CRS with NP was stopped. Participants were randomly allocated in a 
1: 1 ratio to receive prednisolone 25mg/day or identical placebo for 2 weeks, 
followed by fluticasone propionate nasal drops (Flixonase® nasule, Allen & 
Hanburys Ltd, Uxbridge, Middlesex, United Kingdom) 400µg twice daily for 2 
months and then fluticasone propionate nasal spray (Flixonase® nasal spray, Allen 
& Hanburys Ltd, Uxbridge, Middlesex, United Kingdom) 200µg twice daily for a 
further 4 months. From screening until the end of the study, no other rhinitis 
medications were permitted, including: antihistamines, leukotriene receptor 
antagonists, intranasal corticosteroids, and nasal decongestants. No antibiotics were 
permitted during study. 
OUTCOMES AND MEASUREMENTS 
Baseline measurements 
To characterise the upper and lower airway disease and identify potential predictive 
factors that could influence therapeutic effectiveness, the following measurements 
were made at baseline. Presence and severity of asthma was made by history, 
spirometry (MicroMedical SuperSpiro, Chatham, Maritime, Kent, United 
Kingdom)(267), body plethysmography (Jaeger MasterScreen, CareFusion, 
Basingstoke, Hampshire, United Kingdom)(268), tidal and nasal nitric oxide 
(Niox®, Aerocrine, Solna, Sweden)(223), and bronchial methacholine 
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challenge(269). Aspirin sensitivity was diagnosed by history and nasal lysine-aspirin 
challenge(102). Rhinosinusitis extent was staged by computerised tomography scans 
of the paranasal sinuses. Computed Tomography (CT) scans of the paranasal sinuses 
were scored using the modified Lund-Mackay system based on reconstructed axial 
sections(270). Atopy was evaluated by total serum immunoglobulin E (IgE), RAST 
for specific IgE to grass pollen, house dust mite, cat, dog and aspergillus and 
immunoglobulin G (IgG) to aspergillus. A polyp biopsy to determine tissue 
eosinophil count was performed. Specific IgE to serum staphylococcus aureus 
enterotoxins A, B and TSST-1 (inter-assay CV 4.3%) levels were also measured 
(UniCAP, Phadia,Uppsala, Sweden).  
Longitudinal measurements 
Primary and secondary efficacy and safety outcomes were measured at 
randomisation (baseline) and after each treatment period i.e. at 2 weeks, 10 weeks 
and 28 weeks from baseline.  
The primary outcome measure was nasoendoscopic polyp grading between 
prednisolone and placebo groups, relative to baseline. Nasoendoscopy was 
performed using a 2.7 mm 30° endoscope (Karl Storz-Endoskope; Tuttlingen, 
Germany) with an integrated endoscopy camera system (LCH 01-D, Xion Medical, 
Berlin, Germany) and standard video sequences were stored on a computer. These 
were viewed by two independent observers blinded to subject, treatment and 
sequence. Disagreements were resolved by discussion. Inter-rater reliability using a 
weighted Kappa score was 0.75 (SEM= 0.079). Secondary efficacy outcomes were: 
a 100mm visual analogue scale for hyposmia, Pocket Smell Test® (Sensonics, Inc. 
New Jersey, United States)(242), total nasal symptoms score(271), peak nasal 
inspiratory flow rate(13), Juniper mini rhinoconjunctivitis quality of life 
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questionnaire (231), Serum Eosinophil Derived Neurotoxin (intra-assay coefficient 
of variation 9.1%, inter-assay coefficient of variation 20%) and serum high-
sensitivity C-reactive Protein (HS-CRP; intra-assay coefficient of variation 8.5, 
inter-assay coefficient of variation 16%) levels were measured using commercially 
available immunoassays (Enzyme-linked immunosorbent assay, Immunodiagnostik 
AG, Bensheim, Germany; Enzyme-linked immunosorbent assay, Kalon Biological 
Ltd, Guildford, United Kingdom respectively).  
Secondary safety measures included overnight (10:00 PM to 8:00 AM) urinary free 
cortisol, overnight urinary cortisol corrected for creatinine (intra-assay and inter-
assay coefficient of variation 9% and 6.2% for cortisol, and 2.9% and 4.6% for 
creatinine with no cross sensitivity with fluticasone), 8:00 AM serum cortisol, low 
dose 1µg adrenocorticotropic hormone stimulation test and markers of bone 
turnover: serum Osteocalcin (interassay coefficient of variation 10%; 
immunoradiometric assay, Diasorin, Bracknell, United Kingdom), Procollagen-1 N-
Terminal Peptide (P1NP; intra-assay coefficient of variation 5.8%, inter-assay 
coefficient of variation 6.4%, radioimmunoassay, Orion Diagnostica Oy, Espoo, 
Finland) and Procollagen-3 N-Terminal Peptide (P3NP; intra-assay coefficient of 
variation 3%, inter-assay coefficient of variation 4.6%, radioimmunoassay, Orion 
Diagnostica Oy, Espoo, Finland). 
STATISTICAL ANALYSIS 
Analyses were performed on an intent-to-treat basis and last observation carried 
forward principle. The study was powered at > 90 % with an alpha-error of 0.05 
(two-tailed) in order to detect a 0.5 unit difference in the endoscopy polyp grading 
score between randomized treatments at two weeks, with an estimated sample size of 
30 participants in each group using a parallel design and assuming the SD to be 0.4 
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units(272). This also provided a > 90% power to detect a 6 mm improvement 
(minimal important difference) in the hyposmia visual analogue scale score. Each 
outcome was assessed for normality using the Shapiro-Wilk test and by visual 
inspection of histograms and Q-Q plots, with consideration of previous datasets and 
literature. Non-normal data were logarithmically transformed where appropriate 
except for the hyposmia VAS where a square root transformation was employed. An 
analysis of covariance (ANCOVA) was performed at each time point with subject 
and treatment as factors and adjusted for baseline value. Polyp grading was assessed 
non-parametrically. Minimal important differences (MID) were estimated for polyp 
grading as 1 unit and hyposmia VAS as 6 mm based on consensus and Cohen’s 
small change respectively(273). Participants improving by more than 1 MID in 
polyp grading or their hyposmia VAS at the end of 6 months were classed as 
‘responders’. Minimal important difference’s for mini rhinoconjunctivitis quality of 
life questionnaire  (0.7 units), PNIF (6 L.min-1) and TNSS (0.55 units) have been 
described in the literature previously, but were not used to estimate response(230, 
231). Responders and non-responders were evaluated using unpaired t-tests for all 
interval variables and Pearson’s χ2 tests for categorical data for the following 
outcomes: Oral steroid induction, age, duration of rhinitis, previous sinus surgery, 
historical and challenge based aspirin intolerance, serum IgE, systemic and tissue 
eosinophilia, presence of asthma, spirometry, body plethysmography, bronchial 
methacholine challenge, nasal and tidal nitric oxide and paranasal sinus CT scan 
scores.  
A secondary analysis was conducted using longitudinal random effects models. This 
was performed to ensure non-overestimation of treatment effects at 10 and 28 weeks. 
In the secondary analysis, for estimating overall treatment effects between groups, 
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repeated measures outcomes were analysed using random effects models. This has 
the benefit of allowing for the correlation of measurements over time and allowing 
some measurements to be missing on occasions, assuming these are missing at 
random (MAR). The effect of time was modeled with polynomials and the best fit 
obtained using Akaike’s Information Criterion (AIC).  AIC was also employed to 
assess random intercepts and random slopes in all models. All models were adjusted 
for age and sex. The outcomes were assessed for deviations from normal 
distributions and suitable transformations applied. Model-based predicted means 
were calculated by fitting treatment by time interactions and all random effects 
models were implemented in PROC MIXED in SAS (version 9.1, SAS Institute Inc., 
Cary, North Carolina, United States) and SPSS (version 15, SPSS® an IBM® 
company, Chicago, Illinois, United States). In the random effects models, time in 
terms of weeks was found to fit a cubic best (smallest AIC), along with random 
intercepts and random coefficients. Most outcomes including the primary outcome of 
polyp grading were reasonably normally distributed. Natural log transformations 
were applied to OUCC, TNSS, serum HS-CRP and serum P1NP. Finally, the best 
transformation for Mini RQLQ was the square root transformation and for serum 
P3NP was the reciprocal. The number of missing measurements varied by outcome 
with 7% missing for the main outcome which is small and unlikely to introduce 
major biases. To further interrogate each time-point and to calculate between group 
differences, an analysis of covariance was performed at each time point with subject 
and treatment as factors and baseline values as covariates. 
The results of the secondary analysis are not presented in this thesis, solely for the 
fact that the a priori analysis of choice, which this study was powered on, was the 
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ANCOVA analysis. The results of this analysis can be referred to in the published 
article.  
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Results 
!
Figure 8: Participant enrolment and outcomes. 
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PARTICIPANTS 
Of the 118 patients screened, 60 underwent randomisation and 51 completed the 
study (Figure 9). The study was conducted from January 2005 to February 2008. 3 
patients in the prednisolone group and 4 in the placebo group had received previous 
oral steroids and the mean duration prior to recruitment (range) was 14 months (6-
24) and 12 months (8-18) respectively. Similarly, 9 patients in the prednisolone and 
10 in the placebo group had oral antibiotics in the past; mean duration prior to 
recruitment (range) was 17 months (2-30) and 14 months (3-25) respectively.  
Baseline characteristics including demographics, disease duration, upper and lower 
airway inflammation, airway calibre, and indices of severity such as aspirin 
sensitivity, atopy and asthma were similar in both treatment groups (Table 3). 
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Table 4: Demographics and baseline characteristics. 
Variable 
Prednisolone Arm 
N = 30 
Placebo Arm 
N = 30 
Age — yr   
Mean 49 52 
Range 24—70 17—78 
Male — no. (%) 14 (47) 20 (67) 
Rhinosinusitis Duration — yr 11 (11) 17 (15) 
Previous Surgery — no. (%) 7 (23) 9 (30) 
Previous oral steroids — no. (%) 3 (10) 4 (13) 
Previous oral antibiotics — no. (%) 9 (30) 10 (33) 
Historical Aspirin Intolerance — no. (%) 7 (23) 6 (20) 
Nasal Lysine-Aspirin Challenge Positive — no. 
(%) 
16 (53) 15 (50) 
Atopic — no. (%) 13 (43) 16 (53) 
House Dust Mite 12 (40) 12 (50) 
Grass Pollen 5 (17) 6 (20) 
Cat 9 (30) 8 (26) 
Dog 9 (30) 7 (23) 
Aspergillus  2 (6) 3 (10) 
Serum IgE — kU.L-1† 
93.32 (58.88—147.91) 
101.71 (56.23—
177.83) 
Blood Eosinophil Count — cells x 109.L-1† 0.34 (0.27—0.42) 0.35 (0.28—0.43) 
Tissue Eosinophil Count — cells.4HPF-1† 70.79 (35.48—141.25) 41.16 (20.63—82.13) 
Aspergillus IgG — kU.L-1† 9.60 (4.70—19.60) 12.81 (9.71—16.88) 
Asthmatics — no. (%)  11 (37) 16 (53) 
BDP dose equivalent—µg‡ 400 (400—800) 700 (400—1250) 
Spirometry     
FEV1 — % of predicted value 95.6 (15.8) 93.2 (17.2) 
FEF25-75 — % of predicted value  78.7 (26.3) 75.6 (29.6) 
FEV1/FVC — %  74 (9) 83 (9) 
Specific Airways Resistance — % of predicted 
value 
97.4 (52.7) 103.3 (67.2) 
AHR — no. (%)  9 (30) 11 (37) 
Methacholine PC20 — mg.L-1† 1.20 (0.56—2.58) 1.60 (0.96—1.75) 
Exhaled NO — ppb† 28.32 (20.14—39.45) 32.35 (23.66—44.26) 
Nasal NO — ppb† 426.58 (338.84—
524.81) 
392.28 (295.12—
501.19) 
CT Scan score 25.1 (10.8) 22.5 (10.6) 
Serum IgE to S. Aureus enterotoxin A — kUA.L-1† 0.04 (0.02—0.07) 0.06 (0.03—0.10) 
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Serum IgE to S. Aureus enterotoxin B — kUA.L-1† 0.05 (0.02—0.14) 0.05 (0.03—0.10 
Serum IgE to S. Aureus enterotoxin TSST — 
kUA.L-1† 
0.26 (0.14—0.46) 0.24 (0.13—0.43) 
* Values are arithmetic means (SD) except as indicated.  
Abbreviations: IgE— immunoglobulin E; IgG — immunoglobulin G; BDP — chlorofluorocarbon 
beclomethasone dipropionate equivalent units; HPF— high power field; FEV1 — forced expiratory 
volume in 1 second; FEF25-75 — forced expiratory flow 25 -75 %; FVC — forced vital capacity; 
AHR— airway hyperresponsiveness defined by a positive methacholine bronchial challenge; PC20— 
provocative concentration of methacholine causing a 20% drop in post-diluent baseline FEV1; NO — 
nitric oxide; CT — computed tomography. Atopy refers to positive serum RAST testing for total IgE 
(>100 kU.L-1) or a positive specific IgE (> 0.35 kU.L-1). 
† Geometric mean (95% Confidence Intervals).  
‡ Dose of inhaled corticosteroid expressed as median (IQR) of chloroflurocarbon beclomethasone 
dipropionate equivalent units. 
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Table 5: Efficacy outcomes at baseline and after each treatment period. 
Variable Prednisolone Arm 
N = 30 
Placebo Arm 
N = 30 
P 
value 
Endoscopy Score (0-6)    
Baseline 4.7 (4.3—5.0) 4.8 (4.4—5.2) 0.66 
Post tablets 2.6 (2.1—3.1)§ 4.7 (4.4—5.0) <0.001 
Post nasal drops 2.2 (1.6—2.8)‡ 3.2 (2.8—3.5)† 0.002 
Post nasal spray 2.8 (2.2—3.4)† 3.3 (2.8—3.7)† 0.04 
Hyposmia VAS (0-100 mm)    
Baseline 58.64 (46.48—72.22) 53.14 (39.27—69.03) 0.59 
Post tablets 27.52 (18.37—38.53)§ 54.55 (41.29—69.64) <0.001 
Post nasal drops 27.24 (17.41—39.25)‡ 38.12 (26.31—52.10)† 0.05 
Post nasal spray 29.27 (19.84—40.53)‡ 41.33 (28.96—55.92) 0.02 
Pocket Smell Test® Score (0-3)    
Baseline 1.65 (1.10—2.21)  
1.54 (1.01—2.07) 
 0.53 
Post tablets 2.50 (2.13—2.86)‡  
1.58 (1.03—2.13) 
 0.04 
Post nasal drops 2.50 (2.13—2.86)‡  
2.04 (1.53—2.55)† 
 0.40 
Post nasal spray 2.31 (1.84—2.78)† 1.67 (1.12—2.21) 0.34 
TNSS (units)    
Baseline 3.39 (2.35—4.43) 3.26 (2.19—4.33) 0.43 
Post tablets 1.03 (0.40—1.67)§  3.22 (1.86—4.57) <0.001 
Post nasal drops 1.14 (0.69—1.59)§  
1.30 (0.69—1.91)‡ 
 0.008 
Post nasal spray 1.00 (0.58—1.41)§  1.54 (0.95—2.14)† 0.14 
Mini RQLQ (units)    
Baseline 1.62 (1.23—2.01) 2.17 (1.51—2.83) 0.75 
Post tablets 0.75 (0.33—1.16)§ 1.73 (1.21—2.24) 0.001 
Post nasal drops 0.75 (0.46—1.03)§ 0.69 (0.45—0.94)§ 0.25 
Post nasal spray 0.66 (0.45—0.87)§ 1.08 (0.72—1.44)‡ 0.12 
PNIF (L.min-1)    
Baseline 107.08 (92.96—121.20) 122.35 (85.39—159.32) 0.22 
Post tablets 146.67 (129.43—163.90)§ 132.94 (100.08—165.80) 0.003 
Post nasal drops 148.33 (131.77—164.93)§ 160.29 (125.91—194.67)‡ 0.64 
Post nasal spray 146.88 (129.00—164.75)§ 146.47 (110.34—182.59) 0.27 
Serum EDN (ng.L-1)¶    
Baseline 32.22 (25.28—38.31) 31.21 (23.26—40.50) 0.99 
Post tablets 25.28 (19.43—32.89)‡ 32.90 (25.63—42.52) 0.01 
Post nasal drops 30.48 (24.25—38.05) 29.86 (24.08—37.27) 0.91 
Post nasal spray 31.12 (18.37—37.01) 38.32 (30.48—48.50) 0.25 
Serum HS-CRP (mg.L-1)¶    
Baseline 0.77 (0.53—1.11) 1.13 (0.75—1.70) 0.10 
Post tablets 0.59 (0.46—0.78) 1.00 (0.65—1.51) 0.005 
Post nasal drops 0.96 (0.66—1.40) 1.20 (0.82—1.76) 0.16 
Post nasal spray 0.96 (0.68—1.36) 1.12 (0.77—1.64) 0.32 
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Serum IgE to S. Aureus enterotoxin 
A — kUA.L-1¶    
Baseline 0.04 (0.02—0.07) 0.06 (0.03—0.10) 0.95 
Post tablets 0.04 (0.02—0.07) 0.06 (0.03—0.10) 0.93 
Serum IgE to S. Aureus enterotoxin 
B — kUA.L-1¶    
Baseline 0.05 (0.02—0.14) 0.05 (0.03—0.10 0.39 
Post tablets 0.05 (0.02—0.13) 0.06 (0.04—0.11) 0.86 
Serum IgE to S. Aureus enterotoxin 
TSST — kUA.L-1¶    
Baseline 0.26 (0.14—0.46) 0.24 (0.13—0.43) >0.99 
Post tablets 0.25 (0.13—0.45) 0.26 (0.15—0.44) 0.86 
* Data shown are arithmetic means (95 % Confidence Intervals) except where indicated. P values are for 
between-group comparisons for each outcome measure at sequential timepoints. 
† P < 0.05 for within-participant comparisons from respective baselines. 
‡ P < 0.01 for within-participant comparisons from respective baselines. 
§ P < 0.001 for within-participant comparisons from respective baselines. 
¶ Geometric mean (95% Confidence Interval). 
Abbreviations: VAS— visual analogue scale; TNSS— total nasal symptom score; RQLQ— Juniper mini-
rhinoconjunctivitis quality of life questionnaire; EDN— eosinophil derived neurotoxin; HS-CRP— high 
sensitivity C-reactive protein; S. Aureus— Staphylococcus Aureus. 
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Figure 9: Efficacy outcomes. 
Mean values of efficacy outcomes after each stage of treatment. 
* denotes an overall significant mean difference between groups.
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Values at each timepoint and changes in primary and secondary efficacy outcomes 
are presented in Table 4 and Figure 6. The percentage of missing data for polyp 
grading for the prednisolone group was: 3% at 2 weeks, 7% at 10 weeks, 4% at 28 
weeks, and for the placebo group was: 7% at 2 weeks, 7% at 10 weeks and 4% at 28 
weeks. The mean decrease in polyp grade from baseline to 2 weeks was 2.1 units 
(SD 1.1) for the prednisone group and 0.1 units (SD 1.0) for the placebo group 
(mean difference between groups, –1.8 units (95% CI –2.4, –1.2; P < 0.001)). The 
difference between groups at 10 and 28 weeks was: –1.08 units (95% CI –1.74, –
0.42; P = 0.001) and –0.8 units (95% CI –1.8 to 0.2; 0.11). Mean decrease in 
hyposmia score from baseline to 2 weeks was 31.12 mm (SD 30.1) for the 
prednisolone group and 1.41 mm (SD 30.6) for the placebo group (mean difference 
between groups, –28.33 mm (95% CI –42.71, –13.96; P = 0.002)). The difference 
between groups at 10 and 28 weeks was: –16.06 mm (95% CI –30.99, –1.13; P = 
0.03) and –12.13 mm (95% CI –30.55, 6.29; P = 0.19). !
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Figure 10:  Safety outcomes. 
 Mean!values!of!safety!outcomes!after!each!stage!of!treatment. 
 *!denotes!an!overall!significant!mean!difference!between!groups.!
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SAFETY OUTCOMES 
Table 6: Adverse events. 
Event Prednisolone arm Placebo arm 
Epistaxis triggered by nasal spray 2 1 
Viral rhinitis 6 6 
Facial pain 1 1 
Tonsillitis 0 1 
Headache 2 1 
Flu-like symptoms 2 5 
Rash 1 1 
Conjunctivitis 1 0 
Musculoskeletal pain 4 4 
Nausea 0 1 
Asthma exacerbation 0 1 
37 participants (19 in prednisolone and 18 in the placebo group) reported an adverse event.  
No serious adverse events (SAE) were reported. An SAE was defined as one of the 
following: an event causing the death of the participant, a life-threatening event, 
hospitalization, persistent or significant disability affecting important life functions, 
congenital anomaly or birth defect in the offspring of a woman treated before or during 
pregnancy, pregnancy, and important medical events requiring urgent and intensive 
intervention to prevent one of the outcomes listed in the definition above. 
 
 
Following randomization, 1 participant withdrew because of nausea and another had 
an asthma exacerbation (‘other medical reasons’ in Figure 9). 37 participants (19 in 
prednisolone and 18 in the placebo group) reported an adverse event. Adverse events 
did not differ between groups (Table 5). There were no serious adverse events as 
defined in the protocol. Basal and dynamic adrenal function was suppressed by oral 
prednisolone but recovered after switching to nasal drops (Table 6 and Figure 11). 
Overnight urinary cortisol corrected for creatinine (OUCC) was suppressed to 50% 
of its baseline value and ACTH stimulated serum cortisol suppressed by 86% 
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following 2 weeks of oral prednisolone treatment. At 10 and 28 weeks, however, 
there was no significant residual adrenal suppression compared to baseline. Markers 
of osteoblastic activity showed a similar transient decrement during oral steroid 
therapy, with a return to baseline with subsequent topical treatment (Table 6). 
 
Table 7: Safety outcomes at baseline and after each treatment period. 
Variable Prednisolone Arm 
N = 30 
Placebo Arm 
N = 30 
P  
OUCC (nmol.mmol-1)§    
Baseline 8.07 (6.27—10.40) 8.70 (7.04—10.73) 0.93 
Post tablets 3.14 (2.47—3.97)‡ 7.62 (6.39—9.09) <0.001 
Post nasal drops 7.74 (5.79—10.37) 7.48 (5.98—9.35) 0.68 
Post nasal spray 8.51 (6.36—11.35) 8.14 (6.38—10.42) 0.83 
OUC  (nmol.10 h)    
Baseline 31.74 (22.78—40.69) 36.23 (28.13—44.34) 0.93 
Post tablets 15.26 (10.58—19.93)† 38.94 (28.56—49.33) 0.009 
Post nasal drops 27.62 (19.75—35.49) 35.51 (26.10—44.03) 0.89 
Post nasal spray 29.54 (21.60—37.48) 30.90 (22.87—38.93) 0.14 
Pre-ACTH 0800 h Serum 
Cortisol (nmol.L-1)    
Baseline 435.03 (352.34—517.73) 391.25 (334.66—447.84) 0.64 
Post tablets 184.76 (152.61—216.91)‡ 327.81 (284.53—371.08) <0.001 
Post nasal drops 387.01 (329.13—444.89) 345.46 (303.60—387.31) 0.72 
Post nasal spray 370.96 (313.86—428.06) 353.57 (308.38—398.75) 0.65 
Post-ACTH Serum Cortisol 
(nmol.L-1)    
Baseline 736.56 (645.85—827.27) 661.77 (608.67—714.87) 0.32 
Post tablets 225.83 (191.96—259.70)‡ 616.23 (584.65—647.81) <0.001 
Post nasal drops 670.01 (606.53—733.49) 590.47 (544.34—636.60) 0.10 
Post nasal spray 684.98 (627.87—742.10) 611.00 (570.71—651.30) 0.18 
Serum Cortisol increment 
(nmol.L-1)    
Baseline 289.51 (209.32—369.71) 246.26 (193.24—299.28) 0.56 
Post tablets 39.22 (26.39—52.04)‡ 273.34 (231.57—315.11) <0.001 
Post nasal drops 294.88 (249.82—339.94) 207.32 (146.28—268.36) 0.25 
Post nasal spray 309.30 (258.63—359.96) 219.06 (157.80—280.32) 0.24 
Serum Osteocalcin (nmol.L-1)    
Baseline 1.06 (0.93—1.18) 1.23 (1.04—1.42) 0.20 
Post tablets 0.72 (0.55—0.88)‡ 1.15 (0.97—1.32) 0.03 
Post nasal drops 1.03 (0.89—1.18) 1.33 (1.14—1.52) 0.29 
Post nasal spray 1.08 (0.91—1.24) 1.39 (1.11—1.68) 0.27 
Serum P1NP (µg.L-1)    
Baseline 31.13 (27.55—34.71) 36.78 (31.85—41.71) 0.19 
Post tablets 23.40 (20.70—26.09) 38.31 (33.13—43.48) 0.003 
Post nasal drops 28.40 (24.96—31.85) 39.45 (33.23—45.67) 0.12 
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Post nasal spray 30.81 (27.02—34.59) 41.39 (31.92—50.85) 0.16 
Serum P3NP (µg.L-1)    
Baseline 2.38 (2.19—2.56) 2.67 (2.38—2.96) 0.88 
Post tablets 2.18 (1.96—2.40)‡ 2.78 (2.38—3.18) 0.01 
Post nasal drops 2.42 (2.23—2.61) 2.89 (2.31—3.47) 0.25 
Post nasal spray 2.50 (2.27—2.74) 3.03 (2.47—3.59) 0.24 
* Data shown are arithmetic means (95 % Confidence Intervals) unless indicated otherwise. P values 
are for between-group comparisons for each outcome measure at sequential timepoints. 
† P < 0.05 for within-participant comparisons from respective baselines. 
‡ P < 0.01 for within-participant comparisons from respective baselines. 
§ Geometric means (95 % Confidence Intervals). 
¶ P < 0.001 for within-participant comparisons from respective baselines. 
Abbreviations: OUCC— overnight urinary cortisol creatinine ration; OUC— overnight urinary free 
cortisol; ACTH— synthetic adrenocorticotrophic hormone (Synacthen); P1NP— Procollagen-1 N-
Terminal Peptide; P3NP— Procollagen-3 N-Terminal Peptide. 
 
 
STAPHYLOCOCCUS AUREUS ENTEROTOXINS 
Circulating IgE antibodies to serum S.aureus enterotoxins A (SEA), B (SEB) and 
TSST-1 levels were detected in 53%, 53% and 68% of participants respectively. 
SEA and TSST-1 were not statistically different between groups as 0.11 kUA.L-1 (–
0.01, 0.23) and 0.52 kUA.L-1 (–1.15, 0.31) respectively. Levels of SEB were 
significantly higher in the subgroup of participants with a positive history of aspirin 
intolerance as mean difference (95%CI) 0.16 kUA.L-1 (0.01, 0.32). Enterotoxin IgE 
levels were not different between nasal lysine-aspirin challenge positive and 
negative groups. Levels of enterotoxin-specific IgE did not alter with systemic 
corticosteroid therapy (Table 4, Figure 12). 
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Figure 11: S aureus enterotoxin specific IgE pre and post oral steroids. 
 
Levels of staphylococcus aureus enterotoxin-specific IgE did not change (P> 0.05) 
with oral prednisolone. The figure above shows individual patients within the 
prednisolone arm only before and after receiving 25 mg of oral prednisolone once 
daily for 2 weeks. Symbols are individual patient arithmetic means. No significant 
mean difference was demonstrated. 
 
There were no differences in baseline predictors between responders and non-
responders at 6 months. (Table 7). Twenty five (83%) of participants in the 
prednisolone group responded to therapy as indicated by an improvement by more 
than 1 MID in either polyp grade or hyposmia visual analogue scale at the end of 28 
weeks (“responders”) as compared to 17 (57%) of participants in the placebo group.  
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Table 8: Comparisons between responders and nonresponders at 28 weeks. 
Variable Responders 
N = 42 
Non-responders 
N = 18 
P value 
Steroid induction group — no. (%) 25 (60) 5 (17) 0.03 
Age — yr 51(13) 49(13) 0.55 
Previous Surgery — no. (%) 9 (22) 7 (39) 0.16 
Rhinosinusitis Duration — yr 14(13) 17(14) 0.53 
Historical Aspirin Intolerance — no. 
(%) 10 (24) 3 (17) 0.54 
Nasal Lysine-Aspirin Challenge 
Positive — no. (%) 20 (48) 11 (61) 0.34 
Atopic — no. (%) 13 (43) 16 (53) 0.44 
Serum IgE — kU.L-1† 109.17(87.36 — 
136.5) 
70.79(54.45 — 
92.02) 0.31 
Blood Eosinophil Count — cells x 
109.L-1† 0.33(0.30 — 0.36) 0.40(0.37 — 0.43) 0.25 
Tissue Eosinophil Count — cells.4HPF-
1† 64 (41 — 102) 28 (7 — 117) 0.31 
Aspergillus IgG — kU.L-1† 11.35(9.08 — 
14.18) 9.88(6.29 — 15.51) 0.78 
Asthmatics — no. (%)  19 (45) 8 (44) 0.95 
Spirometry      
FEV1 — % of predicted value 92.9(16.9) 98.8(14.7) 0.19 
FEF25-75 — % of predicted value  73.7(27.3) 85.3(27.3) 0.14 
FEV1/FVC — % 74(6.5) 76(8.4) 0.61 
Specific Airways Resistance — % of 
predicted value 106.1(63.0) 88.6(60.9)  
AHR — no. (%)  15 (36) 5 (29) 0.64 
Methacholine PC20 — mg.L-1† 1.28(1.04 — 1.57) 1.82(1.07 — 3.09) 0.55 
Baseline CT Scan score 23 (2) 22 (3.5) 0.72 
* Values are arithmetic means (SD) except as indicated. Numbers (%) indicate number (%) treated 
in either prednisolone or placebo groups.  
Responders were participants in both groups and were defined as having more than 1 ‘minimal 
important difference’ improvement in their polyp score (1 unit) or anosmia visual analogue 
score (6 mm).   
P values represent comparisons between responders and nonresponders using unpaired Student 
t-tests for all interval variables and Pearson’s χ2 tests for categorical data. 
† Geometric mean (95% Confidence Intervals). 
Abbreviations: IgE, immunoglobulin E; HPF, high power field; FEV1 — forced expiratory 
volume in 1 second; FEF25-75 — forced expiratory flow 25 -75 %; FVC — forced vital capacity; 
AHR— airway hyperresponsiveness defined by a positive methacholine bronchial challenge; 
PC20— provocative concentration of methacholine causing a 20% drop in post-diluent baseline 
FEV1; CT — computed tomography. 
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Figure 12: Proportional change in responders and nonresponders at each stage of treatment. 
 
Change in polyp grade and hyposmia VAS score from respective baseline values in 
the prednisolone (Pred) and placebo (Pl) arms at each stage of treatment. Responders 
were defined as a change in polyp grading > 1 unit or an improvement in the 
Hyposmia VAS score of more than or equal to 6 mm. The graph demonstrates a 
significantly higher proportion of responders among participants who had received 
initial oral steroids as compared to placebo at each stage of treatment at 2, 10 and 28 
weeks i.e. after oral steroids (Pred or Pl), after nasal steroid drops (N) and nasal 
steroid spray (S), respectively. 
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Discussion 
At 6 months, patients with CRSwNP who underwent oral prednisolone induction 
showed a sustained and significantly greater improvement in nasal function, 
systemic inflammation and quality of life parameters, without compromising 
systemic safety than those with sham-induction. These benefits were not modified by 
indices of disease severity such as aspirin intolerance, atopy, duration of illness, and 
concomitant asthma.  
 
Our study demonstrates a parallel and sustained improvement in polyp size and the 
sense of smell. This unique finding was supported objectively using the Pocket 
Smell Test® which showed a similar trend within the prednisolone group, although 
it did not reach statistical significance between groups. This is particularly important, 
as nasal obstruction and hyposmia constitute the two primary symptoms of CRSwNP 
and have the most significant impact on the patient’s quality of life(1, 239). 
CRSwNP causes olfactory impairment due to mechanical obstruction, sensorineural 
defects secondary to mucosal inflammation and stem cell loss(239). When treated 
with topical steroids alone, improvement in the patient’s sense of smell often ‘lags 
behind’ the improvement in nasal obstruction(240), possibly due to limited access to 
the olfactory cleft. This disconnect between congestion and olfaction is even more 
apparent following endoscopic sinus surgery(241). Indeed, after surgical treatment, 
patients’ sense of smell has been known to worsen or in the rare instance disappear 
altogether(274). Systemic steroid induction overcomes the deficiencies of both these 
approaches. Indeed, there is evidence that oral steroids have a direct stimulatory 
effect on olfactory neurons(275). However, the sustained improvement observed in 
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this study with sequential topical corticosteroids points to a reduction in local 
mucosal inflammation and oedema as a more likely mechanism. 
 
A literature search of MEDLINE (1950 to present), EMBASE (1996 to present) and 
COCHRANE CENTRAL did not yield any randomized controlled clinical trials in 
the long-term treatment of CRSwNP. Hissaria et. al. conducted a randomized 
controlled trial evaluating the efficacy of  2 weeks of oral prednisolone in nasal 
polyposis(256). In an uncontrolled trial by Benitez et. al. 63 participants receiving 2 
weeks of oral prednisolone followed by 12 weeks of topical steroid showed overall 
symptomatic improvement, while the 21 participants in the control group received 
no treatment(276). Neither examined the importance of systemic induction on long 
term maintenance topical corticosteroid therapy with a comprehensive array of 
efficacy and safety outcomes. 
We chose a dose of 25mg/day of prednisolone for induction as it provides good 
systemic anti-inflammatory effect and is available as a single, once daily tablet. This 
regimen is frequently used in our clinical practice to aid compliance and reduce 
potential side-effects of higher doses, such as sleep disturbance. Indeed, in our study 
no adverse events attributable to oral steroids were reported. We hypothesized that 
improvement in CRS with NP would require adequate clearance of the ostiomeatal 
complex, and therefore steroid induction was followed by 2 months treatment with 
intranasal drops. Compared to nasal sprays, drops provide better deposition to the 
ostiomeatal complex with a low systemic bioavailability(154, 277). However, they 
are relatively expensive and not universally available. For this reason participants 
were maintained on intranasal spray for the remainder of the study. 
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Whist we demonstrated additional long-term efficacy with initial systemic induction, 
it is perhaps of greater importance to the clinician to know if this is a safe approach. 
Indeed, more than 50% of our patients had concomitant asthma and were on inhaled 
corticosteroids, similar to figures reported in literature(13). To our knowledge, there 
are no long-term studies evaluating the hypothalamic-pituitary-adrenal axis or bone 
turnover in CRSwNP patients from the general population. Reassuringly, we found 
no residual adrenal suppression or reduction in osteoblastic activity with our 
treatment regimen at 2 and 6 months. Whereas previous studies in healthy volunteers 
with fluticasone nasal drops and spray have shown low systemic bioavailability even 
at supranormal dosages, this cannot be generalised to patients with CRSwNP(154). 
The pan-mucosal inflammation and impaired mucociliary clearance characteristic of 
CRSwNP may influence nasal retention, corticosteroid absorption and systemic 
bioavailability, and the use of concomitant inhaled corticosteroid may add to the 
systemic steroid burden. 
 
Crucially, this paper brings into focus some of the wider issues around current 
international guidelines for the management of CRSwNP. For instance, current 
guidelines do not advocate the use of oral steroid induction as an initial approach to 
treatment(13). Indeed, in accordance with these guidelines, a patient who presents to 
a primary care physician would be treated with monotherapy with intranasal 
corticosteroids and then referred on to a specialist if there is no significant 
improvement in symptoms. As demonstrated by our study, without the initial 
induction, such patients with polyposis will have been undertreated, as the crucial 
ostiomeatal complex obstruction would not have been addressed. This study 
therefore, highlights the need to establish a more unified; evidence based approach to 
 114!
CRS therapy, and suggests that an initial induction and maintenance regime may 
more appropriate even in mild-moderate disease for long-lasting benefit and to 
reduce specialist referrals and hospital costs. 
 
Interestingly, in half of our patients we detected serum IgE to staphylococcus aureus 
enterotoxins (SAE). Ever since they were first detected in nasal polyp tissue 
homogenates, there has been growing fascination with these ‘superantigens’, in 
particular their ability to drive the persistent eosinophilic airways inflammation, 
characteristic of CRSwNP, through multiclonal IgE activation(50, 278). Similar 
findings have been reported in atopic dermatitis, asthma and COPD, suggesting a 
significant role of SAEs in eosinophilic inflammatory conditions and the unified 
airway(13). Indeed, patients with concomitant asthma or aspirin intolerance have 
higher detectable levels of these superantigens compared to CRS alone, 
corresponding to the greater burden of eosinophilic inflammation in these 
conditions(46). In the present study, we found significantly higher serum SAE levels 
in patients reporting a positive history of aspirin induced symptoms compared to 
those without a positive history. However, this was not seen in patients who had a 
positive nasal aspirin challenge. This could be due to a milder degree of aspirin 
sensitivity being detected by a positive nasal aspirin challenge as, it is well known 
that the prevalence of aspirin intolerance based on challenge testing is higher than by 
verbal history alone(93). Ours is the first randomized clinical trial to evaluate if 
systemic corticosteroid therapy influences the serum specific IgE to these 
superantigens. A lack of effect observed in our study suggests that either 
corticosteroids influence eosinophilic inflammatory pathway further downstream, or 
that disease modification by superantigens is principally a local process. Further, our 
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results also show that systemic markers of eosinophil activation (EDN) and 
inflammation (HS-CRP) were suppressed by systemic but not topical corticosteroid 
therapy. This in turn perhaps suggests that nasal drops influenced polyp reduction by 
a direct topical anti-inflammatory effect rather than any systemic effect on 
eosinophil function. 
We recognise the limitations of our study. We did not use a detailed validated 
measure of olfaction such as the 40-item University of Pennsylvania Smell 
Identification Test (UPSIT), but the decision to use a combination of a subjective 
visual analogue score and the Pocket Smell Test ® was based on subject visit length. 
It is also well-recognized that the UPSIT has some scents which are not indigeneous 
to the UK. We did not measure nasal inflammation using surrogates such as nitric 
oxide, eosinophils from repeated biopsies or cytokines obtained from nasal lavage. 
We believe that while there is a plethora of literature using these measures, their 
clinical relevance is still unclear. To this end, we used a clinically meaningful set of 
subjective, objective and quality of life efficacy outcomes. Direct assessment of the 
ostiomeatal complex using serial CT scanning would have been desirable, but does 
not reflect routine clinical practice in the UK, where the majority of nasal polyposis 
are treated in primary care and such investigations are not readily accessible. 
Moreover, this would have exposed patients to an unacceptable level of radiation, 
and would be unlikely to add much to endoscopy scoring. We used the Juniper 
rhinoconjucntivitis questionnaire as a quality of life assessment tool. This might 
seem unorthodox in the presence of other disease-specific questionnaires like the 
SNOT-20(236). However, since 50% of our patients were atopic, it was felt to be a 
comprehensive tool to evaluate quality of life.  
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Future studies should consider whether an ‘induction and maintenance’ approach 
should be considered at the point of first diagnosis of CRS with NP (e.g., as made in 
primary care) and whether it is beneficial in milder disease, where ostiomeatal 
complex obstruction is less severe. Short-term nasal decongestants may further 
improve access of intranasal corticosteroids and should be assessed in conjunction 
with prednisolone induction. Finally, large long-term studies are required to assess 
whether steroid induction can delay or reduce the need for surgical intervention and 
influence post-surgical recurrence rates. 
 
To summarise, the present study shows that oral corticosteroid induction followed by 
intranasal maintenance therapy is more effective than topical therapy alone as 
recommended by current guidelines. This can be achieved without lasting adverse 
effects of corticosteroids. This model could serve as an initial treatment approach for 
nasal polyposis in primary care. 
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Chapter 5: To evaluate if a positive 
nasal lysine-aspirin challenge 
predicts a more severe phenotype of 
chronic rhinosinusitis 
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Introduction 
Chronic rhinosinusitis with nasal polyposis (CRSwNP) is one of the commonest 
chronic respiratory disorders with significant morbidity, major healthcare costs and a 
high socioeconomic burden(26). Aspirin intolerant rhinosinusitis (AIR) is a clinical 
syndrome characterized by a combination of CRSwNP with or without asthma; and 
precipitation of asthma and rhinitis attacks after ingestion of aspirin and most of the 
nonsteroidal anti-inflammatory drugs (NSAIDs)(100). Around 5 to 8% of patients 
with CRSwNP give a history of aspirin intolerance and almost invariably have 
associated asthma; this trio of disorders is often referred to as 'aspirin triad' or 
'Samter's triad'(95, 186, 279). Aspirin intolerant patients have a greater burden of 
illness, worse quality of life and experience frequent disease recurrences(1, 280). 
Their illness is recalcitrant to medical and surgical treatment and they are often 
highly steroid dependant and steroid unresponsive(9, 99, 281). Establishing a 
diagnosis of aspirin intolerance is important as it provides the patient with a host of 
common drugs that must be avoided, diagnoses a particularly severe and recalcitrant 
form of disease phenotype, and allows a choice of specific therapy such as 
leukotriene modifiers or aspirin desensitisation(282). Interestingly, studies including 
a recent meta-analysis have shown that the prevalence of aspirin intolerance may be 
as high as 21% when diagnosed with aspirin provocation testing as compared to 3 - 
11% with a history of intolerance(93, 102).  The 2007 EAACI/GA2LEN guidelines 
consequently recommend greater use of aspirin provocation testing in routine 
clinical practice, in order to prevent under-diagnosis(102). It is, however, unclear 
what the indication for such testing is and to our knowledge clinicians do not 
routinely test for aspirin sensitivity and as such it remains a predominantly research 
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tool. Indeed, in a small group of nasal polyposis with (n=15) and without asthma 
(n=17) but without a history of aspirin intolerance, Killen and co-workers failed to 
show a significant prevalence of a positive bronchial aspirin challenge(283). There 
are no data in the literature on whether a positive aspirin challenge test is indicative 
of a more severe phenotype of CRSwNP in those without symptoms, making the 
clinical significance of conducting such a test in asymptomatic individuals dubious. 
We evaluated a cohort of patients with CRSwNP with and without asthma for aspirin 
intolerance using nasal lysine-aspirin provocation tests in accordance with current 
guidelines(102). We also evaluated a host of upper and lower airway parameters, 
quality of life and systemic bioactivity to establish factors associated with aspirin 
intolerance. 
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Methods 
Participants and Settings 
Non-smoking, adult patients with CRSwNP, with or without asthma attending our 
research group for screening were invited to participate. CRSwNP was diagnosed 
based on current criteria as having at least two of the following symptoms for more 
than 12 weeks – anterior and/or posterior nasal discharge, nasal obstruction, 
decreased sense of smell and presence of bilateral nasal polyposis of grade 2 or 
above using the Lildholdt grading(266). Asthma was defined as those with known 
asthma as diagnosed by primary or secondary care physicians and on treatment. 
Aspirin intolerance was diagnosed in those with a documented reaction or a history 
of ingestion of aspirin or non-steroidal anti-inflammatory drugs followed by a typical 
reaction. Patients who were treated with oral corticosteroid within three months, 
sinus surgery within one year, recent upper respiratory tract infection within 1 
month, recent antibiotic course within 1 month, mechanical nasal airway obstruction 
due to septal deviation >50%, pregnancy and lactation were excluded. The Tayside 
Committee for Medical Research Ethics gave full approval and all participants gave 
written informed consent. No alterations were made to their regular medications.  
Measurements 
At screening, inclusion status was determined, medical history was taken and an ear 
nose and throat examination was carried out. Atopic status was established and 
defined as having a positive skin prick test to a panel of common aeroallergens 
and/or a serum IgE level of > 100 kU.L-1 The nasal lysine-aspirin challenge was 
conducted as described previously in the literature(102, 284-286). In brief, patients 
were challenged with 25 mg of lysine-aspirin (L-ASA, Aspisol; Bayer PLC, 
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Newbury, England) with direct endoscopic visualization on each inferior turbinate, 
in a seated position and their head tilted back. PNIF and the total nasal volume (cm3) 
using an acoustic rhinometer (A1 Executive; GM Instruments Ltd, Kilwinning, 
Scotland), at 10-minute intervals, for 120 minutes after challenge. Prior to this, at 
baseline nasal symptoms, inspiratory flows and nasal volumes are recorded during 
the first 30 min at 10-min intervals. Then the nasal challenge with 0.9% NaCl (80 µl) 
instilled into each nostril under direct endoscopic visualization for assessment of 
nonspecific nasal hyperreactivity. Nasal symptoms, inspiratory flow and nasal 
volumes are measured over the following 30 min at 10- min intervals. If a change 
over 20% in the recorded values occurs then the upper airway was considered 
hyperreactive and further challenge could not take place. A positive nasal L-ASA 
test was defined as a 25% reduction in total nasal volume measured by acoustic 
rhinometry or a 40% reduction in PNIF as recommended in guidelines(102). 
In order to characterise the upper and lower airway disease and to identify potential 
predictive factors associated with a positive challenge the following measurements 
were made at baseline. For the upper airway, endoscopic polyp grading using 
Lildholdt grading(253), Peak nasal inspiratory flow (PNIF)(205, 230, 287), total 
nasal symptoms score(271), Pocket Smell Test® (Sensonics, Inc. New Jersey, 
USA)(242), Juniper mini rhinoconjunctivitis quality of life questionnaire (Mini 
RQLQ)(231) and nasal nitric oxide (Niox®, Aerocrine)(223) were measured. For the 
lower airway , presence and severity of asthma was made by history, spirometry 
(MicroMedical SuperSpiro)(267), body plethysmography (Jaeger)(288), tidal nitric 
oxide (Niox®, Aerocrine)(223), and bronchial methacholine challenge(269). 
Rhinosinusitis extent was staged by CT scans of the paranasal sinuses which were 
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scored using the modified Lund-Mackay system based on reconstructed axial 
sections(6).  
For purposes of comparison, four groups were defined as CRSwNP with and without 
asthma with a positive or negative nasal L-ASA challenge test.  
Statistical Analysis 
Each outcome was assessed for normality using the Shapiro-Wilk test and by visual 
inspection of histograms and Q-Q plots, with consideration of previous datasets and 
literature. Nongaussian data were log-transformed prior to analysis to normalize the 
distribution. Groups were compared using an overall analysis of variance with 
Bonferroni correction for multiple pairwise comparisons and a two-tailed 
significance set at p<0.05. We also conducted a multiple regression analysis using 
the baseline outcomes as predictors and the area under the curve of the total nasal 
volume curve for the 2 hours after the L-ASA challenge as the outcome variable. A 
multiple regression model was constructed using predictor variables shown to be 
significantly associated with a history of aspirin sensitivity on an initial univariate 
analysis or deemed of importance a priori from the literature or biological 
plausibility. The resultant model consisted of: age, sex, duration of rhinitis, polyp 
score, Mini RQLQ, Pocket Smell Test® score, history of aspirin intolerance and 
tidal NO. Residuals were tested for normality to ensure assumptions for the models 
had been met. Statistical analyses were performed using SPSS version 17.0 
(Chicago, Illinois, USA).  
 
 123!
Results 
Baseline demographics are presented in Table 8. N = 75 
 
Table 9: Baseline characteristics. 
Variable Value 
Demographics  
Age, years – mean (range) 51 (34 – 75) 
Sex, males – No. (%) 39 (52) 
Duration of rhinosinusitis – years 15 (2) 
Previous surgery – No. (%) 22 (29%) 
Atopy – No. (%) 29 (39%) 
Asthma – No. (%) 39 (52) 
Methacholine responders– No. (%) 20 (27) 
Baseline nasal outcomes  
CT score—units  22.8 (1.7) 
Polyp score—units 4.5 (0.2) 
Peak nasal inspiratory flow—L/min 114.9 (6.3) 
Total nasal symptoms score—units 3.3 (0.3) 
Mini RQLQ—units 1.87 (0.14) 
Pocket Smell Test®—units 1.6 (0.1) 
Nasal NO—ppb* 389.04 (1.07) 
Baseline lower airway outcomes  
Exhaled  NO—ppb* 30.47 (1.09) 
FEV1—% predicted 94.7 (2.1) 
FEF25-75—% predicted 75.4 (3.2) 
sReff— % predicted 100.0 (7.5) 
Methacholine PC20—mg/ml 8.94 (1.22) 
Serum IgE—kU/L* 97.49 (1.20) 
Eosinophil count—cells/uL* 0.35 (1.07) 
Data are presented as arithmetic mean (SEM) except where indicated. 
* Geometric mean (SEM) 
Abbreviations: CRSwNP, chronic rhinosinusitis with nasal polyposis; L-ASA, lysine-aspirin nasal 
challenge test; CT, computed tomography; RQLQ, rhinoconjunctivitis quality of life questionnaire; 
NO, nitric oxide; FEV1,  FEV1 %, forced expiratory volume in 1 second % of predicted value; FEF25-
75,  FEF25-75, forced expiratory flow between 25% and 75% % of predicted value; sREFF, specific 
airways resistance % of predicted value; PC20,  provocative concentrations of methacholine required 
to produce a 20% drop in FEV1. 
A positive nasal L-ASA test was defined as a 25% decrease in total nasal volume using acoustic 
rhinometry. 
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75 participants (39 males) with a mean age (range) 51 (34-75) years completed the 
study. There were no allergic reactions or other serious adverse events during the 
course of the study.  
23 (31%) participants gave a history of aspirin intolerance and 38 (51%) had a 
positive nasal L-ASA challenge according to acoustic rhinometry criteria and 30 
(40%) with PNIF criteria. Test sensitivity was 48%, specificity was 52%, positive 
predictive value was 29% and negative predictive value was 68%.  
Using the EACCI/GA2LEN 2007 criteria there was no difference in various 
baseline, upper and lower airway outcomes in patients with CRSwNP (with and 
without asthma) when comparing a history of aspirin tolerance versus intolerance.
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Similarly there was no difference in the phenotypic characteristics of patients with or 
without a positive aspirin tolerance test (Table 9). 
Table 10: Outcome comparison between groups. 
 
 CRSwNP CRSwNP with asthma  
Variable L-ASA positive 
L-ASA 
negative 
L-ASA 
positive 
L-ASA 
negative P  
No. 20 19 19 17  
Age—years 53±2 
 
51±4 
 
54±4 
 
49±4 
 
.44 
Duration of 
rhinosinusitis—years 18±4 12±3 19±3 17±3 .45 
Previous surgery—No.(%) 5 (25.7) 5 (26.3) 6 (31.6) 6 (35.3) .92 
CT score—units 18.5±3.0 24.9±2.5 27.3±4.1 22.5±6.8 .47 
Polyp score—units 4.3±0.4 4.5±0.3 4.9±0.3 4.5±0.4 .56 
Peak nasal inspiratory 
flow—L/min 140.6±13.7 94.7±8.8 114.1±12.6 109.1±12.8 .78 
Total nasal volume—cm3* 33.8 (1.34) 45.39 (1.17) 22.39 (1.18) 41.69 (1.25) .09 
Total nasal symptoms 
score—units 
3.4±0.5 4.1±0.7 2.7±0.5 2.9±0.6 .82 
Mini RQLQ—units 1.96±0.26 1.99±0.28 1.57±0.28 2.00±0.36 .32 
Pocket Smell Test®—units 2.1±0.3 1.4±0.3 1.5±0.3 1.3±0.3 .70 
Exhaled  NO—ppb* 32.26 (1.16) 27.41 (1.21) 30.68 (1.27) 32.15 (1.22) .87 
Nasal NO—ppb* 387.25 (1.13) 400.19 (1.16) 389.10 (1.18) 402.22 (1.19) .88 
FEV1—% predicted 104.3±3.2 98.8±3.3 82.4±4.2 86.8±3.0 .37 
FEF25-75—% predicted 90.9±5.8 86.3±5.7 60.2±5.2 61.9±5.8 .83 
sReff— % predicted 73.6±7.2 81.4±5.2 139.5±35.9 126.9±12.9 .57 
Methacholine PC20—
mg/ml 
32.0 (1.0) 24.5 (1.2) 2.9 (1.6) 1.9 (1.4) .37 
Serum IgE—kU/L* 86.31 (1.32) 69.72 (1.58) 142.55 (1.48) 133.11 (1.36) .91 
Eosinophil count—
cells/uL* 
0.31 (1.14) 0.31 (1.19) 0.35 (1.09) 0.44 (1.09) .38 
Plus-minus are arithmetic mean±SEM.  
* Geometric mean (SEM). 
Abbreviations: CRSwNP, chronic rhinosinusitis with nasal polyposis; L-ASA, lysine-aspirin nasal challenge 
test; CT, computed tomography; RQLQ, rhinoconjunctivitis quality of life questionnaire; NO, nitric oxide; 
FEV1,  FEV1 %, forced expiratory volume in 1 second % of predicted value; FEF25-75,  FEF25-75, forced 
expiratory flow between 25% and 75% % of predicted value; sREFF, specific airways resistance % of 
predicted value; PC20,  provocative concentrations of methacholine required to produce a 20% drop in FEV1. 
A positive nasal L-ASA test was defined as a 25% decrease in total nasal volume using acoustic rhinometry. 
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Univariate analyses demonstrated a moderate association between aspirin challenge 
AUC and duration of rhinitis (R=.35, P=.01), FEV1% (R=.30, P=.04) and FEF25-75% 
(R=.30, P=.03). In univariate analysis, Mini RQLQ, smell test score, history of 
aspirin intolerance, FENO and sex approached statistical significance (P<.1 and >.05). 
These variables were therefore included with duration of rhinitis, FEV1%, FEF25-75% 
and age in the regression model. In the multivariate regression analysis, after 
correction for other variables FEF25-75% (P=.004), history of aspirin intolerance 
(P=.013) and duration of rhinitis (P<.001) were the only independent predictors of 
aspirin challenge AUC (R=.59 for the model). 
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Discussion 
We aimed to characterize the phenotype of a cohort of adult patients with CRSwNP 
with or without asthma undergoing a nasal lysine-aspirin (L-ASA) challenge. In the 
present study, we have shown that patients with CRSwNP and a positive nasal L-
ASA challenge do not have significantly more severe disease as compared to their 
test negative counterparts. We have also shown that a prolonged duration of disease 
and a history of aspirin intolerance highly correlate with a positive nasal L-ASA 
challenge test.  
The EACCI/GA2LEN 2007 guidelines specify cut-off points for defining a positive 
nasal L-ASA test(102). When we evaluated patients with these criteria, they did not 
differ significantly in nasal, lower airway or quality of life outcomes (Table 9). 
Indeed, the positive predictive value of this test in our cohort was only 29%. This 
indicates that using a cut-off point to define aspirin sensitivity may be a blunt 
instrument, especially when applied to a mixed population with regards to a history 
of aspirin intolerance. It has been suggested that history alone may overdiagnose 
aspirin sensitivity due to confounding factors and that ‘subclinical’ aspirin 
intolerance does not exist, thus explaining the need for formalised testing to diagnose 
this condition(283, 289). In our study, out of 52 patients without a history of aspirin 
intolerance, 27 had a positive test (52%). This is at odds with the findings of Killen 
and coworkers where apparently only 4 out of 32 patients with CRSwNP (with or 
without asthma) had a positive L-ASA test in the absence of historical aspirin 
intolerance(283). On closer evaluation, it is seen that the authors did not confirm the 
presence or grade of nasal polyps with endoscopy at initial selection. Moreover, they 
performed bronchial L-ASA testing; it may be that nasal response to aspirin precedes 
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the lower airways response. It is also possible that in our group, with an endoscopic 
confirmation of nasal polyps, a tighter diagnosis of asthma (including methacholine 
challenge and symptoms) and a history of surgery in 29% of patients, we had a 
cohort with greater disease severity. Our prevalence of aspirin sensitivity with 
clinical history and nasal L-ASA test is generally in agreement with the 
literature(95). Thus, in our population there were many patients with a positive L-
ASA test without overt symptoms or without severe CRSwNP bringing into focus 
the possible lack of clinical correlation of this test. 
 
Our multivariate regression analysis demonstrated that FEF25-75, history of aspirin 
intolerance and duration of rhinosinusitis were the only significant predictors of 
response to nasal L-ASA. FEF25-75 is a well-known predictor of small airways 
disease in patients with rhinitis and may be an early marker of lower airway 
dysfunction(290). Both FEV1 and FEF25-75 have been seen to fall at 4-year follow-up 
in treatment-resistant CRSwNP whereas treatment-responsive patients remained 
stable (291). The role of FEF25-75 in CRSwNP and AIR remains to be defined. It is 
well known that AIR does not occur randomly in CRSwNP and asthma. It is 
believed that the onset of AIR starts in early life, progressing through the stages of 
rhinitis and finally attaining full clinical expression in the fourth decade of life(35). 
Perhaps, longitudinal community-based studies could investigate the role of FEF25-75 
in patients who subsequently develop AIR, similar to allergic rhinitis. That the 
duration of rhinosinusitis symptoms and a history of aspirin sensitivity correlate with 
a nasal L-ASA challenge is unsurprising, given the pathogenesis of the disease. This 
is similar to the findings of Hope and colleagues where they demonstrated an 
increased frequency of more severe reactions to oral aspirin in patients with a history 
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of aspirin sensitivity and reduced lung function(292). It is well known that aspirin 
intolerance is a significant predictor of severe recalcitrant disease and is associated 
with greater exacerbations and poorer response to treatment than aspirin tolerant 
patients(35, 99). 
 
Current guidelines recommend greater use of aspirin challenge testing in the 
diagnosis of AIR, but fail to mention which population these tests are to be applied. 
Killen and coworkers suggested that in the absence of a positive clinical history, L-
ASA challenge testing was not likely to be positive(283). Our results would also not 
support the use of nasal L-ASA challenge test with single cut-off points as a 
screening tool in patients with rhinosinusitis as a whole. This is so, because it is 
unclear what the clinical significance of a positive test in patients without a history 
of clear reactions to aspirin or NSAIDs is, as clearly this test fails to select out a 
more severe phenotype of CRSwNP with/without asthma. It is to be borne in mind 
that ours is a single snapshot view, and that such patients may over time go on to 
develop severe symptoms and exacerbations. In the absence of prospective, 
longitudinal data, we accept that one cannot rule out the yield or usefulness of this 
test. Perhaps, in well-selected patients who have severe symptoms, long duration of 
illness, with a verbal history of aspirin intolerance, and associated spirometric 
abnormalities this test yield may go up.  Further, at present there is a paucity of 
randomized placebo controlled studies looking at definitive treatment options like 
aspirin desensitization(9, 102). It is difficult at present to recommend a test without a 
clear treatment protocol to follow a positive test, especially if patients are 
asymptomatic.  
We haven’t performed oral aspirin challenge tests in our patients.  
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Milewski et al.(293) and Alonso-Llamazares et al.(294) found that the specificity of 
nasal challenge with lysine- aspirin reached 95.7% and 92.5% respectively, whereas 
its sensitivity was 86.7% and 80%, respectively. The predictive value of a negative 
result of l-ASA nasal challenge was 78.6% and 89.2%, respectively. More recently, 
Gonzalez-Perez et al. showed sensitivity, 87%; specificity, 100%; positive predictive 
value, 100%; negative predictive value, 86%(286). These show that nasal L-ASA 
tests have comparable test characteristics to oral aspirin challenge testing. Moreover, 
they are safer with regard to the likelihood of allergic and anaphylactic 
reactions(102).  
In our experience of treating patients with chronic rhinosinusitis and asthma for over 
a decade, we have most commonly seen clinicians rely on a history of aspirin 
sensitivity rather than offer a provocation test it in a general group of CRS patients. 
While this may be said to underdiagnose patients with ‘aspirin sensitivity’ in that 
there are likely to be undiagnosed patients who may have a positive challenge test, 
routine testing in an unselected group of patients with CRS may be of very low 
yield. Moreover, the significance of a positive test in an individual with mild-
moderate CRS (our cohort) is unclear, i.e. would such patients benefit from 
desensitization?  
Our study was not designed to look at the test characteristics of nasal aspirin 
provocation testing vis-à-vis oral provocation testing. Instead, we studied an 
unselected cohort of patients with CRS with and without asthma to see if a positive 
nasal aspirin test would predict a more severe disease phenotype. We believe that 
our patients reflect a large majority of CRS in terms of disease severity, and we wish 
to question the wisdom of routine aspirin sensitivity testing as proposed by the 2007 
EACCI/GA2LEN guidelines(102). 
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In summary, we showed in a cohort of CRSwNP with and without asthma that a 
positive nasal aspirin challenge test does not predict a more severe disease 
phenotype. Factors associated with a positive nasal aspirin challenge include a 
history of aspirin intolerance, duration of rhinitis and FEF25-75.  
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Chapter 6: To optimise and extend 
the duration of use of nasal 
sympathomimetic decongestants by 
evaluating tachyphylaxis of 
response to nasal oxymetazoline 
and its reversal by fluticasone 
Study Aims – Using a double-blind randomized placebo-controlled 
crossover design to 
1. Establish if tachyphylaxis and rebound congestion occurs after use 
of oxymetazoline nasal spray. 
2. Demonstrate if reversal of effect can be achieved by intranasal 
fluticasone propionate. 
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3. Dissect out the relative α1-/α2-adrenoceptor components of 
tachyphylaxis using the α1-antagonist prazosin. 
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Introduction 
Alpha-adrenoceptor agonists, in particular, imidazoline derivatives like 
oxymetazoline are the most efficacious medications available for the acute relief of 
nasal congestion in chronic rhinosinusitis(2). It is held that prolonged use is heralded 
by a reduction in efficacy (tachyphylaxis), as well as a rebound increase in nasal 
airway congestion and non-specific nasal hyper-reactivity, which have been 
combined under the umbrella term of ‘rhinitis medicamentosa’(118). The in vitro 
regulation of adrenoceptors by agonists has been extensively studied and is 
characterized by a combination of rapid internalization and uncoupling, with delayed 
degradation and sub-sensitivity(111). However, the clinical onset of tachyphylaxis 
and rebound congestion in patients remains controversial. A randomized double 
blind controlled trial by Morris et al showed an increase in baseline nasal airway 
resistance after 3 days of treatment with oxymetazoline in healthy volunteers(295). 
A series of clinical trials by Graf et al have shown that 4 weeks of treatment with 
oxymetazoline causes nasal congestion and hyper-reactivity, an effect aggravated by 
the preservative benzalkonium chloride(296-298). Conversely, in a randomized 
clinical trial in healthy volunteers, Watanabe et al did not demonstrate any change in 
subjective or objective outcomes after 4 weeks of oxymetazoline(299). The onset, 
mechanism and modulation of alpha-adrenoceptor tolerance in the nose are poorly 
understood. Despite an absence of definitive evidence, international guidelines 
restrict the use of topical decongestants in rhinitis to less than 10 days, limiting their 
potential role as a treatment(2).  
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While various studies have investigated the putative role of intranasal corticosteroids 
in the treatment of decongestant overuse, it is difficult to establish true efficacy due 
to underlying pre-existing rhinitis(118). For example, in a randomized clinical trial 
by Ferguson et al, 20 treatment naïve subjects with perennial allergic rhinitis were 
randomized to receive budesonide nasal spray or placebo after 2 weeks of 
oxymetazoline nasal spray(300). Unsurprisingly, participants receiving budesonide 
experienced greater symptomatic relief than those on placebo. Crucially, the onset of 
tolerance was not demonstrated and one could only conclude that corticosteroids 
were beneficial in treating allergic rhinitis. In contrast, beta-adrenoceptor tolerance 
with prolonged agonist use has been comprehensively investigated in the lower 
airways(301). We have previously demonstrated that systemic corticosteroid 
treatment acutely reverses formoterol induced bronchodilator sub-sensitivity and 
beta-adrenoceptor down-regulation in asthmatics within 1 hour of administration 
(138).  
 
Lastly, in an in vitro study it has been suggested that nasal decongestion occurs 
mainly at the deep venous sinusoids via α2-adrenoceptor(116). On the other hand, 
intense arteriolar vasoconstriction at the α1-adrenoceptors has been implicated for 
side effects such as rebound congestion, purportedly due to mucosal ischemia(302). 
Thus, it is theorized that a selective α2-agonist (which is not presently available) 
may have an improved safety profile(116, 303).  
 
We have dissected out α1-/α2-adrenoceptor mediated components of tachyphylaxis 
and associated rebound congestion with oxymetazoline (a mixed α1-/α2-agonist), by 
using the selective α1-antagonist prazosin. We have also evaluated if reversal of 
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tachyphylaxis and associated rebound congestion occurs with the concomitant use of 
an intranasal corticosteroid as fluticasone propionate. We used peak nasal inspiratory 
flow and nasal airway resistance to measure nasal airway congestion (as surrogates 
of venous sinusoidal filling) and mucosal laser Doppler flowmetry as a measure of 
superficial arteriolar flow. 
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Methods 
The Tayside committee for medical research ethics gave institutional approval to the 
study protocol before commencement of the trial, and written informed consent was 
obtained from each participant. All authors had full access to the data and 
manuscript content and contributed to the data analysis. The trial was registered on 
www.clinicaltrials.gov, identifier number NCT00487032.  
 
PARTICIPANTS 
Using our research volunteer database, we recruited healthy adults, none of whom 
were smokers. Inclusion criteria were: male or female healthy volunteers, aged 18 to 
65 years, without nasal or ocular symptoms suggestive of rhinitis or rhinosinusitis as 
per the 2008 ARIA(2) and 2007 EPOS(13) guidelines respectively, negative skin 
prick test to common aeroallergens, normal ECG, normal blood pressure with no 
postural hypotension, peak nasal inspiratory flow rate (PNIF) > 100L.min–1 (best 
effort of three), and PNIF reversibility with oxymetazoline 0.05% w/v 2 squirts in 
each nostril (20 min reading) > 20L.min–1. Exclusion criteria were: a history of 
sympathomimetic decongestants or alpha blockers in the previous 6 months, recent 
or concomitant upper respiratory tract infection, mechanical nasal airway obstruction 
due to septal deviation greater than 50% at nasoendoscopy, pregnancy, lactation or 
any medical condition or screening blood result likely to compromise participant 
safety.  
 
STUDY DESIGN 
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In this randomized, double-blind, placebo-controlled, cross-over design study, 
participants attended the research unit 6 times between July 2008 and July 2009, in 
Dundee, Scotland (Figure 10). Following a 1 week run-in, participants received 
oxymetazoline hydrochloride nasal spray (0.05% w/v) 2 squirts in each nostril (200 
µg) 3 times daily (on waking up, after lunchtime and before going to bed) for 14 
days. For the next 3 days, in addition to this dose of oxymetazoline, participants 
were given fluticasone propionate nasal spray, 2 squirts in each nostril (200µg) twice 
daily for a further 3 days, making the total length of each treatment period 17 days. 
At each visit, after the baseline efficacy and safety measurements were taken, a 
single dose of prazosin hydrochloride 1mg or matching placebo was administered 
orally with participants in a supine position. For each treatment period, prazosin (a 
selective α1-antagonist) or placebo was administered in a randomised assignment 
order i.e. participants were given prazosin for the first 3 visits followed by placebo 
or vice versa. A week’s washout separated each treatment period.  
 
MEASUREMENTS 
At screening, inclusion and exclusion status was determined as per above. All 
participants were issued with a PNIF and symptom diary. Each visit started between 
8 am and 9 am and measurements were taken at a room temperature of 21–23ºC and 
at constant relative humidity after a 20 minute acclimatization period. No caffeine 
containing drinks were permitted in the preceding 2 hours and alcohol for 24 hours. 
At the first treatment visit, baselines values for all primary and secondary efficacy, 
and safety outcomes were established. PNIF (primary outcome), and total nasal 
airway resistance (NAR) with active anterior rhinomanometry were used as 
measures of nasal airways patency. The PNIF measurements were taken as the best 
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of 3 measures from an In-check flow meter (Clement Clarke International Ltd, 
Harlow, England). Technique was evaluated to ensure a seated posture, horizontal 
positioning of the meter, correct restoration of the reading to zero, a closed mouth, 
and an adequate mask seal while making a maximal nasal inspiration. NAR using 
active anterior rhinomanometry was measured at 150 Pa using an NR6 
rhinomanometer (GM instruments, Kilwinning, UK) according to the 
recommendations of the Standardisation Committee on Objective Assessment of the 
Nasal Airway, I.R.S. and E.R.S.(221) In order to reflect the adrenoceptor status on 
the arterioles, single point laser Doppler flowmetry (LDF) was employed using a 
custom built PF-5 needle probe attached to the MBF3D™ monitoring system (Moor 
Instruments, UK) to estimate mucosal blood flow(210). The probe was positioned on 
the nasal mucosa of the inferior turbinate (the position marked and used at each 
subsequent visit) using a 2.7 mm 30° endoscope (Karl Storz-Endoskope; Tuttlingen, 
Germany). Horizontal head position and immobilisation was achieved with a 
custom-made head strap and chin-stabilizer. A micromanipulator with an x-y-z axis 
translator was used for fine adjustment of probe position. An average of 3 minutes of 
reading was taken after an initial stable tracing was achieved.  
 
2 hours after the administration of prazosin or placebo, a dose-response curve was 
constructed using doubling doses (sum of both nostrils) of oxymetazoline of 25µg, 
50µg, 100µg and 200µg at 20 minute intervals. PNIF was measured at baseline and 
after each successive dose. As safety outcomes, lying/standing blood pressure (BP) 
and heart rate was measured at half-hourly intervals for the first two hours and 
hourly thereafter until either 4 hours had elapsed or no postural drop in blood 
pressure (or reflex tachycardia) was recorded, whichever came first. Index finger-tip 
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blood flow using the laser Doppler flowmeter was measured at baseline and 2 hours 
after prazosin or placebo as an estimate of systemic alpha blockade(304). 
 
Participants were sent home with instructions to use the oxymetazoline at the 
abovementioned doses and canister weights were measured at each visit to assess 
compliance. They also recorded domiciliary PNIF and a nasal blockage score on a 
scale of 0-3 before the evening dose to assess any rebound nasal congestion at 
trough. Participants withheld their previous night’s oxymetazoline prior to their visit. 
 
RANDOMIZATION AND BLINDING 
An independent off-site clinical trials pharmacist (Pharmacy Production Unit, 
Western Infirmary, Glasgow, UK) used a computer-generated random allocation 
sequence to randomize the trial. The same pharmacist masked and blinded the 
prazosin 1mg tablet and an identical placebo tablet to double-blind the study from 
the investigator and participants. These were administered using sealed opaque 
envelopes at the research unit.  
 
STATISTICAL ANALYSIS 
The study was powered at > 80 % with an alpha-error of 0.05 (two-tailed) in order to 
detect a 10L.min–1 difference in PNIF between randomised treatments, with an 
estimated sample size of 16 participants assuming the within-subject SD to be 9.2 
L.min–1 (205). This was considered adequate to demonstrate tolerance to 
oxymetazoline i.e. change in PNIF within each subject, considering previous 
literature(298, 305). Each outcome was assessed for normality using the Shapiro-
Wilk test and by visual inspection of histograms and Q-Q plots, with consideration 
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of previous datasets and literature. Non-normal data were logarithmically 
transformed. An overall analysis of variance was performed with subject, treatment 
and sequence as cofactors followed by Bonferroni-corrected pair-wise comparisons 
with a 2-tailed α-error set at 0.05. The dose-response curves was analyzed using a 
two-way ANOVA factoring in time in addition to the above mentioned factors, in 
order to obviate multiple comparisons at several time points. All analyses were 
performed on a per-protocol basis using SPSS version 17, Chicago, IL, USA. 
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Results 
PARTICIPANTS 
Of the 33 patients screened, 25 underwent randomization to a treatment group. 6 
participants were withdrawn: 3 could not complete for personal reasons, 1 withdrew 
after an episode of vasovagal syncope prior to administration of prazosin, 2 because 
of non-compliance with the requirements of the protocol. 12 female and 7 male 
participants with a mean (range) age of 33 (21-55) years completed per protocol. 
There were no serious adverse events. 2 participants had dizziness on standing up 
after taking prazosin, but this resolved spontaneously.  
 
 
!
Figure 13: Study design. 
 
V0 is screening visit, V1-V6 are study visits. Abbreviations: OXY is 
oxymetazoline 200µg TDS from Day 1 till Day 17; DRC is 
Oxymetazoline dose response curve estimation (25µg, 50µg, 100µg, 
200µg) 2 hours after administration of oral prazosin or placebo; FP refers 
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to Fluticasone aqueous nasal spray started as add-on to OXY from Day 
14 till Day 17.              
 
 
BASELINES 
For all outcomes, there were no significant differences between the first and second 
baseline visits in sequence after run-in and washout, respectively; or between the 
baselines prior to each respective treatment arm, irrespective of sequence. 
 
Table 11: Comparisons of baselines. 
 Baselines according to sequence Baselines according to treatment 
 Baseline 1 Baseline 2  Baseline 1 Baseline 2  
 Mean (95% CI) Mean (95% CI) P Mean (95% CI) Mean (95% CI) P 
PNIF 
(L.min–1) 
185.3 
(166.4,204.1) 
190.0 
(168.5,211.4) .74 
194.7 
(173.7,215.7) 
180.5 
(161.7,199.3) .32 
NAR 
(Pa.s.cm–
3) 
0.31 (0.25,0.36) 0.25 (0.21,0.29) .08 0.29 (0.25,0.33) 0.25 (0.20,0.30) .26 
LDF 
(units) 
287.0 
(255.1,319.0) 
299.0 
(259.5,338.5) .64 
298.2 
(262.6,333.9) 
288.4 
(252.0,329.8) .70 
Abbreviations: PNIF, Peak Nasal Inspiratory Flow Rate; NAR, Nasal Airway Resistance; LDF, 
Laser Doppler Flowmetry; CI, Confidence Intervals 
*Data are arithmetic mean (95% Confidence Intervals) 
 
Thus outcomes prior to oxymetazoline dose-response challenge were therefore 
pooled for the purpose of subsequent analyses. 
 
CHANGE IN NASAL AIRWAY PATENCY WITH CHRONIC DOSING 
The effects of chronic dosing with oxymetazoline on PNIF and NAR are shown in 
Figure 15.  
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Figure 14: Outcomes before and after chronic dosing with oxymetazoline. 
 
 Effect of oxymetazoline on peak nasal inspiratory flow rate (PNIF), 
nasal airway inspiratory resistance (NAR) and laser Doppler mucosal 
blood flow (LDF), and reversal with fluticasone. Symbols represent 
individual patients and pooled values for both treatment periods. 
Horizontal bars represent arithmetic means. Measurements were 
taken at baseline (Day 1), after oxymetazoline 200µg tid (Day 14), 
and addition of fluticasone 200µg bid for 3 days (Day17).  
 
 
Visit-based PNIF decreased at Day 14 compared to Day 1 as mean difference (95% 
CI, P): – 47.9 L.min-1(–63.92 to –31.87, P < .001). NAR increased by 0.05 Pa.s.cm-3 
(0.004 to 0.11, P = .12).  
 
CHANGE IN NASAL MUCOSAL BLOOD FLOW WITH CHRONIC 
DOSING 
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The effect of chronic oxymetazoline dosing on nasal mucosal blood flow as 
measured by laser Doppler flowmetry is shown in Figure 16. Nasal blood flow 
increased by 65.4 units (10.7 to 120.1, P = 0.01) on Day 14 compared to Day 1.  
 
EFFECT OF PRAZOSIN ON OUTCOMES 
Effect of 1mg oral prazosin and placebo on PNIF, NAR, nasal blood flow and 
fingertip blood flow (positive control) is shown in Figure 16, Figure 17 and Table 
11.  
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Figure 15: Effect of prazosin and placebo at baseline, post oxymetazoline, and post fluticasone. 
 
Effect of 1mg oral prazosin (Panel A) and placebo (Panel B) on peak nasal 
inspiratory flow rate (PNIF) at baseline (Day 1), after oxymetazoline 200µg tid (Day 
14) and after the addition of fluticasone 200µg bid for 3 days (Day17). 
Measurements were made before and 2 hours after prazosin was administered. 
Horizontal bars are arithmetic means. Effect of prazosin on PNIF (Day1) due to 
alpha-1 adrenoceptor blockade is masked due to down-regulation after chronic 
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dosing of oxymetazoline (Day14). Fluticasone up-regulates the alpha-1 
adrenoceptors and ‘restores’ the congestive effect of prazosin (Day17). 
 
!
Figure 16: Effect of prazosin on nasal and skin blood flow. !
Effect of 1 mg oral prazosin on nasal mucosal blood flow (Panel A) and fingertip 
blood flow (Panel B) at baseline (Day 1), after oxymetazoline 200µg tid (Day 14) 
and addition of fluticasone 200µg bid for 3 days (Day17). Measurements were made 
before and 2 hours after prazosin was administered. Horizontal bars represent 
arithmetic means. Prazosin had no significant effect on nasal blood flow but 
increased fingertip blood flow (positive control). 
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T
able 12: E
ffect of prazosin and placebo on nasal patency and m
ucosal blood flow
. 
V
ariable 
Prazosin 
Placebo 
 
Pre 
Post 
P 
Pre 
Post 
P 
PN
IF (L.m
in
-1) 
 
 
 
 
 
 
D
ay1 
194.7(172.8–216.7) 
142.1(121.9–162.3) 
<.001 
180.5(160.9–200.2) 
165.8(145.1–186.4) 
.28 
D
ay14 
137.4(120.4–154.4) 
129.5(110.8–148.1) 
.51 
142.1(126.2-158.0) 
143.2(127.9–159.4) 
.88 
D
ay17 
186.8(159.1–214.6) 
138.4(113.9–162.9) 
.009 
182.6(160.1–205.2) 
173.7(152.5–194.9) 
.55 
N
A
R
 (Pa.s.cm
-3) 
 
 
 
 
 
 
D
ay1 
0.25(0.20–0.30) 
0.35(0.28–0.43) 
.03 
0.29(0.25–0.33) 
0.38(0.25–0.51) 
.17 
D
ay14 
0.32(0.23–0.40) 
0.52(0.36–0.69) 
.03 
0.33(0.26–0.40) 
0.32(0.25–0.38) 
.79 
D
ay17 
0.26(0.22–0.29) 
0.60(0.28–0.92) 
.03 
0.26(0.22–0.29) 
0.27(0.25–0.31) 
.61 
N
asal blood flow
 (units) 
 
 
 
 
 
 
D
ay1 
288.4(250.4–326.4) 
325.3(276.2–374.5) 
.23 
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OXYMETAZOLINE DOSE RESPONSE  
The oxymetazoline DRC before and after chronic dosing with oxymetazoline 200µg 
tid, and after the addition of intranasal fluticasone is shown in Figure 18.  
!
Figure 17: Oxymetazoline dose response curves at baseline, post chronic oxymetazoline dosing 
and post fluticasone. 
 
Oxymetazoline dose-response curves (DRC) for peak nasal inspiratory flow at 
baseline (Day 1), after oxymetazoline 200µg tid (Day 14) and addition of fluticasone 
200µg bid for 3 days (Day17). Symbols represent mean and SEM. * represents a 
significant (P < .05) difference between baseline (Day 1) and chronic dosing (Day 
14) with oxymetazoline. 
The DRC (as absolute PNIF values) after either administration of placebo or 
prazosin showed dose-dependent increases in PNIF, and a plateau in response was 
not attained at the end of the dose range, at t = 80 min. There was a downward 
parallel shift of the PNIF DRC after chronic oxymetazoline dosing, after placebo 
(24.8 L.min-1; 20.3 to 29.3, P < .001) and prazosin (12.0 L.min-1; 1.1 to 22.9, P < 
.05).  
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EFFECTS OF INTRANASAL STEROID   
As depicted in Figure 16, at Day 17 compared to Day 1, administration of intranasal 
fluticasone reversed the reduction in PNIF (–2.9 L.min-1; –18.9 to 13.1) and increase 
in NAR (–0.01 Pa.s.cm-3; – 0.06 to 0.05) to baseline levels, but did not influence 
nasal mucosal blood flow (60.2 units;–5.5 to –114.9). There was significant reversal 
of  PNIF DRC tachyphylaxis on Day 17 (Figure 18), evidenced by an upward and 
parallel shift of the curve as compared to Day 14 after placebo (26.2 L.min-1; 21.7 to 
30.7, P < .001) and prazosin (19.3 L.min-1; 8.4 to 30.2, P < .01).  
 
DOMICILIARY MEASURES 
There was a significant increase in the mean nasal blockage score on Day 14 vs. 
Day1 (0.45 units; 0.10 to 0.79), with a non-significant reduction after fluticasone on 
Day 17 vs. Day 14 (–0.29 units; –0.64 to 0.06). Evening PNIF decreased non-
significantly at Day 14 vs. Day 1 (– 7.4 L.min-1; –40.1 to 25.4), but increase 
significantly after fluticasone on Day 17 vs. Day 14 (36.6 L.min-1; 3.9 to 69.3).  
 
CARDIOVASCULAR OUTCOMES  
The mean standing blood pressure fell (P < .05) after the administration of prazosin 
with a peak fall at t = 120 minutes (see Figure 19). The mean heart rate increased 
after prazosin to a peak rise at t = 90 minutes (see Figure 20). The time profile curve 
for standing mean arterial pressure and standing heart rate was significantly different 
for prazosin compared to placebo as mean difference (95% CI): – 3.2 mmHg (– 6.4 
to –0.1) and 11 bpm ( 5 to 18). 
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Figure 18: Time-profile curve for mean arterial pressure after prazosin 1mg vs. placebo. 
 
Supine and standing mean arterial pressure time profile before (t = 0) and after 1mg 
of prazosin or placebo. Symbols denote mean pooled values for all visits. * denotes a 
significant mean difference (P<.05) between the prazosin and placebo arms. 
!
Figure 19: Time-profile curve for heart rate after prazosin 1mg vs. placebo. 
 
Serial heart rate measurements before (t = 0) and after 1mg oral prazosin or placebo. 
Symbols denote mean pooled values for all visits. * denotes a significant mean 
difference (P<.05) between the prazosin and placebo arms.   
Discussion 
The results of the present study demonstrate that tachyphylaxis of response to 
oxymetazoline and rebound nasal congestion occurs after 14 days of treatment. The 
relative α1/α2 components to sub-sensitivity were ascertained from the nasal patency 
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measures and oxymetazoline dose response curve pre- and post-prazosin. We also 
demonstrated for the first time, reversal of tachyphylaxis with intranasal 
corticosteroid. Our data suggest that the nasal congestive response is predominantly 
mediated by α1-adrenoceptors. 
 
We chose to conduct the present study in healthy subjects to obviate any 
confounding nasal congestion due to pre-existing allergic or non-allergic nasal 
disease. We hypothesized that decongestant sub-sensitivity was primarily due to 
receptor down-regulation, and could be demonstrated on healthy nasal mucosa. We 
used oxymetazoline at its maximum recommended dose of 200µg tid to ensure 
maximal occupancy of nasal adrenoceptors and withholding the previous night’s 
dose was adequate to washout the drug(306). The doses of oxymetazoline used to 
construct the DRC were estimated from previous pilot studies (unpublished) 
conducted by our department and from literature which showed that they would 
represent the steep portion of the curve for PNIF(307). The dosing intervals were 
selected so as to ensure maximal decongestion at each dose within time constraints 
of the overall DRC(306). Finally, we constructed the DRC 2 hours after prazosin or 
placebo to reflect time of peak prazosin plasma concentration and peak alpha1 
receptor blockade(304, 308).  
 
We demonstrated a statistically and clinically significant reduction in PNIF (Figure 
15), but not in NAR, after 14 days of oxymetazoline with a mean reduction of 47 
L.min-1 (7 times the minimal important difference)(271). This rebound congestion is 
most likely a result of receptor down-regulation and uncoupling, indirectly 
influencing the basal sympathetic tone of the mucosal sinusoids i.e. by decreasing 
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sensitivity to endogenous circulating catecholamines at trough(309). We also 
showed tachyphylaxis to the decongestant response by a downward parallel shift of 
the PNIF DRC after 14 days of oxymetazoline (Figure 18). These findings are in 
keeping with the majority of literature in alpha-agonist use in healthy 
volunteers(209). We believe that the lack of effect using rhinomanometry can be 
explained by its high within-subject variability as compared to PNIF and that it is a 
measure probably more suited to short-term intra-individual measurements, such as 
in a nasal challenge(205). We also ensured a priori that our participants were on the 
top of the learning curve for PNIF by sending them away with a PNIF diary prior to 
randomization.  
 
We were able to estimate the differential effects of oxymetazoline and receptor 
tolerance on the α1- and α2-adrenoceptors by using prazosin, a selective α1-
antagonist(113). A single dose of prazosin reduced mean PNIF by 50 L.min-1 and 
shifted the decongestive dose-response to the right (Figure 15 and Figure 18). Our 
study is the first clinical trial to document the acute congestive effect of prazosin 
objectively, a phenomenon that has only been anecdotally observed for the last 4 
decades, since the inception of its use. 
 
Oxymetazoline, a noradrenaline analogue is a mixed alpha-adrenoceptor agonist 
with predominant action at the α2 adrenoceptor and an α2: α1 potency ratio of 
5:1(113). Under resting conditions (absence of ligand), endogenous circulating 
catecholamines act on nasal α-adrenoceptors and keep the deep venous sinusoids 
under a state of dynamic venous contraction, which manifests as a decongested 
nose(110). Under the influence of a ligand like chronic oxymetazoline, rapid 
 153!
receptor internalization followed by uncoupling occurs(309) and the sinusoids 
‘dilate’ leading to congestion (decrease in PNIF). Likewise, in the current study, 
chronic dosing with oxymetazoline resulted in tachyphylaxis at the deep venous 
sinusoidal adrenoceptors, an effect manifested by a reduction in PNIF on Day 14 
(Figure 15). Moreover, the congestive effect of a single dose of the α1-antagonist 
prazosin seen on Day 1 is lost on Day 14 (Figure 16).  This suggests that the 
predominant adrenoceptor in the venous sinusoids is α1 and also that tachyphylaxis 
occurs predominantly at the α1-adrenoceptor. This seeming paradox, whereby 
despite using a predominant α2-agonist, the tachyphylaxis is observed at the α1-
adrenoreceptor, can only be explained if the predominant functioning receptor 
subtype in the sinusoids is α1. This also indicates that the resting sympathetic tone in 
the deep venous sinusoids is predominantly α1 mediated. This is in keeping with the 
findings of Ichimura et al, who found that while the human nasal mucosa has both 
post-junctional α1 and α2 adrenoceptors, the α1 mediated contractile response was 
larger(119). This contrasts with the ex vivo findings of Corboz et al and highlights 
the pitfalls of making conclusions about functionality using tissue isolates(116). It is 
important to note that we showed tolerance at the α2 receptor as well, with the 
downward parallel shift of the PNIF DRC post-prazosin (Figure 18).  
 
In our study, prazosin had no effect (P = .23) on nasal mucosal blood flow as 
measured by laser Doppler flowmetry (Figure 17). This is in contrast to the effect of 
prazosin on fingertip blood flow, where it caused a significant increase. It has been 
previously shown that fingertip blood flow is tightly regulated by α1-
adrenoceptors(304). It is also known that the predominant adrenoceptor type in the 
nasal arterioles and pre-capillary sphincter is α1(116, 117). Moreover, chronic 
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oxymetazoline dosing resulted in an increased mucosal blood flow (Figure 10). 
Laser Doppler flowmetry of the nasal mucosa is thought to measure blood flow in 
the superficial capillary bed, arterioles and the copious arterio-venous shunts(210). 
One plausible hypothesis is that the blood flow measured by laser Doppler 
flowmetry may be primarily α2 mediated, and that the increase with chronic 
oxymetazoline is due to tachyphylaxis. Another likely explanation could be that 
mucosal blood flow might be at a near maximum and hence was not influenced by 
prazosin. Indeed, the magnitude of nasal blood flow is almost 3 times as compared to 
fingertip blood flow (Figure 17), which also has numerous arterio-venous shunts. 
This disconnect between the superficial mucosal blood flow and the deep venous 
sinusoidal response to prazosin, could exist to keep the nasal mucosa perfused 
despite fluctuations in nasal blood volume occurring many times a day as part of the 
nasal cycle.  
 
 
A noteworthy fact is that the effect of chronic oxymetazoline dosing and acute 
prazosin dosing on the baseline PNIF (Figures 15,16) and the PNIF DRC (Figure 18) 
was similar. The PNIF DRC demonstrated a downward parallel shift, rather than a 
downward and rightward shift after chronic oxymetazoline dosing. To establish a 
rightward shift, an increase in ED50 would have to be demonstrated. We did not 
calculate the ED50 in this study, as we could not be certain we had established the 
maximal response to oxymetazoline. We used oxymetazoline at clinically 
recommended doses and measured the maximum elicitable response in PNIF at such 
doses. As such, whether this ‘maximum’ represents the maximal response to the 
ligand cannot be determined as the doses of oxymetazoline needed to establish this 
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would be outwith the recommendations of the British National Formulary guidelines 
and ethically challenging. Moreover, PNIF demonstrates a ceiling effect(310), in that 
it tends to plateau off despite continued increase in nasal airway patency, as it is 
limited by factors such as effort and baseline pulmonary function. However, the 
observed reduction in the maximal elicitable response at clinically recommended 
dosages is consistent with receptor internalization and G-protein-α-adrenoceptor 
uncoupling at the molecular level. A depletion of the receptor reserve would lead to 
a reduction of the maximum response rather than a rightward shift(311).  
 
Intranasal corticosteroid as fluticasone at the maximum recommended dose of 200ug 
bid was highly effective in reversing the rebound congestion and PNIF increased 
back to baseline levels. Additionally, receptor sub-sensitivity was reversed as 
evidenced by the upward parallel shift in the PNIF DRC (Figure 16 and Figure 18). 
However, we could not demonstrate an effect of corticosteroid on mucosal blood 
flow. This may indicate that corticosteroids might reverse tolerance at the α1- but not 
α2-adrenoceptors, in the short term at least. Data on nasal α-adrenoceptor regulation 
is conspicuously absent in the rhinology literature. Likewise, while there is some 
data on α-adrenoceptor downregulation under the influence of agonists in vitro and 
in vivo, the regulatory mechanisms underpinning receptor expression and up-
regulation, evaluation of the heterologous influences through interaction with other 
receptors, and subtype or tissue specific regulation are yet to be fully 
elucidated(309). Data from β-adrenoceptors suggests that corticosteroids acting 
through glucocorticoid response elements, restore G-protein-β2-adrenoceptor 
coupling, increasing cell surface receptor numbers and inhibit and reverse β2-
adrenoceptor downregulation(312). 
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Inspite of the many similarities between the structure and behaviour of α and β-
adrenoceptors under agonist influence, an extrapolation of the mechanisms of 
regulation from one to the other may be too simplistic(313). Nonetheless, it may be 
hypothesized that corticosteroids influence α-adrenoceptors in a similar fashion to β-
adrenoceptors through the restoration of receptor numbers and reversal of G-protein-
α-adrenoceptor uncoupling. Such a mechanism would explain the upward parallel 
shift of the PNIF DRC after treatment with fluticasone. 
In conclusion, the present study shows that oxymetazoline induced tachyphylaxis of 
response and associated rebound congestion is reversed by fluticasone. 
Tachyphylaxis occurs predominantly at the α1 receptor type with chronic 
oxymetazoline dosing with a smaller α2 component. Further studies are now 
indicated to evaluate the role of nasal blood flow as an outcome measure in CRS. 
Research studies would also be welcome in assessing if combination nasal sprays of 
decongestant and corticosteroid are an effective strategy to obviate tachyphylaxis 
and rebound congestion in patients with chronic rhinosinusitis. 
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Chapter 7: Comparative evaluation 
of nasal blood flow and airflow in 
the decongestant response to 
oxymetazoline 
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Introduction 
Nasal blood flow plays a crucial role in many physiological processes such as 
filtering and conditioning inspired air, counter-current mechanisms in the control of 
body temperature, nasal cycle, and in various pathological disease processes such as 
nasal congestion, mucosal hyperaemia and inflammation in rhinosinusitis or possibly 
in nasal septal ischaemia and perforation(108, 314). The microvasculature of the 
nose is unique in the human body in that it has multiple components. It consists of 
copious superficial fenestrated capillaries that have nutritive functions and help with 
water evaporation, a system of capacitance venous sinusoids with erectile properties 
that mediate nasal congestion, and lastly numerous arteriovenous shunts, which are 
probably involved in the warming of inspired air rapidly and in temperature 
regulation(108, 314). The anatomic structure of these vascular beds in humans is 
poorly understood, as are the regulatory mechanisms that exert differential influence 
neurologically or via mediators. We have demonstrated in a previously published 
study!that there is a disconnect between the regulatory mechanisms of venous 
capacitance vessels and the more superficial blood flow measured by laser Doppler 
flowmetry(315). We showed that the predominant adrenoceptor type in the venous 
sinusoids was α-1, the stimulation of which changed the nasal luminal volume and 
consequently nasal airflow, whilst the blood vessels interrogated by laser Doppler 
flowmetry was likely α-2. To our knowledge, there is only one study in the literature 
from 1989 that has evaluated nasal blood flow and its relationship with 
rhinomanometry in response to a topical decongestant and did not find a significant 
correlation(316).!This is unsurprising as the superficial and deep vascular systems 
are linked in parallel not in series and have differential regulation and functions, 
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possibly to preserve mucosal flow during varying levels of nasal congestion(108, 
109, 315). What has not been evaluated in the literature is a broad comparative 
evaluation of nasal blood flow, airflow and subjective outcomes.  
We conducted a study to measure parameters of nasal airway patency, nasal blood 
flow and subjective and objective measures of decongestion using dose response 
curves, and assessed their reproducibility and responsiveness to decongestion. 
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Methods 
PARTICIPANTS 
Using our research volunteer database in Tayside, Scotland, we recruited healthy 
adults, none of whom were smokers. Inclusion criteria were: male or female healthy 
volunteers, aged 18 to 65 years, without nasal or ocular symptoms suggestive of 
rhinitis or nasal polyposis as per the 2008 ARIA(2) and 2007 EPOS!guidelines 
respectively(1), negative skin prick test to common aeroallergens, peak nasal 
inspiratory flow rate (PNIF) > 100 L.min–1 (best effort of three), and PNIF 
responsiveness to oxymetazoline 0.05% w/v 2 squirts in each nostril (20 min 
reading) > 20 L.min–1. Exclusion criteria were: use of any nasal or oral decongestant, 
recent or concomitant upper respiratory tract infection, mechanical nasal airway 
obstruction due to septal deviation greater than 50% at nasoendoscopy, pregnancy, 
lactation or any medical condition or screening blood result likely to compromise 
participant safety. The Tayside committee for medical research ethics gave 
institutional approval to the study and written informed consent was obtained from 
each participant.  
 
STUDY DESIGN 
All authors had full access to the data and manuscript content and contributed to the 
data analysis.  The data for this study were obtained from the screening for a clinical 
trial, which has been registered in accordance with ICMJE standards at 
ClinicalTrials.gov (NCT 00487032). 
Ours was a prospective observational study in which participants attended the 
research unit twice at least 48 hours apart. The initial visit determined the inclusion 
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and exclusion status. A medical history was taken and ear nose and throat 
examination was carried out. Routine blood tests (full blood count, urea and 
electrolytes and liver function tests), rigid nasal endoscopy (2.7 mm, 30° Karl Storz-
Endoskope; Tuttlingen, Germany) and skin prick testing were performed.  
MEASUREMENTS 
Each visit started between 8 am and 9 am and measurements were taken at a room 
temperature of 21–23ºC and at constant relative humidity after a 20-minute 
acclimatization period. No caffeine containing drinks were permitted the morning of 
the visit and no alcohol for 24 hours. Nasal blood flow was measured using single 
point laser Doppler flowmetry (LDF) with a custom built PF-5 needle probe attached 
to the MBF3D™ monitoring system (Moor Instruments, UK).!The probe was 
positioned gently on the nasal mucosa of the inferior turbinate (the position marked 
and used at each subsequent visit) using a 2.7 mm 30° endoscope (Karl Storz-
Endoskope; Tuttlingen, Germany). Horizontal head position and immobilisation was 
achieved with a custom-made head strap and chin-stabilizer. A micromanipulator 
with an x-y-z axis translator was used for fine adjustment of probe position. An 
average of 5 minutes of reading was taken after an initial stable tracing of 3 minutes 
was achieved.  PNIF and the total nasal airway resistance (NAR) with active anterior 
rhinomanometry were used as measures of nasal airways patency. The PNIF 
measurements were taken as the best of 3 measures from an In-check flow meter 
(Clement Clarke International Ltd, Harlow, England). Technique was evaluated to 
ensure a seated posture, horizontal positioning of the meter, correct restoration of the 
reading to zero, a closed mouth, and an adequate mask seal while making a maximal 
nasal inspiration. NAR using active anterior rhinomanometry was measured at 150 
Pa using an NR6 rhinomanometer (GM instruments, Kilwinning, UK) according to 
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the recommendations of the Standardisation Committee on Objective Assessment of 
the Nasal Airway, I.R.S. and E.R.S.(221) 
Following the baseline measurements, a dose-response curve was constructed using 
doubling doses (sum of both nostrils) of oxymetazoline of 25µg, 50µg, 100µg and 
200µg at 20-minute intervals. PNIF and NAR were measured at baseline and after 
each successive dose. Nasal blood flow was measured at baseline, 50 µg and 200 µg. 
Finally, as a subjective measure of decongestion, participants filled in a decongestion 
visual analogue scale (0-100 mm) with the minimum anchor ‘0’ denoting no change 
and the maximum anchor ‘100’ denoting ‘most excellent change’ after the final dose 
of oxymetazoline.  
STATISTICAL ANALYSIS 
The study was powered at > 80 % with an alpha-error of 0.05 (two-tailed) in order to 
detect a 10L.min–1 difference in PNIF after 200 µg of intranasal oxymetazoline with 
an estimated sample size of 16 participants assuming the within-subject SD to be 9.2 
L.min–1 .(205)!This was considered adequate to demonstrate a true response to 
oxymetazoline i.e. change in PNIF within each subject, with adequate consideration 
for previous literature(298, 305). The distribution of each outcome was assessed for 
plausibility of the assumption of approximate normality using the Shapiro-Wilk test 
and by visual inspection of histograms and Q-Q plots, with consideration of previous 
datasets and literature. The area under the curve (AUC) for the decongestive 
response to oxymetazoline were calculated at each of the above mentioned time 
points from baseline using a linear trapezoidal rule. Comparisons for outcomes 
before and after decongestion were made using a paired t-test with a 2-tailed α-error 
set at 0.05. Standardized response means were calculated by dividing the mean 
change in an outcome by the standard deviation of the difference, i.e. a measure of 
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effect size or responsiveness to provide an indication of the ‘signal-to-noise’ ratio.  
All analyses were performed on a per-protocol basis using SPSS version 17, 
Chicago, IL, USA. 
 
 164!
Results 
27 participants were screened of which 21 were eligible for the study according to 
our inclusion/exclusion criteria. 2 did not fulfil the requirements of the protocol with 
regard to PNIF technique. 12 female and 7 male participants with a mean (range) age 
of 33 (21-55) years completed the protocol. There were no serious adverse events. 
There were no missing data. 
For all outcomes, there were no significant differences between the first and second 
visits for the baseline and post-decongestion subjective and objective measurements 
(Table 12).  
 
Table 13: Within subject change in outcomes. 
Variable Visit 1 Visit 2 Mean difference (95% CI; P) 
CV 
(%) 
Baseline     
Nasal Blood Flow (units) 277.9 (12.7) 
255.7 
(13.4) 22.2 (–9.0 to 53.5; .32) 7.7 
Nasal Airway Resistance 
(Pa.s.cm –3) 0.24 (0.03) 0.26 (0.02) –0.01 (–0.07 to 0.04; .65) 19.7 
Peak Nasal Inspiratory Flow 
(L.min–1) 174.4 (9.5) 
178.3 
(10.4) –3.9 (–30.8 to 23.0, .39) 8 
Post-decongestion*     
Nasal Blood Flow (units) 138.3 (13) 156.3 (13.5) –17.9 (–49.2 to 13.3; .78) 12 
Nasal Airway Resistance 
(Pa.s.cm –3) 0.16 (0.01) 0.17 (0.01) –0.02 (–0.08 to 0.04; .38) 18 
Peak Nasal Inspiratory Flow 
(L.min–1) 
223.3 
(10.8) 
217.2 
(12.6) 6.1 (–20.8 to 33.0; .22) 6 
Decongestion Dose Response     
AUC Nasal Blood Flow (units.h) 214.5 (13.8) 
230.1 
(12.8) –11.5 (–52.1 to 29.1; .56) 12 
AUC Nasal Airway Resistance 
(Pa.s.cm –3.h) 0.22 (0.03) 0.19 (0.01) 0.03 (–0.01 to 0.07; .13) 15 
AUC Peak Nasal Inspiratory 
Flow (L.min–1.h) 
218.0 
(15.4) 
207.5 
(16.3) 10.5 (7.4 to 28.5; .23) 7 
Decongestion Visual Analogue 
Scale (0 – 100 mm) 37.3 (3.8) 35.5 (4.8) 1.8 (–6.1 to 9.6; .63) 16 
All data are arithmetic means (SEM) unless indicated. 
*Post-decongestion values given here were measured after the final dose of 200 mcg of oxymetazoline.  
Visual Analogue Scale scoring was performed after decongestion only. 
Abbreviations: CV, within-subject coefficient of variation; AUC, area under the dose response curve.  
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Figure 20: Nasal air-flow and blood-flow outcomes pre and post decongestion. 
 
Decongestive response in nasal blood flow, peak nasal inspiratory flow and nasal 
airway resistance to 200 mcg of oxymetazoline. Symbols demonstrate individual 
values. Error bars indicate mean (95% CI). Post decongestion measurements were 
obtained after the final dose (200mcg cumulative) of oxymetazoline.  
 
After the final dose of oxymetazoline (cumulative dose 200 µg) nasal blood flow 
decreased by a mean (95% CI, P) of 139.6 (108.3 to 170.8, P < .001) units and 99.4 
(68.1 to 130.7, P < .001) units at the first and second visits respectively (Table 12, 
Figure 17). Similarly, PNIF increased by 48.9 (22.0 to 75.8, P < .001) L.min–1 and 
38.9 (12.0 to 65.8, P = .003) L.min–1, and NAR decreased by 0.1 (0.02 to 0.15, P < 
.001) Pa.s.cm-3 and 0.09 (0.02 to 0.15, P = .002) Pa.s.cm-3 at the first and second 
visits respectively (Table 12, Figure 21). The area under the decongestant response 
curve was estimated and was not significantly different between visits for each 
variable (Table 12). The standardized response means (signal to noise ratio) were 
estimated for the overall decongestant response for each outcome as follows: NBF, 
1.41; PNIF, 1.03; and NAR, 0.97.  
The within-subject coefficient of variation was estimated as a measure of 
reproducibility and the results are given in Table 12. There was no significant 
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correlation between nasal blood flow, measures of nasal patency and subjective 
scores (Table 13). 
Table 14: Correlation matrix. 
Variables) NBF) PNIF) NAR) VAS)
NBF) 2) –0.18)(.50)) 0.01)(.96)) 0.04)(.89))
PNIF) –0.18)(.50)) 2) –0.33)(.20)) –0.04)(.87))
NAR) 0.01)(.96)) –0.33)(.20)) 2) 0.22)(.40))
VAS) 0.04)(.89)) –0.04)(.87)) 0.22)(.40)) 2)
*)Values)are)given)as)the)correlation)coefficient)R)(P)value).)
Abbreviations:)NBF,)nasal)blood)flow)(units);)PNIF,)Peak)Nasal)Inspiratory)Flow)(L.min–1);)
NAR,)Nasal)Airway)Resistance)(Pa.s.cm)–3);)VAS,)Decongestion)Visual)Analogue)Scale)(0)–)100)
mm).)
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Discussion 
In this study we have demonstrated that nasal blood flow measured by laser Doppler 
flowmetry is a reproducible and responsive measure that fluctuates in parallel with 
measures of nasal patency and symptoms.  
The first reported use of laser Doppler flowmetry was by Stern in 1975(317).!Since 
then it has been widely applied in various fields other than rhinology. Some of the 
challenges faced in rhinology are the lack of specific nasal probes, stunted evolution 
of equipment, motion artefact, the need for a stable head assembly and patient 
discomfort with the inability to tolerate measurements for long. Consequently, the 
role of nasal blood flow as an outcome measure within modern rhinological research 
is yet to be fully determined. This is despite the fact that nasal blood flow is the 
critical factor underpinning many physiological and pathological processes and is 
influenced by drugs such as decongestants and corticosteroids among others(318). 
Laser Doppler flowmetry represents the only non-invasive method currently 
available for the evaluation of superficial nasal blood flow, while nasal patency 
measures such as PNIF are presumed as surrogates of venous  sinusoidal flow and 
hence mucosal congestion .   
The within subject coefficient of variation for NBF was 7.7 % as compared to 19.7 
% for NAR and 8% for PNIF. This shows that NBF measured by laser Doppler 
flowmetry is reproducible with low variability. PNIF has been shown to be more 
sensitive and reproducible than acoustic rhinometry or rhinomanometry in evaluating 
nasal congestion(204, 205). It is also less prone to be influenced by the nasal cycle, 
the commonest cause of false positive responses in nasal patency testing(101). 
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In our study, we did not evaluate the effect of the nasal cycle on NBF measured by 
laser Doppler flowmetry. One reason for this was that decongestant agents abolish 
the cycle(319). Moreover, the definition of what constitutes a nasal cycle is under 
debate, quantitative studies having failed to adequately demonstrate the presence of a 
cycle of spontaneous congestion and decongestion of the venous sinusoids(320). 
Lastly, while the nasal cycle is purported to play a role in nasal defence, however, its 
functional significance remains uncertain(314). To our knowledge the nasal cycle 
has only ever been evaluated in terms of nasal airway patency in the literature(320), 
future physiological studies would be required to shed more light on this 
phenomenon. In a recent paper published by our group, we demonstrated a 
disconnect between nasal blood flow measured by laser Doppler flowmetry and 
nasal airflow (PNIF, NAR), with regard to response to an alpha-1 antagonist 
prazosin(315). One plausible hypothesis could be that the regulation of nasal 
mucosal perfusion is independent of the filling of deep sinusoids, which determines 
congestion. This would ensure that the nasal mucosal blood flow is kept at near 
maximum with minimal variation with the nasal cycle. 
Standardized response means (SRM) are highly informative measures calculated by 
dividing the mean change in an outcome by the standard deviation of the difference, 
i.e. it is a measure of effect size or responsiveness. Because the denominator 
examines response variance, it provides a sensitive indication of ‘signal-to-noise’ 
ratio.  It is readily apparent that the SRM of laser Doppler flowmetry was high at 
1.41, making it an extremely sensitive indicator of nasal vasoconstriction. Further 
research is needed to evaluate the utility of nasal blood flow in rhinological research 
and clinical practice. For example it could prove beneficial in studies looking at 
adrenoreceptor function, rhinitis medicamentosa, post-operative monitoring of nasal 
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blood flow or in furthering our understanding of the regulation of nasal function. It 
could also be useful in the evaluation of intermittent and persistent allergic rhinitis in 
the research and perhaps in the clinical setting. It could be used diagnostically such 
as in nasal provocation testing using histamine(321) or adenosine 
monophosphate(255, 322) and to assess therapeutic efficacy of say intranasal 
steroids or immunotherapy. Our study has its limitations as an observational study, a 
placebo-controlled study would be more informative and could be considered in the 
future.  
In conclusion, nasal blood flow using laser Doppler flowmetry is a sensitive and 
reproducible outcome to decongestion with oxymetazoline, similar to nasal patency 
and symptoms. 
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Summary 
The current series of studies have explored various treatment paradigms in patients 
with CRS in order to optimize their therapeutic index and in turn their disease 
outcomes and quality of life. In this regard, this thesis is unique in the rhinology 
literature in its balance and bringing together the facets of efficacy and safety, 
anatomy and physiology, and the macroscopic and the molecular. We believe that 
one of the strongest points of this oeuvre is in its methodological meticulousness, 
with the utilization of well-powered outcomes with minimal important differences 
and in the use of prospective randomized placebo controlled study designs. Finally, 
while these works hopefully strengthen the body of evidence in rhinology, adding to 
it, enhancing some aspects; I hope that this also challenges the status quo in a few 
ways in terms of current guidelines. 
The third chapter explores the issue of having a suitable, cheap and portable but 
sensitive marker of ostiomeatal complex patency in CRSwNP. The importance of the 
ostiomeatal complex in the disease perpetuation and recurrence is well known in the 
realm of surgery and treatments are focused on improving paranasal sinus drainage 
rather than merely debulking nasal polyposis(1). However, nasal endoscopy and CT 
scanning has its limitations in the assessment of ostiomeatal complex patency. They 
both provide vital information, but merely demonstrating middle meatal polyps or 
mucosal thickening on sinus CT scans does not necessarily corroborate with 
functional OM complex obstruction(12, 42). However, a failed outcome measure in 
nasal NO may provide the answer. The role of exhaled tidal NO in asthma is well 
established and it represents a powerful noninvasive biomarker of lower airways 
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inflammation(223, 323). Unfortunately its counterpart in the nose, the nasal NO has 
failed to demonstrate similar responsiveness to treatment(230, 255). I believe this is 
because nasal nitric oxide actually is ‘sinus’ nitric oxide, i.e. the supersaturated 
reservoirs of NO are actually in the sinuses and these concentrations eclipse the 
lesser contribution from the nasal passageways. The paranasal sinuses increase the 
mucosal surface area of the upper airways considerably in comparison with the nasal 
passage. Indeed, one only has to look at patients with mucociliary dyskinesia and 
their ‘nasal’ NO concentrations or patients with CRSwNP to know this fact(227, 
250, 324). Thus within an inadequate measure for nasal mucosal inflammation 
resides a hidden gem, which may provide a more true measure of intra-sinus 
inflammation. Clearly, sinus washouts are not practicable and not likely to be 
acceptable within clinical practice. While the humming technique requires training 
and is not intuitive, it is more likely to have a high signal to noise ratio given its 
supersaturated concentrations in the sinuses(325). We have demonstrated a high 
inverse correlation (R = 0.57, P <.001 between humming ‘nasal’ NO and CT scan 
assessments of OM complex patency(228). Humming NO has also now in this 
thesis, been proven to reduce substantially with oral corticosteroid therapy and 
further research is needed to assess it again in AR where previously the results have 
been disappointing. An approach that uses humming and quiet exhaled NO using a 
handheld analyzer as described in Chapter 3, could help evaluate post-humming 
spent NO which is likely a more true reflection of nasal NO levels. Interestingly, we 
also showed that humming NO correlated significantly only with hyposmia VAS (R 
= 0.59, P = 0.04) of all outcomes. It is interesting that humming NO improves in 
parallel with one of the most disabling symptoms of CRSwNP i.e. the loss of sense 
of smell. Further controlled studies may be able to differentiate humming responders 
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and non-responders and possibly see if an improvement in the sense of smell can be 
predicted based on baseline humming NO or a change in NO after the initial oral 
steroid bolus. It is also readily apparent that humming nasal NO is the most 
responsive followed by exhalation and lastly aspiration with the highest SRMs. This 
will hopefully foster further research in this arena and future guidelines will include 
this method of measuring upper airways inflammation. 
 
We demonstrate subsequently in Chapter 4, in the first long-term randomized 
clinical trial looking at sequential induction and maintenance treatment in patients 
with CRSwNP, the benefits of such an approach on a wide range of subjective, 
objective and quality measures. Uniquely, this is the first study to also look at a 
comprehensive array of safety outcomes in the medium-long term. We evaluated 
stimulated and unstimulated markers of adrenal suppression and bone turnover, to 
demonstrate clear evidence of safety over 6 months on maintenance topical 
corticosteroids. Whereas previous studies in healthy volunteers with fluticasone 
nasal drops and spray have shown low systemic bioavailability even at supranormal 
dosages, this cannot be generalised to patients with CRSwNP(154). The pan-
mucosal inflammation and impaired mucociliary clearance characteristic of 
CRSwNP may influence nasal retention, corticosteroid absorption and systemic 
bioavailability, and the use of concomitant inhaled corticosteroid may add to the 
systemic steroid burden. Notably, improvement in the total nasal symptoms score 
(TNSS) demonstrated some attrition of effect after switching to nasal sprays. 
Compared to nasal sprays, drops provide better deposition to the ostiomeatal 
complex with a low systemic bioavailability(154, 277). However, they are relatively 
expensive and not universally available. Still this reflects our clinical experience 
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where carefully instilled nasal drops with the right technique, are more effective than 
nasal spray.  
Interestingly, levels of staphylococcus aureus enterotoxin-specific IgE did not 
change (P> 0.05) even with oral prednisolone. We believe that our study was 
powered adequately to assess this, as evidenced by the marked significant reduction 
in serum EDN and HS-CRP at 2 weeks. Thus it may be hypothesized that it is the 
local inflammatory pathways involving the staphylococcal superantigens that play a 
key role in the amplification and perpetuation of CRS. This is a similar to what Van 
Zele and colleagues have previously reported with a marked increase in local 
immunoglobulin production with S aureus enterotoxin stimulation but not in the 
serum(49). Future studies could look at these local immunological outcomes with 
greater effect, using a simple scoop-curette or a polyurethane foam sampling 
technique developed by Deutschle and coworkers, to make it more acceptable for 
patients and to evaluate a variety of mediators at once(220, 326). !
Our findings in Chapter 5 question the the EAACI/GA2LEN 2007 guidelines in 
recommending routine aspirin challenge testing in CRS. In our experience of treating 
patients with chronic rhinosinusitis and asthma for over a decade, we have most 
commonly seen clinicians rely on a history of aspirin sensitivity rather than offer a 
provocation test it in a general group of CRS patients. While this may be said to 
underdiagnose patients with ‘aspirin sensitivity’ in that there are likely to be 
undiagnosed patients who may have a positive challenge test, routine testing in an 
unselected group of patients with CRS may be of very low yield. Our results do not 
support this recommendation and further research is needed to identify the 
phenotype/endotype of CRS most likely to benefit from this approach. I hope these 
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results will inform further evaluation of steroid-refractory AIR patients in terms of 
aspirin desensitization therapy, which I believe is an underutilized tool. 
Perhaps the findings in Chapters 6 and 7 are of greatest importance in creating new 
uses of existing medical therapy in CRS/AR, in terms of increasing the time for 
which nasal sympathomimetics can be safely prescribed in these patients by 
modulating adrenceptor tachyphylaxis with the concomitant use of corticosteroid. 
This is potentially of tremendous benefit in acute exacerbations of rhinosinusitis, 
where there is a need for a fast-acting efficacious and safe decongestant. Further 
studies, could evaluate a combination spray of corticosteroid and sympathomimetic 
in AR/CRS. Moreover, it can lead to more molecular level studies where receptor 
upregulation studies in the human nose can lead to a new area of research into the 
little understood regulatory system of the human nose. 
While it is well known that topical sympathomimetics are highly efficacious 
decongestants, the role of the alpha-adrenoceptor and the cross-talk with nasal 
inflammation may open up new avenues of research. Since the work of Hanania and 
coworkers has opened a new and paradoxical view of traditional pharmacology with 
their open label study in 10 subjects with asthma, in which nine weeks of nadolol 
treatment produced a significant, dose-dependent increase two-fold increase in the 
methacholine PC20 at 40 mg (p < 0.0042)(327). However, there was also a minor 
dose-independent 5% reduction in mean FEV1 over the study period (p < 0.01). In 
our current experience, this is still an area of promise despite negative early results in 
the first randomized clinical trial in asthma using propranolol(136). Now there is 
evidence that prazosin acts as an inverse agonist at the alpha-1 adrenoceptor in 
chronic dosing regimes(328, 329). This area holds tremendous potential in rhinology 
in terms of if there is an inverse agonist effect of prazosin in the human nose, this 
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may provide a new inexpensive treatment for nasal congestion and inflammation by 
altering nasal hyper-reactivity similar to the findings by Hanania et al(327). 
The collection and reporting of patient reported and disease-sensitive and specific 
outcomes is a key priority as set out in the Government’s July 2010 White Paper, 
Equity and excellence: Liberating the NHS  and The NHS Outcomes Framework 
2012/13. Indeed, rhinology is a specialty that has traditionally lagged behind in 
having validated, reproducible disease-specific outcomes, although considerable and 
commendable progress has been made in the last decade(1, 6). Such a need also 
exists in the realm of rhinology research where intervention-sensitive, precise and 
accurate outcomes are evolving currently. Rhinology belongs to a group of 
traditionally undervalued illnesses in terms of recognition, trivialization of 
symptoms, adequate therapy, poor research funding and lack of national awareness 
of its tremendous impact on the youth, the productive and the able. The research 
conducted by the Asthma and Allergy Research Group along with their clinical 
partners in Otorhinolaryngology, the basic sciences, and family practitioners 
represents a multidisciplinary approach to address a much neglected but incredibly 
vital area of research and clinical need. 
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